

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 22, 2003, 15:46:12 / Search time 34.0597 Seconds
(without alignments)
1067.227 Million cell updates/sec

Title: US-09-856-320A-2_COPY_54_282

Perfect score: 1258
Sequence: 1 IIXGFEKPHSQPQNALFE.....GVYTKVKVQVNIQETWKN 229

Scoring table: BLOSUM62

Gapop 10.0 / Gapext 0.5

Searched: 1107863 segs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database: A_Geneseq_19Jun03.*

```
1: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2003.DAT.*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1258	100.0	250	21	Human TUSP. Homo
2	1258	100.0	250	21	Human PRO1279 (UNQ)
3	1258	100.0	250	22	Human secreted pro
4	1258	100.0	250	22	Human PRO1279 poly
5	1258	100.0	250	22	Protein of the inv
6	1258	100.0	250	22	Prostate cancer-as
7	1258	100.0	250	23	Human angiogenesis
8	1258	100.0	250	23	Human PRO1279 prot
9	1258	100.0	250	23	Human PRO protein,

10	1258	100.0	250	24	ABU65822	Human PRO polypept
11	1258	100.0	250	24	ABU57098	Human secreted/tra
12	1258	100.0	250	24	ABU59903	Novel secreted and
13	1258	100.0	250	24	ABU56739	Lung cancer-associ
14	1258	100.0	282	20	AAV42439	CASB12 amino acid
15	1258	100.0	282	21	AAV11712	Human serine prote
16	1258	100.0	282	21	AAV43636	A human prostate-a
17	1252	99.5	281	20	AAV42440	CASB12 polypeptide
18	1235.5	98.2	275	21	AAV11714	Human serine prote
19	1231	97.9	228	21	AAV11714	Human TUSP. Homo
20	1228	97.6	250	20	AAV36093	Extended human sec
21	1227	97.5	248	22	AAV508017	Human PS133 consen
22	1219.5	96.9	289	21	AAV36483	Fusion gene with h
23	1219.5	96.9	289	22	AAV67543	Amino acid sequenc
24	1062	84.4	276	21	AAV11713	Mouse serine prote
25	1014.5	80.6	247	23	ABG70276	Human serine prote
26	736	58.5	250	21	AAV21298	Human KUK-L3 prote
27	736	58.5	250	21	ABP64969	Human protein SEQ
28	736	58.5	251	22	AAU16971	Human novel secret
29	734	58.3	247	22	AAU23217	Novel human enzyme
30	731.5	58.1	296	21	AAV21297	Human KUK-L3 prote
31	716	56.9	247	22	AAU86677	Novel human connec
32	716	56.9	247	22	AAU23752	Novel human enzyme
33	716	56.9	247	22	AAU17043	Human novel secret
34	688	54.7	273	21	AAV21311	Human neuropilin.
35	684	54.4	260	17	AAV10694	Human recombinant
36	684	54.4	260	18	AAV12393	Mouse neuropilin pr
37	684	54.4	260	23	ABV57219	Mouse ischaemic co
38	682	54.2	256	23	AAU79390	Novel human kalik
39	682	54.2	320	23	AAE19166	Human protease, PR
40	682	54.2	320	23	AAU82732	Amino acid sequenc
41	681	54.1	260	20	AAV41744	Human PRO322 prote
42	681	54.1	260	20	AAV32852	Human serine prote
43	681	54.1	260	20	AAV03220	Amino acid sequenc
44	681	54.1	260	20	AAV87703	A human serine pro
45	681	54.1	260	21	AAV21322	Human neuropilin.

ALIGNMENTS

RESULT 1
AAB21325
ID AAB21325 standard; Protein: 250 AA.
XX
AC AAB21325;
XX
DT 02-FEB-2001 (first entry)
XX
DS Human TUSP.
XX
KW Human; KUK-L1; KUK-L2; KUK-L3; KUK-L4; KUK-L5; KUK-L6; TUSP;
KW trypsin-like serine protease; kallikrein-like protein; serine protease;
KW cytosolic; cancer; prostrate cancer.
XX
OS Homo sapiens.
XX
PN WO2000053776-A2.
XX
PD 14-SEP-2000.
XX
PF 09-MAR-2000; 2000WO-CR00258.
XX
PR 11-MAR-1999; 99US-0124260.
PR 01-APR-1999; 99US-0127386.
PR 21-JUL-1999; 99US-0144915.
PA (MOUN) MOUNT SINAI HOSPITAL.
XX
PI Yousef GW, Diamandis EP;
XX
DR WPI; 2000-587440/55.
XX

PT New kallikrein-like (KLK-L) proteins for diagnosing and treating KLK-L
PT protein mediated disorders, especially cancer. -
PS Example 5; Fig 27; 184pp; English.
XX
XX The present sequence is human trypsin-like serine protease (TUSP), a
CC member of the serine protease family. Kallikreins and
CC kallikrein-like proteins are a subgroup of the serine protease enzyme
CC family. They catalyze the selective cleavage of specific polypeptide
CC precursors to release peptides with potent biological activity. Nucleic
CC acids encoding kallikrein-like proteins KLK-L1, KLK-L2, KLK-L3, KLK-L4,
CC KLK-L5 and KLK-L6 have been isolated. The proteins are useful in the
CC treatment, monitoring and diagnosis of cancers, especially prostate
CC cancer. They can also be used to identify a substance that can associate
CC with or mediate the biological activity of the proteins. Antibodies can
CC be used to treat conditions mediated by the kallikrein-like proteins.
XX
XX Sequence 250 AA;

Query Match 100.0%; Score 1258; DB 21; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 IIKGPECKPHSQPQAAALPEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
Db 22 IIKGPECKPHSQPQAAALPEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 81
Oy 61 GCOTATATESPHGCFNNSLPNKDHNDMLVQMASPVSIITWAVRPLTSLSRCTAGTS 120
Db 82 GCOTATATESPHGCFNNSLPNKDHNDMLVQMASPVSIITWAVRPLTSLSRCTAGTS 141
Oy 121 CLISGNGSTSSQLRPLHTLCANITIEHOKENAYPGNITDTWVCASVQEGKDSGCG 180
Db 142 CLISGNGSTSSQLRPLHTLCANITIEHOKENAYPGNITDTWVCASVQEGKDSGCG 201
Oy 181 DSGGPLVCNQSLOGIISWQDPCATIRKPGVYTKVCKYVDWIOETMKN 229
Db 202 DSGGPLVCNQSLOGIISWQDPCATIRKPGVYTKVCKYVDWIOETMKN 250

RESULT 2
RAY99390
ID AAY99390 standard; Protein; 250 AA.

XX AC AAY99390;

XX DT 08-AUG-2000 (first entry)

XX DE Human PRO1279 (UN0649) amino acid sequence SEQ ID NO.170.

XX KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening.

XX OS Homo sapiens.

XX PN WO200012708-A2.

XX PD 09-MAR-2000.

XX PP 01-SEP-1999; 99WO-US20111.

XX PR 01-SEP-1998; 98US-0098716.

XX PR 01-SEP-1998; 98US-0098749.

XX PR 02-SEP-1998; 98US-0098750.

XX PR 02-SEP-1998; 98US-0098803.

XX PR 02-SEP-1998; 98US-0098821.

XX PR 02-SEP-1998; 98US-0098842.

XX PR 09-SEP-1998; 98US-0099336.

XX PR 09-SEP-1998; 98US-0099396.

XX PR 09-SEP-1998; 98US-0099598.

XX PR 09-SEP-1998; 98US-0099602.

XX PR 09-SEP-1998; 98US-0099642.

XX PR 10-SEP-1998; 98US-0099741.

PR 10-SEP-1998; 98US-0099754.
PR 10-SEP-1998; 98US-0099763.
PR 10-SEP-1998; 98US-0099792.
PR 10-SEP-1998; 98US-0099808.
PR 10-SEP-1998; 98US-0099812.
PR 10-SEP-1998; 98US-0099815.
PR 10-SEP-1998; 98US-0099816.
PR 13-SEP-1998; 98US-0100385.
PR 13-SEP-1998; 98US-0100388.
PR 15-SEP-1998; 98US-0100390.
PR 16-SEP-1998; 98US-0100384.
PR 16-SEP-1998; 98US-0100827.
PR 16-SEP-1998; 98US-0100861.
PR 16-SEP-1998; 98US-0100862.
PR 16-SEP-1998; 98US-0100864.
PR 17-SEP-1998; 98US-0100883.
PR 17-SEP-1998; 98US-0100884.
PR 17-SEP-1998; 98US-0100710.
PR 17-SEP-1998; 98US-0100711.
PR 17-SEP-1998; 98US-0100919.
PR 17-SEP-1998; 98US-0100910.
PR 18-SEP-1998; 98US-0100848.
PR 18-SEP-1998; 98US-0100849.
PR 18-SEP-1998; 98US-0101014.
PR 18-SEP-1998; 98US-0101068.
PR 18-SEP-1998; 98US-0101071.
PR 22-SEP-1998; 98US-0101279.
PR 23-SEP-1998; 98US-0101471.
PR 23-SEP-1998; 98US-0101472.
PR 23-SEP-1998; 98US-0101474.
PR 23-SEP-1998; 98US-0101475.
PR 23-SEP-1998; 98US-0101476.
PR 23-SEP-1998; 98US-0101477.
PR 23-SEP-1998; 98US-0101479.
PR 24-SEP-1998; 98US-0101738.
PR 24-SEP-1998; 98US-0101741.
PR 24-SEP-1998; 98US-0101743.
PR 24-SEP-1998; 98US-0101915.
PR 24-SEP-1998; 98US-0101916.
PR 29-SEP-1998; 98US-0102407.
PR 29-SEP-1998; 98US-0102409.
PR 29-SEP-1998; 98US-0102307.
PR 29-SEP-1998; 98US-0102330.
PR 29-SEP-1998; 98US-0102331.
PR 30-SEP-1998; 98US-0102484.
PR 30-SEP-1998; 98US-0102487.
PR 30-SEP-1998; 98US-0102570.
PR 30-SEP-1998; 98US-0102571.
PR 01-OCT-1998; 98US-0102684.
PR 01-OCT-1998; 98US-0102687.
PR 02-OCT-1998; 98US-0102965.
PR 06-OCT-1998; 98US-0103258.
PR 06-OCT-1998; 98US-0103449.
PR 07-OCT-1998; 98US-0103314.
PR 07-OCT-1998; 98US-0103315.
PR 07-OCT-1998; 98US-0103328.
PR 07-OCT-1998; 98US-0103395.
PR 07-OCT-1998; 98US-0103396.
PR 07-OCT-1998; 98US-0103401.
PR 08-OCT-1998; 98US-0103633.
PR 08-OCT-1998; 98US-0103678.
PR 08-OCT-1998; 98US-0103679.
PR 08-OCT-1998; 98US-0103711.
PR 14-OCT-1998; 98US-0104257.
PR 20-OCT-1998; 98US-0104987.
PR 20-OCT-1998; 98US-0105000.
PR 20-OCT-1998; 98US-0105002.
PR 21-OCT-1998; 98US-0105104.
PR 21-OCT-1998; 98US-0105169.
PR 22-OCT-1998; 98US-0105266.
PR 26-OCT-1998; 98US-0105693.
PR 26-OCT-1998; 98US-0105694.
PR 27-OCT-1998; 98US-0105807.

PR 27-OCT-1998; 98US-0105881.
 PR 27-OCT-1998; 98US-0105882.
 PR 27-OCT-1998; 98US-0106062.
 PR 28-OCT-1998; 98US-0106023.
 PR 28-OCT-1998; 98US-0106029.
 PR 28-OCT-1998; 98US-0106030.
 PR 28-OCT-1998; 98US-0106032.
 PR 28-OCT-1998; 98US-0106033.
 PR 28-OCT-1998; 98US-0106178.
 PR 29-OCT-1998; 98US-0106248.
 PR 29-OCT-1998; 98US-0106384.
 PR 29-OCT-1998; 98US-0108500.
 PR 30-OCT-1998; 98US-0106464.
 PR 03-NOV-1998; 98US-0106856.
 PR 03-NOV-1998; 98US-0106902.
 PR 03-NOV-1998; 98US-0106905.
 PR 03-NOV-1998; 98US-0106919.
 PR 03-NOV-1998; 98US-0106932.
 PR 03-NOV-1998; 98US-0106934.
 PR 10-NOV-1998; 98US-0107783.
 PR 17-NOV-1998; 98US-0108775.
 PR 17-NOV-1998; 98US-0108779.
 PR 17-NOV-1998; 98US-0108787.
 PR 17-NOV-1998; 98US-0108788.
 PR 17-NOV-1998; 98US-0108801.
 PR 17-NOV-1998; 98US-0108802.
 PR 17-NOV-1998; 98US-0108806.
 PR 17-NOV-1998; 98US-0108807.
 PR 17-NOV-1998; 98US-0108867.
 PR 17-NOV-1998; 98US-0108925.
 PR 18-NOV-1998; 98US-0108848.
 PR 18-NOV-1998; 98US-0108849.
 PR 18-NOV-1998; 98US-0108850.
 PR 18-NOV-1998; 98US-0108851.
 PR 18-NOV-1998; 98US-0108852.
 PR 18-NOV-1998; 98US-0108858.
 PR 18-NOV-1998; 98US-0108904.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 DR WPI; 2000-237871/20.
 DR N-PSDB; AAA37072.
 XX
 PT New mammalian DNA sequences encoding transmembrane, receptor or
 PT secreted PRO polypeptides, useful for screening of potential peptide or
 PT small molecule inhibitors of the relevant receptor/ligand interactions
 XX
 PS Claim 12; Fig 102; 773pp; English.
 XX
 CC AAA37022 to AAA37144 encode the new isolated human transmembrane
 CC receptor or secreted PRO polypeptides given in AA993140 to AA99462. The
 CC transmembrane and receptor PRO proteins can be used for screening of
 CC potential peptide or small molecule inhibitors of the relevant
 CC receptor/ligand interactions. The polypeptides and nucleotide sequences
 CC encoding then have various industrial applications, including uses as
 CC pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent
 CC PCR primers and hybridisation probes used in the isolation of the PRO
 CC polypeptides from the present invention.
 XX
 SQ Sequence 250 AA;
 Query Match 100.0%; Score 1258; DB 21; Length 250;
 Best Local Similarity 100.0%; Freq. No. 6.3e-113;
 Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 IIKGFECKPHSQWQAALFEKTRLLCGATLTAAPWLLTAACHLKPRYIVHLQCHNLQKEE 60
 DB 22 IIKGFECKPHSQWQAALFEKTRLLCGATLTAAPWLLTAACHLKPRYIVHLQCHNLQKEE 81
 QY 61 GCEQTRTATESFPHGPNNSLPKNDHRNDIMLVKMASPVSIWAVRPLTSLSRCTAGTS 120
 |||||||

Db 82 GCEQTRTATESFPHGPNNSLPKNDHRNDIMLVKMASPVSIWAVRPLTSLSRCTAGTS 141
 QY 121 CLISGWGSTSSPOLRLPHTLRCAHITIIIEHOKCEYAYPCNITDTWVCASVQEGKDSQCG 180
 Db 142 CLISGWGSTSSPOLRLPHTLRCAHITIIIEHOKCEYAYPCNITDTWVCASVQEGKDSQCG 201
 QY 181 DSGGPLYCNQSLQGIISWGQDPCAIITRKPVGVTCKYKVDWMIQETMKNN 229
 Db 202 DSGGPLYCNQSLQGIISWGQDPCAIITRKPVGVTCKYKVDWMIQETMKNN 250
 RESULT 3
 ABB50479
 ID ABB50479 standard; Protein; 250 AA.
 AC ABB50479;
 XX
 DT 07-FEB-2002 (first entry)
 XX
 DE Human secreted protein encoded by gene 179 SEQ ID NO:427.
 XX
 KW Human; secreted protein; immunomodulatory; antisclerotic; anti-HIV;
 KW dermatological; immunosuppressive; antiinflammatory; immunostimulant;
 KW cytotatic; cardiant; vascular; anti-angiogenic; ophthalmological;
 KW neuroprotective; nootropic; anticonvulsant; antiaizheimers; vulnerary;
 KW antiparkinsonian; antimicrobial; gene therapy; vaccine; immune disorder;
 KW multiple sclerosis; systemic lupus erythematosus; HIV infection; cancer;
 KW human immunodeficiency virus; hyperproliferative disorder; wound healing;
 KW Gaucher's disease; cardiovascular disease; scintar syndrome; chetotaxis;
 KW Chaga's cardiomyopathy; coronary arteriosclerosis; angiogenic disorder;
 KW corneal graft neovascularisation; diabetic retinopathy; regeneration;
 KW neurological disorder; Huntington's chorea; Alzheimer's disease;
 KW Parkinson's disease; infectious disease.
 XX
 OS Homo sapiens.
 XX
 PN WO200162891-A2.
 XX
 PD 30-AUG-2001.
 XX
 PP 21-FEB-2001; 2001WO-US05614.
 XX
 PR 24-FEB-2000; 2000US-184836P.
 PR 29-MAR-2000; 2000US-193170P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Ni J, Ebner R, Latleur DW, Moore PA, Olsen HS, Rosen CA;
 PI Ruben SM, Soppet DR, Young PE, Shi Y, Florence KA, Wei Y;
 PI Florence C, Hu J, Li Y, Kyaw H, Fischer CL, Ferrie AM, Fan P;
 PI Feng P, Endress GA, Dillon PJ, Carter KC, Brewer LA, Yu G;
 PI Zeng Z, Greene JW;
 XX
 XX WPI; 2001-625724/72.
 DR N-PSDB; ABA83372.
 XX
 PT Nucleic acids encoding 207 human secreted polypeptides, useful for
 PT preventing, diagnosing and/or treating, e.g. cancers, Parkinson's
 PT disease and diabetic retinopathy -
 XX
 PS Claim 11; Page 1181-1182; 1533pp; English.
 XX
 CC ABB50101 to ABB51287 and ABA83194 to ABA83441 represent human secreted
 CC proteins (I) and polynucleotide (II) sequences. (I) and (II) have various
 CC activities based on the tissues and cells the genes are expressed in.
 CC Example of these activities include: immunomodulatory; antisclerotic;
 CC dermatological; immunosuppressive; antiinflammatory; immunostimulant;
 CC anti-HIV; cytostatic; cardiant; anti-angiogenic; ophthalmological;
 CC neuroprotective; nootropic; anticonvulsant; antiaizheimers; vascular;
 CC antiparkinsonian; antimicrobial; and vulnerary. (I) and (II) can be used
 CC in gene therapy and vaccine production. (I) and (II) can be used in the
 CC prevention, diagnosis and treatment of immune disorders (e.g. multiple
 CC sclerosis, systemic lupus erythematosus and human immunodeficiency virus

CC (HIV) infections), hyperproliferative disorders (e.g. cancers and
 CC Gaucher's disease), cardiovascular diseases (e.g. Scimitar syndrome,
 CC Chaga's cardiomyopathy and coronary arteriosclerosis), angiodysic
 CC disorders (e.g. corneal graft neovascularisation and diabetic
 CC retinopathy), neurological disorders (e.g. Huntington's chorea,
 CC Alzheimer's disease and Parkinson's disease), infectious diseases and/or
 CC for promoting wound healing, regeneration and/or chemotaxis. AAS3185 to
 CC ABA8193 and ABB5300 represent sequences used in the exemplification of
 CC the present invention.

XX Sequence 250 AA;
 SQ

Query Match 100.0%; Score 1258; DB 22; Length 250;
 Best Local Similarity 100.0%; Pred. No. 6.3e-113;
 Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 IIKGFCKPHSQPQWQALFEKTRLLCGATLIAPRWLLTAACHCLKPRYIVHLGQHNLOKEE 60
 Db 22 IIKGFCKPHSQPQWQALFEKTRLLCGATLIAPRWLLTAACHCLKPRYIVHLGQHNLOKEE 81

Oy 61 GCEQTRTATESFPHPGFNNSLPKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 120
 Db 82 GCEQTRTATESFPHPGFNNSLPKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 141

Oy 121 CLISGWGSTSSPOLRPHLTRCANITIIHOKCNAYPGNITDTWVCASVOEGKDCSCG 180
 Db 142 CLISGWGSTSSPOLRPHLTRCANITIIHOKCNAYPGNITDTWVCASVOEGKDCSCG 201

RESULT 4
 AAU12424
 ID AAU12424 standard; Protein: 250 AA.
 XX
 AC AAU12424;
 D^T 24-OCT-2001 (first entry)
 DE Human PRO1279 polypeptide sequence.
 DX Human secretory and transmembrane; PRO: mammalian; cancer; lung;
 KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
 KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
 KW adipocyte; A-peptide; factor VIIA; gene therapy.
 XX Homo sapiens.
 OS
 XX WO200140466-A2.
 XX 07-JUN-2001.
 XX 01-DEC-2000; 2000MO-US32678.
 XX 01-DEC-1999; 99MO-US28301.
 XX 01-DEC-1999; 99MO-US28534.
 XX 02-DEC-1999; 99MO-US28551.
 XX 02-DEC-1999; 99MO-US28564.
 XX 02-DEC-1999; 99MO-US28565.
 XX 09-DEC-1999; 99US-0170262.
 XX 16-DEC-1999; 99MO-US30095.
 XX 20-DEC-1999; 99MO-US30911.
 XX 20-DEC-1999; 99MO-US30999.
 XX 30-DEC-1999; 99MO-US31243.
 XX 06-JAN-2000; 2000MO-US02077.
 XX 06-JAN-2000; 2000MO-US03076.
 XX 11-FEB-2000; 2000MO-US03565.
 XX 18-FEB-2000; 2000MO-US04344.
 XX 18-FEB-2000; 2000MO-US04342.
 XX 22-FEB-2000; 2000MO-US04414.
 XX 24-FEB-2000; 2000MO-US04914.

24-FEB-2000; 2000MO-US05004.
 01-MAR-2000; 2000MO-US05601.
 20-MAR-2000; 2000MO-US07377.
 21-MAR-2000; 2000MO-US07532.
 30-MAR-2000; 2000MO-US08439.
 17-MAY-2000; 2000MO-US13705.
 22-MAY-2000; 2000MO-US14042.
 30-MAY-2000; 2000MO-US14941.
 02-JUN-2000; 2000MO-US15264.
 10-NOV-2000; 2000MO-US30873.
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI: 2001-408281/43.
 DR N-PSDB; AAS21496.
 XX
 PT Isolated, secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing
 PT PRO polypeptides, and detect the presence of mammalian tumours e.g.
 PT lung, breast, prostate, cervical
 XX
 PS Claim 12; Fig 506; 81pp; English.
 XX
 CC AAU12172-AAU12446 represent novel human secretory and transmembrane
 CC PRO polypeptides. The PRO polypeptides are useful to detect other
 CC PRO polypeptides, to link bioactive molecules to cells expressing
 CC PRO polypeptides, to modulate biological activities of cells expressing
 CC PRO polypeptides, and to detect the presence of mammalian lung, colon,
 CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
 CC polypeptide expression in a cell sample to that in a control sample.
 CC Some of the 275 sequences are also useful to stimulate the release of
 CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the
 CC proliferation or differentiation of chondrocytes, the proliferation or
 CC gene expression in pericyte cells, the release of proteoglycans from
 CC cartilage, the proliferation of inner ear utricular supporting cells or
 CC of T-lymphocytes, the release of a cytokine from peripheral blood
 CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of
 CC the PRO polypeptides may modulate glucose or free fatty acid uptake by
 CC skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
 CC to factor VIIA. The PRO polypeptides can be used in assays to identify
 CC molecules involved in binding interactions. The polynucleotides encoding
 CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,
 CC transgenic or knock out animals and can be used in gene therapy.
 XX
 SQ Sequence 250 AA;
 Query Match 100.0%; Score 1258; DB 22; Length 250;
 Best Local Similarity 100.0%; Pred. No. 6.3e-113; Indels 0; Gaps 0;
 Matches 229; Conservative 0; Mismatches 0;

Oy 1 IIKGFCKPHSQPQWQALFEKTRLLCGATLIAPRWLLTAACHCLKPRYIVHLGQHNLOKEE 60
 Db 22 IIKGFCKPHSQPQWQALFEKTRLLCGATLIAPRWLLTAACHCLKPRYIVHLGQHNLOKEE 81

Oy 61 GCEQTRTATESFPHPGFNNSLPKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 120
 Db 82 GCEQTRTATESFPHPGFNNSLPKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 141

Oy 121 CLISGWGSTSSPOLRPHLTRCANITIIHOKCNAYPGNITDTWVCASVOEGKDCSCG 180
 Db 142 CLISGWGSTSSPOLRPHLTRCANITIIHOKCNAYPGNITDTWVCASVOEGKDCSCG 201

Oy 181 DSGGPLVCNQSLOGIISWGQDPCAITRPGVYTKVKYVDWIQETMKN 229
 Db 202 DSGGPLVCNQSLOGIISWGQDPCAITRPGVYTKVKYVDWIQETMKN 250

RESULT 5
 AAB66139

ID AAB65139 standard; protein; 250 AA.
XX AAB65139;
AC
XX
DT 02-APR-2001 (first entry)
XX
DE Protein of the invention #51.
XX
XX Secreted; transmembrane; gene therapy.
XX
OS Unidentified.
XX
DN W0200078961-A1.
XX
XX 28-DEC-2000.
XX
XX 18-FEB-2000; 2000WO-US04342.
XX
XX 23-JUN-1999; 99US-0141037.
PR 20-JUL-1999; 99US-0144758.
PR 26-JUL-1999; 99US-0145698.
PR 01-SEP-1999; 99WO-US20111.
PR 29-OCT-1999; 99US-0162506.
PR 30-NOV-1999; 99WO-US28313.
PR 02-DEC-1999; 99WO-US28551.
PR 16-DEC-1999; 99WO-US30095.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Rotstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
PI Pan J, Peoni NF, Roy NA, Smith V, Stewart TA, Tumes D;
PI Matanabe CK, Williams PW, Wood WI;
XX
XX WPI; 2001-071395/08.
XX
XX Secreted and transmembrane proteins and nucleic acids designated PRO,
PT useful as hybridization probes, in chromosome and gene mapping and gene
PT therapy -
XX
XX Claim 1; Fig 102; 787pp; English.
XX
XX The present invention relates to secreted and transmembrane proteins.
CC These proteins and the DNA encoding them may be used as hybridization
CC probes, in chromosome and gene mapping and in the generation of
CC anti-sense RNA and DNA. They may also be used to generate either
CC transgenic animals or knockout animals which are in turn useful for
CC development and screening of therapeutically useful reagents.
CC The nucleic acids may also be used in gene therapy.
XX
XX Sequence 250 AA;
XX
Query Match 100.0%; Score 1258; DB 22; Length 250;
Best Local Similarity 100.0%; Pred. No. 6,3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 IIKGFECKPHSQPQWQAALFEKTLCCGATLAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
Db 22 IIKGFECKPHSQPQWQAALFEKTLCCGATLAPRWLLTAHCLKPRYIVHLGQHNLOKEE 81
QY 61 GCCTRTATESPHPGFNNSLPKDHNDIMLVKQASPSVITWVAPLTLSSRCVTAGTS 120
Db 82 GCCTRTATESPHPGFNNSLPKDHNDIMLVKQASPSVITWVAPLTLSSRCVTAGTS 141
QY 121 CLISGWSTSSPOLRLPHTLRCANITIEHQKCNAYPGNITDTWVCASVQEGKDSQCG 180
Db 142 CLISGWSTSSPOLRLPHTLRCANITIEHQKCNAYPGNITDTWVCASVQEGKDSQCG 201
QY 181 DSGGPLYCNOSLOGIISWGDDPCAITRKPVGVTYKVKYVDWIGETMKN 229
Db 202 DSGGPLYCNOSLOGIISWGDDPCAITRKPVGVTYKVKYVDWIGETMKN 250

RESULT 6
ABG61816
ID ABG61816 standard; Protein; 250 AA.
XX
XX AEG61816;
AC
XX
DT 15-AUG-2002 (first entry)
XX
XX Prostate cancer-associated protein #17.
XX
DE Prostate cancer; prostate tumour tissue; human; mammal; cytostatic.
XX
XX Mammalia.
OS
XX
XX W0200230268-A2.
XX
XX 18-APR-2002.
XX
XX 12-OCT-2001; 2001WO-US32045.
XX
XX 13-OCT-2000; 2000US-0687576.
PR 08-DEC-2000; 2000US-0733288.
PR 08-DEC-2000; 2000US-0733742.
PR 24-JAN-2001; 2001US-243957P.
PR 16-MAR-2001; 2001US-276791P.
PR 16-MAR-2001; 2001US-278888P.
PR 06-APR-2001; 2001US-281922P.
PR 24-APR-2001; 2001US-286214P.
PR 30-APR-2001; 2001US-0847046.
PR 04-MAY-2001; 2001US-288589P.
XX (SCSB-) EOS BIOTECHNOLOGY INC.
XX
XX Gish KC, Mack DH, Wilson KE, Afar D, Hevezi P;
XX
XX WPI; 2002-471135/50.
XX
XX N-PSDB; ABK92131.
XX
XX Detecting a prostate cancer-associated transcript in a cell in a
PT patient, useful for diagnosing prostate cancer (PC) or screening
PT modulators of PC, by determining if prostate cancer-associated genes
PT are expressed in a prostate tissue -
XX
XX Claim 27; Page 314; 436pp; English.
XX
XX The present invention relates to methods of detecting a prostate
CC cancer-associated transcript in a cell from a patient. The method
CC comprises contacting a biological sample from the patient with
CC prostate cancer-associated polynucleotides (designated PC genes) that
CC selectively hybridize to a sequence that is at least 80% identical
CC to them. The prostate cancer-associated polynucleotide sequences
CC are differentially expressed in prostate tumour tissue or in
CC prostate cancer and are derived from the tissues of various
CC organisms such as humans or other mammals (e.g. mice, sheep and dogs).
CC The methods of the invention are useful for diagnosing and treating
CC prostate cancer in mammals. The prostate cancer-associated genes are
CC useful for diagnosing or treating prostate cancer, as well as for
CC identifying modulators of prostate cancer or agents that inhibit
CC prostate cancer. The nucleic acid sequences are particularly useful
CC in gene therapy, as a vaccine or in antisense applications.
CC ASG61800-ASG61944 represent prostate cancer-associated proteins.
XX
XX Sequence 250 AA;
XX
Query Match 100.0%; Score 1258; DB 23; Length 250;
Best Local Similarity 100.0%; Pred. No. 6,3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 IIKGFECKPHSQPQWQAALFEKTLCCGATLAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
Db 22 IIKGFECKPHSQPQWQAALFEKTLCCGATLAPRWLLTAHCLKPRYIVHLGQHNLOKEE 81

QY 61 GCEQTRTATESPPHGGNNSLPNKOHNDIMLVKASPVSIWVRPLTSSRCVTAGTS 120
 DB 82 GCEQTRTATESPPHGGNNSLPNKOHNDIMLVKASPVSIWVRPLTSSRCVTAGTS 141
 QY 121 CLISGWGSTSSPQLRPLPHTLRCAITIEHQKCNAYPGNITDTWVCASVQEGKSCQ 180
 DB 142 CLISGWGSTSSPQLRPLPHTLRCAITIEHQKCNAYPGNITDTWVCASVQEGKSCQ 201
 QY 181 DSGGPLVNCNOSLQGIISWGQDPQCAITRKPGVYTKVCKYVDNIQETMKN 229
 DB 202 DSGGPLVNCNOSLQGIISWGQDPQCAITRKPGVYTKVCKYVDNIQETMKN 250

RESULT 7
 ABB95526
 ID ABB95526 standard; Protein; 250 AA.
 AC ABB95526;
 DT 19-JUL-2002 (first entry)
 XX Human angiogenesis related protein PRO1279 SEQ ID NO: 208.
 DE Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
 KM atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
 KW cardiac; cytosolic; antiangiogenic; hypotensive; vulnerary;
 KW antiarteriosclerotic.
 XX Homo sapiens.
 OS Homo sapiens.
 FN WO200208284-A2.
 XX 31-JAN-2002.
 XX 09-JUL-2001; 2001WO-US21735.
 XX 20-JUL-2000; 2000US-219556P.
 PR 25-JUL-2000; 2000US-220624P.
 PR 25-JUL-2000; 2000US-220654P.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 02-AUG-2000; 2000US-222595P.
 PR 17-AUG-2000; 2000US-264365P.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 07-SEP-2000; 2000US-230978P.
 PR 15-SEP-2000; 2000US-200000P.
 PR 18-SEP-2000; 2000US-0664610.
 PR 24-OCT-2000; 2000US-242922P.
 PR 08-NOV-2000; 2000US-0709238.
 PR 10-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US30873.
 PR 20-DEC-2000; 2000US-0747359.
 PR 20-DEC-2000; 2000WO-US34356.
 PR 22-JAN-2001; 2001US-0767609.
 PR 28-FEB-2001; 2001US-0796498.
 PR 01-MAR-2001; 2001WO-US06520.
 PR 09-MAR-2001; 2001US-0802706.
 PR 14-MAR-2001; 2001US-0808689.
 PR 22-MAR-2001; 2001US-0816744.
 PR 05-APR-2001; 2001US-0828366.
 PR 10-MAY-2001; 2001US-0854208.
 PR 25-MAY-2001; 2001US-0854280.
 PR 25-MAY-2001; 2001US-0865028.
 PR 25-MAY-2001; 2001US-0865034.
 PR 30-MAY-2001; 2001WO-US17092.
 PR 30-MAY-2001; 2001US-0870574.
 PR 01-JUN-2001; 2001WO-US17443.
 PR 20-JUN-2001; 2001WO-US19692.

28-JUN-2001; 2001WO-US00000.
 PR (GETH) GENENTECH INC.
 XX (BAKE) BAKER K P.
 PA (FERR) FERRARA N.
 PA (GERB) GERBER H.
 PA (GERE) GERBETSEN M E.
 PA (GODD) GODDARD A. J.
 PA (GODO) GODOWSKI P. J.
 PA (GURN) GURNEY A L.
 PA (HILL) HILLAN K J.
 PA (MARS) MARSTERS S A.
 PA (PANJ) PAN J.
 PA (PAON) PAONI N F.
 PA (STEP) STEPHAN J F.
 PA (WATA) WATANABE C K.
 PA (WILL) WILLIAMS P M.
 PA (WOOD) WOOD W I.
 XX Baker KP, Ferrara N, Gerber H, Gerbetsen ME, Goddard A,
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF,
 PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
 XX NPI; 2002-171999/22.
 DR N-PSDB; ABL95664.
 XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 PT infarction), endothelial or angiogenic disorders in a mammal -
 XX Claim 11; Fig 208; 567pp; English.
 PS The present invention provides the protein and coding sequences of human
 CC PRO proteins. These are useful for treating or diagnosing a
 CC cardiovascular, endothelial or angiogenic disorder, including cardiac
 CC hypertrophy, trauma, cancer, age-related macular degeneration,
 CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
 CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
 CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
 CC healing. The present sequence is a PRO protein of the invention.
 XX Sequence 250 AA;
 SQ Query Match 100.0%; Score 1258; DB 23; Length 250;
 Best Local Similarity 100.0%; Pred. No. 6.3e-113;
 Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 IIKGECKPHSPQWQALFEKTLCCGATLIAPRMLTAAHCLKPRVIVHLGQHNKKEE 60
 DB 22 IIKGECKPHSPQWQALFEKTLCCGATLIAPRMLTAAHCLKPRVIVHLGQHNKKEE 81
 QY 61 GCEQTRTATESPPHGGNNSLPNKOHNDIMLVKASPVSIWVRPLTSSRCVTAGTS 120
 DB 82 GCEQTRTATESPPHGGNNSLPNKOHNDIMLVKASPVSIWVRPLTSSRCVTAGTS 141
 QY 121 CLISGWGSTSSPQLRPLPHTLRCAITIEHQKCNAYPGNITDTWVCASVQEGKSCQ 180
 DB 142 CLISGWGSTSSPQLRPLPHTLRCAITIEHQKCNAYPGNITDTWVCASVQEGKSCQ 201
 QY 181 DSGGPLVNCNOSLQGIISWGQDPQCAITRKPGVYTKVCKYVDNIQETMKN 229
 DB 202 DSGGPLVNCNOSLQGIISWGQDPQCAITRKPGVYTKVCKYVDNIQETMKN 250

RESULT 8
 ABB84920
 ID ABB84920 standard; Protein; 250 AA.
 XX ABB84920;
 AC ABB84920;
 DT 16-MAY-2002 (first entry)
 XX Human PRO1279 protein sequence SEQ ID NO:208.
 DE

XX Human; angiogenesis; cardiatic; cytostatic; antiangiogenic; hypotensive;
KW vulnary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW age-related macular degeneration; arterial restenosis; angina;
KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW wound healing; chromosome mapping; gene mapping.
XX
OS Homo sapiens.
XX
EN WO200200690-A2.
XX
PD 03-JAN-2002.
XX
PF 20-JUN-2001; 2001WO-US19692.
XX
PR 23-JUN-2000; 2000US-213637P.
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220424P.
PR 25-JUL-2000; 2000US-220664P.
PR 26-JUL-2000; 2000WO-US20710.
PR 02-AUG-2000; 2000US-222895P.
PR 17-AUG-2000; 2000US-0643657.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 07-SEP-2000; 2000US-230978P.
PR 18-SEP-2000; 2000US-0656410.
PR 18-SEP-2000; 2000US-0655350.
PR 24-OCT-2000; 2000US-242922P.
PR 08-NOV-2000; 2000US-0709238.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 10-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 22-JAN-2001; 2001US-0767609.
PR 28-FEB-2001; 2001US-0796498.
PR 28-FEB-2001; 2001WO-US05520.
PR 01-MAR-2001; 2001WO-US05666.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828166.
PR 10-MAY-2001; 2001US-0854280.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 25-MAY-2001; 2001WO-US17092.
PR 30-MAY-2001; 2001US-0870574.
PR 30-MAY-2001; 2001WO-US17443.
PR 01-JUN-2001; 2001WO-US17800.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerecht ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI: 2002-090516/12.
DR N-PSDB; ABL88175.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX
XX Claim 11: Fig 20a; 565pp; English.
PS
XX ABL88072 to ABL88258 encode the PRO proteins given in ABL8817 to
CC ABL885003. The PRO proteins and polynucleotides have cardiac, cytostatic,
CC antiangiogenic, hypotensive, vulnary and antiarteriosclerotic
CC activities, and can be used in gene therapy. The PRO polynucleotides,

CC proteins, agonists and antagonists are useful for treating or diagnosing
CC a cardiovascular, endothelial or angiogenic disorder in a mammal,
CC e.g. cardiac hypertrophy, trauma, cancer, age-related macular
CC degeneration, atherosclerosis, hypertension, arterial restenosis,
CC rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,
CC lymphangitis, tumour angiogenesis (such as breast carcinoma and liver
CC carcinoma) and wound healing. The PRO polynucleotides have applications
CC in molecular biology, including use as hybridisation probes, and in
CC chromosome and gene mapping. ABL88259 to ABL88267 represent primers and
CC probes used in the exemplification of the present invention.
XX
XX Sequence 250 AA;
SQ
Query Match 100.0%; Score 1258; DB 23; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113; Indels 0; Gaps 0;
Matches 229; Conservative 0; Mismatches 0;
QY 1 IIKGFECKPHSQPQAAALFEKTLLOGATLIAPRNLTAACHCLAPRYIVHGLQHNLOKEE 60
DB 22 IIKGFECKPHSQPQAAALFEKTLLOGATLIAPRNLTAACHCLAPRYIVHGLQHNLOKEE 81
QY 61 GCEQTRTATESFPHPGFNNSLPNKHNDIMLVKVASPVSIITWAVRPLTSSRCVTAGTS 120
DB 82 GCEQTRTATESFPHPGFNNSLPNKHNDIMLVKVASPVSIITWAVRPLTSSRCVTAGTS 141
QY 121 CLISGWSTSSPOLRLPHTLRCANITIIHQKCNAYFGNITDTMVCASVOEGGKDCQCG 180
DB 142 CLISGWSTSSPOLRLPHTLRCANITIIHQKCNAYFGNITDTMVCASVOEGGKDCQCG 201
QY 181 DSGGPLVCNQSLQIIISWGQDPCAIITRKPGVYTKVCKYVDMIOETMKN 229
DB 202 DSGGPLVCNQSLQIIISWGQDPCAIITRKPGVYTKVCKYVDMIOETMKN 250
RESULT 9
AAU83684
ID AAU83684 standard; Protein; 250 AA.
XX
AC AAU83684;
XX
DT 08-MAY-2002 (first entry)
XX
DE Human PRO protein, Seq ID No 186.
XX
XX Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha.
XX
OS Homo sapiens.
XX
XX WO200208288-A2.
XX
XX 31-JAN-2002.
XX
XX 29-JUN-2001; 2001WO-US21066.
XX
XX 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220585P.
PR 25-JUL-2000; 2000US-220605P.
PR 25-JUL-2000; 2000US-220607P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220638P.
PR 25-JUL-2000; 2000US-220664P.
PR 25-JUL-2000; 2000US-220666P.
PR 26-JUL-2000; 2000US-220893P.
PR 28-JUL-2000; 2000WO-US20710.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 15-SEP-2000; 2000US-000000P.
PR 10-NOV-2000; 2000WO-US30873.
PR 28-NOV-2000; 2000US-253646P.
PR 01-DEC-2000; 2000WO-US32678.

PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000MO-US34956.
PR 28-FEB-2001; 2001MO-US06520.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001MO-US17092.
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Desnoyers L, Gerritsen ME, Coddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI N-PSDB; ABX33628.
DR WP1; 2002-172001/22.
DR N-PSDB; ABX33628.
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumours
PT such as lung cancer, colon cancer, breast tumour, prostate tumour, rectal
PT tumour or liver tumour
XX
PS Claim 11; Figure 186; 359pp; English.
XX The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumours, especially lung
CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. The PRO polypeptides are useful for stimulating the
CC proliferation of, or gene expression, in pericyte cells, for stimulating
CC the proliferation or differentiation of chondrocyte cells, for
CC stimulating the release of tumour necrosis factor-alpha from human blood,
CC for stimulating or inhibiting the proliferation of normal human dermal
CC fibroblast cells. The PRO polypeptide may also be used as molecular
CC weight markers and for tissue typing. The PRO nucleic acids have
CC applications in molecular biology, including use as hybridisation probes,
CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
CC protein sequences of the invention.
XX
SQ Sequence 250 AA;
Query Match 100.0%; Score 1258; DB 23; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 IIKGFECKPHSQPQWQALFETRLCCATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
Db 22 IIKGFECKPHSQPQWQALFETRLCCATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 81
Qy 61 GGEQRTATSPHGFPGNNSLPNKHNDIMLVKMASPVSIITWAVRPLTSSRCVTAGTS 120
Db 82 GGEQRTATSPHGFPGNNSLPNKHNDIMLVKMASPVSIITWAVRPLTSSRCVTAGTS 141
Qy 121 CLISGWGTSSTPQLRPLHPTLRCAITTIIEHQKCNAYPGNITDTWVCASVQEGKDSQCG 180
Db 142 CLISGWGTSSTPQLRPLHPTLRCAITTIIEHQKCNAYPGNITDTWVCASVQEGKDSQCG 201
Qy 181 DSGGPLVCNQSLOGIISWQDPCAITRKPGYTKVCKYVDWIQETMKN 229
Db 202 DSGGPLVCNQSLOGIISWQDPCAITRKPGYTKVCKYVDWIQETMKN 250
RESULT 10
ABU6822
ID ABU6822 standard; Protein; 250 AA.
XX
AC ABU6822;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human PRO polypeptide #253.
XX
XX Human; PRO polypeptide; secreted and transmembrane protein;
KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
XX

KW differentiation; chondrocyte; tumour; genetic disorder;
XX cytostatic.
OS Homo sapiens.
XX
PN US2003036180-A1.
XX
PD 20-FEB-2003.
XX
XX 09-MAY-2002; 2002US-0143114.
XX
XX 31-MAR-1997; 97MO-US05230.
PR 12-JUN-1998; 98MO-US12456.
PR 14-JUL-1998; 98MO-US14552.
PR 28-AUG-1998; 98MO-US17888.
PR 10-SEP-1998; 98MO-US18824.
PR 14-SEP-1998; 98MO-US19093.
PR 14-SEP-1998; 98MO-US19094.
PR 14-SEP-1998; 98MO-US19177.
PR 16-SEP-1998; 98MO-US19330.
PR 17-SEP-1998; 98MO-US19437.
PR 07-OCT-1998; 98MO-US21141.
PR 29-OCT-1998; 98MO-US22991.
PR 29-OCT-1998; 98MO-US22992.
PR 20-NOV-1998; 98MO-US24855.
PR 01-DEC-1998; 98MO-US25108.
PR 05-JAN-1999; 99MO-US00106.
PR 08-MAR-1999; 99MO-US05028.
PR 10-MAR-1999; 99MO-US05190.
PR 20-APR-1999; 99MO-US08615.
PR 14-MAY-1999; 99MO-US10733.
PR 02-JUN-1999; 99MO-US12252.
PR 01-SEP-1999; 99MO-US20111.
PR 08-SEP-1999; 99MO-US20594.
PR 13-SEP-1999; 99MO-US20944.
PR 15-SEP-1999; 99MO-US21090.
PR 15-SEP-1999; 99MO-US21547.
PR 03-OCT-1999; 99MO-US23089.
PR 29-NOV-1999; 99MO-US28214.
PR 30-NOV-1999; 99MO-US28313.
PR 30-NOV-1999; 99MO-US28409.
PR 01-DEC-1999; 99MO-US28301.
PR 01-DEC-1999; 99MO-US28634.
PR 02-DEC-1999; 99MO-US28551.
PR 02-DEC-1999; 99MO-US28564.
PR 02-DEC-1999; 99MO-US28565.
PR 16-DEC-1999; 99MO-US30095.
PR 20-DEC-1999; 99MO-US30911.
PR 20-DEC-1999; 99MO-US30999.
PR 22-DEC-1999; 99MO-US30720.
PR 30-DEC-1999; 99MO-US31243.
PR 30-DEC-1999; 99MO-US31274.
PR 03-JAN-2000; 2000MO-US00219.
PR 06-JAN-2000; 2000MO-US00277.
PR 06-JAN-2000; 2000MO-US00376.
PR 11-FEB-2000; 2000MO-US03565.
PR 18-FEB-2000; 2000MO-US04341.
PR 18-FEB-2000; 2000MO-US04342.
PR 22-FEB-2000; 2000MO-US04414.
PR 24-FEB-2000; 2000MO-US04914.
PR 24-FEB-2000; 2000MO-US05004.
PR 01-MAR-2000; 2000MO-US05601.
PR 02-MAR-2000; 2000MO-US05746.
PR 02-MAR-2000; 2000MO-US05841.
PR 10-MAR-2000; 2000MO-US06319.
PR 15-MAR-2000; 2000MO-US06884.
PR 20-MAR-2000; 2000MO-US07377.
PR 21-MAR-2000; 2000MO-US07532.
PR 30-MAR-2000; 2000MO-US08439.
PR 17-MAY-2000; 2000MO-US13705.
PR 22-MAY-2000; 2000MO-US14042.
PR 30-MAY-2000; 2000MO-US14941.
PR 02-JUN-2000; 2000MO-US15264.

PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0806889.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0909827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-332040/31.
DR N-PSDB; ACA03855.

XX New secreted and transmembrane PRO nucleic acids, useful for gene
XX therapy, in chromosome and gene mapping, as chromosome markers, in
XX tissue typing, and in chromosome identification
XX
XX Claim 12; Fig 506; 660pp; English.

XX The present invention relates to the isolation of novel human PRO
XX polypeptides, and the polynucleotide sequences encoding them. The
XX PRO polypeptides are secreted and transmembrane proteins. The PRO
XX polypeptides are useful for detecting other PRO polypeptides, for
XX linking bioactive molecules to cells expressing PRO polypeptides,
XX for modulating biological activities of cells expressing PRO
XX polypeptides, and for identifying agonists or antagonists.
XX The PRO polypeptides are useful for stimulating the release of
XX tumour necrosis factor (TNF)-alpha from human blood, for stimulating
XX the proliferation or differentiation of chondrocytes, and detecting the
XX presence of tumours. The polynucleotide sequences encoding PRO
XX polypeptides are useful as hybridisation probes, in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptides, for generating transgenic animals or
XX knockout animals, for the genetic analysis of individuals with genetic
XX disorders, and in gene therapy. ASU6570-ASU66844 represent the human
XX PRO polypeptides of the invention.
XX Note: The sequence data for this patent was obtained in electronic
XX format directly from the USPTO web site at
XX seqdata.uspto.gov/psipdbEntry.html.

XX 90 Sequence 250 AA;
XX Query Match 100.0%; Score 1258; DB 24; Length 250;
XX Best Local Similarity 100.0%; Pred. No. 6.3e-113;
XX Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy. 1 IIKGECKPHSQPQAAALPEKTELLCGATLIAPRWLLTAACHLAPRYIVHLGQHNLOKEE 60
Db 22 IIKGECKPHSQPQAAALPEKTELLCGATLIAPRWLLTAACHLAPRYIVHLGQHNLOKEE 81
Qy 61 GCEQTRTATESFPHPGNNSLPKQKHNDIMLVKASPVSIITWAVRDLTSSRCVITAGTS 120
Db 82 GCEQTRTATESFPHPGNNSLPKQKHNDIMLVKASPVSIITWAVRDLTSSRCVITAGTS 141
Qy 121 CLISGWGSTSSPQLRLPHTLRCAITIIIEHOKCENAYPGNITDTMVCASVQEGKDSQCG 180
Db 142 CLISGWGSTSSPQLRLPHTLRCAITIIIEHOKCENAYPGNITDTMVCASVQEGKDSQCG 201
Qy 181 DSGGPLVCNQSLOQIIISWGODPCAITRKPGVTVTKYKVDWIQETMKNN 229
Db 202 DSGGPLVCNQSLOQIIISWGODPCAITRKPGVTVTKYKVDWIQETMKNN 250
RESULT 11
ABU67098
ID ABU67098 standard; Protein; 250 AA.
XX AC ABU67098;
XX DT 27-MAY-2003 (first entry)
XX DE Human secreted/transmembrane, PRO, protein SEQ ID 506.
XX KW Human; secreted protein; transmembrane protein; PRO;
XX inflammatory disease; organ failure; atherosclerosis; cardiac injury;
XX infertility; birth defects; premature aging; AIDS; biosensor;
XX acquired immunodeficiency syndrome; cancer; diabetic complication;
XX bioreactor; tumour.
XX OS Homo sapiens.
XX PN US2003032155-A1.
XX PD 13-FEB-2003.
XX PF 03-MAY-2002; 2002US-0137865.
XX 31-MAR-1997; 97WO-US05230.
XX 12-JUN-1998; 98WO-US12456.
XX 14-JUL-1998; 98WO-US14552.
XX 28-AUG-1998; 98WO-US17888.
XX 10-SEP-1998; 98WO-US18824.
XX 14-SEP-1998; 98WO-US19093.
XX 14-SEP-1998; 98WO-US19094.
XX 16-SEP-1998; 98WO-US19177.
XX 17-SEP-1998; 98WO-US19330.
XX 17-SEP-1998; 98WO-US19437.
XX 07-OCT-1998; 98WO-US21141.
XX 23-OCT-1998; 98WO-US22931.
XX 20-NOV-1998; 98WO-US24855.
XX 01-DEC-1998; 98WO-US25108.
XX 05-JAN-1999; 99WO-US00106.
XX 08-MAR-1999; 99WO-US05028.
XX 10-MAR-1999; 99WO-US05190.
XX 20-APR-1999; 99WO-US08615.
XX 14-MAY-1999; 99WO-US10733.
XX 02-JUN-1999; 99WO-US12252.
XX 01-SEP-1999; 99WO-US20111.
XX 08-SEP-1999; 99WO-US20594.
XX 13-SEP-1999; 99WO-US20944.
XX 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.
 PR 05-OCT-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US28313.
 PR 30-NOV-1999; 99WO-US28409.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 02-DEC-1999; 99WO-US28551.
 PR 02-DEC-1999; 99WO-US28564.
 PR 02-DEC-1999; 99WO-US28565.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US30999.
 PR 22-DEC-1999; 99WO-US30720.
 PR 30-DEC-1999; 99WO-US31243.
 PR 30-DEC-1999; 99WO-US31274.
 PR 05-JAN-2000; 2000WO-US02119.
 PR 06-JAN-2000; 2000WO-US02377.
 PR 06-JAN-2000; 2000WO-US03076.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04311.
 PR 18-FEB-2000; 2000WO-US04342.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05094.
 PR 01-MAR-2000; 2000WO-US05146.
 PR 02-MAR-2000; 2000WO-US05146.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 21-MAR-2000; 2000WO-US07532.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23322.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 10-NOV-2000; 2000WO-US30873.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 20-DEC-2000; 2000WO-US34956.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-MAR-2001; 2001WO-US06666.
 PR 25-MAY-2001; 2001WO-US17092.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US20116.
 PR 09-JUL-2001; 2001WO-US21066.
 PR 20-DEC-2000; 2000US-0747259.
 PR 28-FEB-2001; 2001US-0796498.
 PR 09-MAR-2001; 2001US-0802706.
 PR 22-MAR-2001; 2001US-0808689.
 PR 05-APR-2001; 2001US-0828366.
 PR 10-MAY-2001; 2001US-0854208.
 PR 18-MAY-2001; 2001US-0860216.
 PR 25-MAY-2001; 2001US-0866028.
 PR 25-MAY-2001; 2001US-0866034.
 PR 01-JUN-2001; 2001US-0872035.
 PR 05-JUN-2001; 2001US-0874503.
 PR 14-JUN-2001; 2001US-0882636.
 PR 19-JUN-2001; 2001US-0886342.
 PR 21-JUN-2001; 2001US-0887879.
 PR 18-JUL-2001; 2001US-0906827.
 PR 06-AUG-2001; 2001US-0924419.
 PR 08-AUG-2001; 2001US-0927756.
 PR 16-AUG-2001; 2001US-0931836.

PR 19-DEC-2001; 2001US-0028072.
 XX (GETH) GENENTECH INC.
 PI Baker KF, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Grithsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-331925/31.
 DR N-PSDB; ACA04276.
 XX New secreted and transmembrane nucleic acids and polypeptides
 PT designated as PRO, useful for treating inflammation, organ failure,
 PT atherosclerosis, cardiac injury, infertility, birth defects, premature
 PT aging, AIDS, or cancer.
 XX
 XX Claim 12; Fig 506; 659pp; English.
 XX The invention relates to an isolated nucleic acid comprising, or which is
 CC at least 80% identical to, or the full-length coding sequence of, any of
 CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
 CC (one of 275 secreted or transmembrane proteins). The nucleic acid
 CC further comprises the full-length coding sequence of the DNA deposited
 CC under American Type Culture Collection (ATCC) accession number in a list
 CC given in the specification. Also included are vectors and host
 CC cells for producing PRO proteins, PRO fusion proteins, anti-PRO
 CC antibodies, PRO extracellular domains and mature sequences, methods
 CC of detecting PRO proteins, methods for stimulating the release of
 CC TNF-alpha (tumour necrosis factor alpha) from human blood,
 CC (and the proliferation of differentiation of chondrocyte cells, the
 CC proliferation of, or gene expression in pericyte cells, the release or
 CC proteoglycans from cartilage, proliferation of inner ear utricular
 CC supporting cells, the proliferation of T-lymphocyte cells, the release
 CC of a cytokine from peripheral blood mononuclear cells (PBMC), or the
 CC proliferation of endothelial cells), a method for modulating the uptake
 CC of glucose or free fatty acid (FFA) by skeletal muscle cells,
 CC a method for inhibiting the binding of A-peptide to factor VIIA,
 CC or the differentiation of adipocyte cells, a method for detecting the
 CC presence of a tumour in a mammal and an oligonucleotide probe derived
 CC from any of the nucleotide sequences cited above. The nucleic acids and
 CC polypeptides are useful for treating inflammatory diseases, organ
 CC failure, atherosclerosis, cardiac injury, infertility, birth defects,
 CC premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or
 CC diabetic complications. The nucleic acids are useful as hybridisation
 CC probes, in chromosome and gene mapping, and in generating antisense RNA
 CC or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,
 CC biosensors or bioreactors. Both are useful in tissue typing.
 CC The present sequence represents a PRO protein of the invention.
 XX
 SQ Sequence 250 AA;

Query Watch 100.0%; Score 1258; DB 24; Length 250;
 Best Local Similarity 100.0%; Pred. No. 6, 3e-113;
 Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IKGFECKPHSQWQALPEKTRLLCGATLIAPRNLTAHCKLPRIYVHIGQNLKOE 60
 DB 22 IKGFECKPHSQWQALPEKTRLLCGATLIAPRNLTAHCKLPRIYVHIGQNLKOE 81
 QY 61 GCEQTRTATESPHFGPNNSLPNKDRNDIMLVKMASPVSIITWVRPLTSSRCVTACTS 120
 DB 82 GCEQTRTATESPHFGPNNSLPNKDRNDIMLVKMASPVSIITWVRPLTSSRCVTACTS 141
 QY 131 CLISGSGTSSPOLRPLHTLRCANITIIHQKCNAYPCNITDTWVCASVQGGKDCSQG 180
 DB 142 CLISGSGTSSPOLRPLHTLRCANITIIHQKCNAYPCNITDTWVCASVQGGKDCSQG 201
 QY 181 DSGGPLVCNOSLOGIISGQDPFCALTRKPGVYTKCKYVDNIQETMGN 229
 DB 202 DSGGPLVCNOSLOGIISGQDPFCALTRKPGVYTKCKYVDNIQETMGN 250

RESULT 12

ABUS9903
 ID ABUS9903 standard; Protein; 250 AA.
 XX AC ABUS9903;
 XX DT 13-MAY-2003 (first entry)
 XX DE Novel secreted and transmembrane protein PRO1279.
 XX KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
 KW cardiac insufficiency disorder; cancer; tumour; immune response;
 KW adrenal cortical capillary endothelial growth; c-fos induction;
 KW vascular endothelial growth factor inhibition; VEGF inhibition;
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
 KW retinal neurons cell survival; rod photoreceptor cell survival;
 KW retinal disorder; retinitis pigmentosa; kidney disorder;
 KW mammalian kidney mesangial cell proliferation; Berger disease;
 KW chondrocyte redifferentiation; Crohn's disease; chondrocyte proliferation;
 XX OS Homo sapiens.
 XX PN US2003017563-A1.
 XX PD 23-JAN-2003.
 XX PF 07-MAY-2002; 2002US-0146808.
 XX PR 31-MAR-1997; 97WO-US05230.
 PR 12-JUN-1998; 98WO-US12456.
 PR 14-JUL-1998; 98WO-US14552.
 PR 28-AUG-1998; 98WO-US17888.
 PR 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19093.
 PR 14-SEP-1998; 98WO-US19094.
 PR 14-SEP-1998; 98WO-US19177.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 29-OCT-1998; 98WO-US22991.
 PR 29-OCT-1998; 98WO-US22992.
 PR 20-NOV-1998; 98WO-US24855.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 10-MAR-1999; 99WO-US05190.
 PR 20-APR-1999; 99WO-US08615.
 PR 14-MAY-1999; 99WO-US10733.
 PR 02-JUN-1999; 99WO-US12252.
 PR 01-SEP-1999; 99WO-US20111.
 PR 08-SEP-1999; 99WO-US20594.
 PR 13-SEP-1999; 99WO-US20944.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 05-OCT-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US28313.
 PR 30-NOV-1999; 99WO-US28409.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 02-DEC-1999; 99WO-US28551.
 PR 02-DEC-1999; 99WO-US28564.
 PR 02-DEC-1999; 99WO-US28565.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US30999.
 PR 22-DEC-1999; 99WO-US30720.
 PR 30-DEC-1999; 99WO-US31243.
 PR 30-DEC-1999; 99WO-US31274.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00277.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03655.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 18-FEB-2000; 2000WO-US04342.
 PR 22-FEB-2000; 2000WO-US04344.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 01-MAR-2000; 2000WO-US05601.
 PR 02-MAR-2000; 2000WO-US05746.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 21-MAR-2000; 2000WO-US07532.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15284.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 10-NOV-2000; 2000WO-US30873.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 20-DEC-2000; 2000WO-US34956.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-MAR-2001; 2001WO-US06666.
 PR 23-MAY-2001; 2001WO-US17092.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 22-JUN-2001; 2001WO-US20116.
 PR 23-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 20-DEC-2000; 2000US-0747259.
 PR 28-FEB-2001; 2001US-0796498.
 PR 09-MAR-2001; 2001US-0802706.
 PR 14-MAR-2001; 2001US-0808689.
 PR 22-MAR-2001; 2001US-0816744.
 PR 05-APR-2001; 2001US-0828366.
 PR 10-MAY-2001; 2001US-0854208.
 PR 10-MAY-2001; 2001US-0854280.
 PR 18-MAY-2001; 2001US-0860216.
 PR 25-MAY-2001; 2001US-0866028.
 PR 25-MAY-2001; 2001US-0866034.
 PR 01-JUN-2001; 2001US-0872035.
 PR 05-JUN-2001; 2001US-0874503.
 PR 14-JUN-2001; 2001US-0882636.
 PR 19-JUN-2001; 2001US-0886342.
 PR 21-JUN-2001; 2001US-0887879.
 PR 18-JUL-2001; 2001US-0908827.
 PR 06-AUG-2001; 2001US-0924419.
 PR 09-AUG-2001; 2001US-0927756.
 PR 16-AUG-2001; 2001US-0931836.
 PR 19-DEC-2001; 2001US-0028072.
 XX (GETH) GENENTECH INC.
 XX Baker KF, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-148238/14.
 XX N-PSDB; ABX89393.
 XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
 PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
 PT are therapeutically useful for enhancing immune response and in cancer
 PT treatments -
 XX Claim 12; Fig 506; 659pp; English.
 PS The invention describes an isolated human PRO polypeptide. The PRO
 XX polypeptides are useful in detecting PRO polypeptides in a sample, in
 CC

CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth and PRO1336,
CC PRO1343, PRO1362, PRO1375, PRO1386, PRO1392, PRO1399, PRO1406,
CC PRO1430, and PRO1437 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and angiogenesis of this polypeptide are
CC useful for treating cancerous tumours. PRO112 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO1326,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO128, PRO1286, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosa, AMD, PRO19, PRO113
CC and PRO1068 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's
CC disease. PRO1310, PRO1312, PRO1313, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and
CC are thus useful for treating sports injuries, and arthritis. This
CC is the amino acid sequence of a novel human PRO protein.

XX SQ Sequence 250 AA;
Query Match 100.0%; Score 1258; DB 24; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 IKGFECKPHSQPQAAALFEKTRLLCGATLIAPRWLTAAHCLKPRYIVHLOHNLQKEE 60
Db 22 IKGFECKPHSQPQAAALFEKTRLLCGATLIAPRWLTAAHCLKPRYIVHLOHNLQKEE 81
Qy 61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSIITWAVRPLTLSSRCVTAGTS 120
Db 82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSIITWAVRPLTLSSRCVTAGTS 141
Qy 121 CLISGWGSTSSPOLRLPHTLRCAITIEHOKCENAYPGNITDTWVCASVQEGKDSQCG 180
Db 142 CLISGWGSTSSPOLRLPHTLRCAITIEHOKCENAYPGNITDTWVCASVQEGKDSQCG 201
Qy 181 DSGGPLVCNQSLOGIISWGQDPCAITRPGVYTKVYVDWIQETMKN 229
Db 202 DSGGPLVCNQSLOGIISWGQDPCAITRPGVYTKVYVDWIQETMKN 250

RESULT 13
ABUS6739
ID ABUS6739 standard; Protein; 250 AA.
XX AC ABUS6739;
XX AC ABUS6739;
DT 02-APR-2003 (first entry)
XX Lung cancer-associated polypeptide #332.
KW Lung cancer-associated polypeptide; cytostatic; emphysema;
KW antiinflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;
KW small cell lung cancer; benign lesion; precancerous lesion; bronchitis;
KW chronic obstructive pulmonary disease; hypersensitivity pneumonitis;
KW interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis.
XX Unidentified.
OS Unidentified.
XX WO200286443-A2.
PN 31-OCT-2002.
XX 31-OCT-2002.
XX

PF 18-APR-2002; 2002MO-US12476.
XX 18-APR-2001; 2001US-284770P.
PR 10-MAY-2001; 2001US-290492P.
PR 09-NOV-2001; 2001US-319245P.
PR 13-NOV-2001; 2001US-350656P.
PR 29-NOV-2001; 2001US-334370P.
PR 12-APR-2002; 2002US-372246P.
XX (EOSB-) EOS BIOTECHNOLOGY INC.
PA Aziz N, Murray R;
PI MPI: 2003-093161/08.
XX N-PSDB; ABX76468.
DR Detecting a lung cancer-associated transcript in a cell from a patient
XX for treating lung cancer, by contacting a biological sample from the
PT patient with a polynucleotide that exhibits increased or decreased
PT expression in lung cancer
XX
PS Claim 27; Page 443-444; 453pp; English.
XX The invention relates to a method for detecting a lung cancer-associated
CC transcript in a cell from a patient, comprising contacting a biological
CC sample from the patient with a polynucleotide that selectively hybridises
CC to a sequence that is at least 80 % identical to a gene that exhibits
CC increased or decreased expression in lung cancer samples. Lung
CC cancer-associated polynucleotides and polypeptides are used for
CC identifying a compound that modulates a lung cancer-associated
CC polypeptide, for inhibiting proliferation of a lung cancer-associated
CC cell, to treat lung cancer in a patient and for treating a mammal having
CC lung cancer by administering a modulatory compound identified. The
CC methods are useful for treating lung cancer, such as small cell lung
CC cancer, non-small cell lung cancer or other benign or precancerous
CC lesions, e.g. atelectasis, emphysema, bronchitis, chronic obstructive
CC pulmonary disease, fibrosis, hypersensitivity pneumonitis, interstitial
CC and polypeptides are useful for diagnostic purposes and as targets for
CC screening for therapeutic compounds that modulate lung cancer, such as
CC antibodies. Sequences ABUS6408-ABUS6745 represent lung cancer-associated
CC polypeptides of the invention.
XX SQ Sequence 250 AA;
Query Match 100.0%; Score 1258; DB 24; Length 250;
Best Local Similarity 100.0%; Pred. No. 6.3e-113;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 IKGFECKPHSQPQAAALFEKTRLLCGATLIAPRWLTAAHCLKPRYIVHLOHNLQKEE 60
Db 22 IKGFECKPHSQPQAAALFEKTRLLCGATLIAPRWLTAAHCLKPRYIVHLOHNLQKEE 81
Qy 61 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSIITWAVRPLTLSSRCVTAGTS 120
Db 82 GCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSIITWAVRPLTLSSRCVTAGTS 141
Qy 121 CLISGWGSTSSPOLRLPHTLRCAITIEHOKCENAYPGNITDTWVCASVQEGKDSQCG 180
Db 142 CLISGWGSTSSPOLRLPHTLRCAITIEHOKCENAYPGNITDTWVCASVQEGKDSQCG 201
Qy 181 DSGGPLVCNQSLOGIISWGQDPCAITRPGVYTKVYVDWIQETMKN 229
Db 202 DSGGPLVCNQSLOGIISWGQDPCAITRPGVYTKVYVDWIQETMKN 250
RESULT 14
AAV42439
ID AAV42439 standard; Protein; 282 AA.
XX AC AAV42439;
XX AC AAV42439;
DT 08-DEC-1999 (first entry)
DT

XX CASB12 amino acid sequence.
DE neuropsin; cancer; assay; inhibitor; serine protease; immunogenic;
XX autoimmune disease.
KW Homo sapiens.
XX
XX W09949055-A1.
XX
XX 30-SEP-1999.
XX
XX 17-MAR-1999; 99WO-EP01894.
XX
XX 20-MAR-1998; 98CB-0006095.
XX
XX (SMIK) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Bruck CEM, Cassart J, Coche T, Vinale-bassols C;
XX
XX WPI; 1999-580450/49.
XX
XX N-PSDB; AA222638.
XX
XX New human serine protease CASB12, for treatment, prevention and
XX diagnosis of cancer and autoimmune diseases -
XX
XX Claim 3; Page 48; 58pp; English.
XX
XX This is the amino acid sequence of the CASB12 protein. The nucleotide
XX sequence of AA222638 shows homology with neutropsin and the encoded
XX protein AA24239 is structurally related to other proteins of the
XX serine protease family, having homology and/or structural similarity
XX with neutropsin. It is expected that as well as similar structure, these
XX proteins will also share similar biological functions and properties.
XX The CASB12 polypeptides and polynucleotides can be used to develop
XX methods for identifying agonists and antagonists/inhibitors of these
XX molecules, and thereby treating conditions associated with CASB12
XX polypeptide imbalance. The invention also provides for diagnostic assays
XX for detecting diseases associated with inappropriate CASB12 polypeptide
XX activity or levels.
XX Since CASB12 is either specifically expressed or highly over-expressed
XX in tumors compared to normal cells, the polypeptides and polynucleotides
XX of the invention are believed to be important immunogens for specific
XX prophylactic or therapeutic immunization against tumors. The
XX polypeptides and polynucleotides can therefore be targeted by antigen
XX specific immune reactions (which result in the destruction of the tumor
XX cell) or they can be used to diagnose the occurrence of tumor cells
XX
XX Sequence 282 AA;
XX
XX Query Match 100.0%; Score 1258; DB 20; Length 282;
XX Best Local Similarity 100.0%; Pred. No. 7.4e-113;
XX Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 IIKGFECKPHSQPQQAALFEKTRLLCGATLTAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
XX
XX 54 IIKGFECKPHSQPQQAALFEKTRLLCGATLTAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 113
XX
XX 61 GCEQTRTATESFPHGPNNSLPNKDHRNDIMLVKASPVSTITWVRPLTSSRCVTAGTS 120
XX
XX 114 GCEQTRTATESFPHGPNNSLPNKDHRNDIMLVKASPVSTITWVRPLTSSRCVTAGTS 173
XX
XX 121 CLISGMGSTSSPOLRPLHTLRCAITITIEHOKENAYPGNITDTWVCASVQEGGKDCSQG 180
XX
XX 174 CLISGMGSTSSPOLRPLHTLRCAITITIEHOKENAYPGNITDTWVCASVQEGGKDCSQG 233
XX
XX 181 DSGGFLVCSNQLGIIISWQDDPCAITRPGVYTKYKVDNIQETMKNN 229
XX
XX 234 DSGGFLVCSNQLGIIISWQDDPCAITRPGVYTKYKVDNIQETMKNN 282
XX
XX RESULT 15
XX AAB11712

ID AAB11712 standard; Protein; 282 AA.
XX
XX AAB11712;
XX
XX 23-OCT-2000 (first entry)
XX
XX Human serine protease BSSP6 (hBSSP6) SEQ ID NO:2.
XX
XX BSSP6; serine protease; human; hBSSP6; mouse; mBSSP6; brain;
XX diagnostic marker; antibody; transgenic animal; Alzheimer's disease;
XX epilepsy; cancer; inflammation; infertility; pancreatitis;
XX prostatic hypertrophy.
XX
XX Homo sapiens.
XX
XX W0200031257-A1.
XX
XX 02-JUN-2000.
XX
XX 19-NOV-1999; 99WO-JP06476.
XX
XX 20-NOV-1998; 98JP-0347802.
XX
XX (FUSO) FUSO PHARM IND LTD.
XX
XX Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;
XX
XX WPI; 2000-400067/34.
XX
XX N-PSDB; AAA61763.
XX
XX Serine protease BSSP6, useful in detecting homologs, mutants and
XX polymorphic variants as markers for diagnosis of Alzheimer's disease,
XX epilepsy, cancer, inflammation, infertility and prostate hypertrophy,
XX using blood or other tissues -
XX
XX Claim 1; Page 69-70; 94pp; Japanese.
XX
XX The invention relates to novel serine proteases designated BSSP6
XX (AAB11712-B11714), and to nucleic acids encoding them (AAA61763-AAA61765).
XX The invention also relates to vectors and transformants comprising BSSP6
XX nucleic acids; transgenic animals in which the expression level of BSSP6
XX can be varied; and an mBSSP6 knockout mouse. The invention additionally
XX encompasses anti-BSSP6 antibodies and methods of production of such
XX antibodies, methods of BSSP6 detection using the antibodies, and the
XX use of BSSP6 proteins or fragments as diagnostic markers for certain
XX medical conditions. Nucleotides encoding BSSP6 were initially
XX isolated in a human brain cDNA library using degenerate PCR primers
XX (AAA61795-AAA61796) based on conserved regions of serine proteases. The
XX BSSP6 serine proteases and nucleotides encoding them are useful in
XX detecting homologues, mutants and polymorphic variants in biological
XX samples (e.g., blood, urine, brain, prostate gland, placenta, testis
XX and spleen) as diagnostic markers for conditions such as Alzheimer's
XX disease, epilepsy, cancer, inflammation, infertility and prostatic
XX hypertrophy. Sequences AAB11712 and AAB11714 represent human BSSP6
XX variants (hBSSP6), and sequence AAB11713 represents murine BSSP6
XX (mBSSP6).
XX
XX Sequence 282 AA;
XX
XX Query Match 100.0%; Score 1258; DB 21; Length 282;
XX Best Local Similarity 100.0%; Pred. No. 7.4e-113;
XX Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 IIKGFECKPHSQPQQAALFEKTRLLCGATLTAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
XX
XX 54 IIKGFECKPHSQPQQAALFEKTRLLCGATLTAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 113
XX
XX 61 GCEQTRTATESFPHGPNNSLPNKDHRNDIMLVKASPVSTITWVRPLTSSRCVTAGTS 120
XX
XX 114 GCEQTRTATESFPHGPNNSLPNKDHRNDIMLVKASPVSTITWVRPLTSSRCVTAGTS 173
XX
XX 121 CLISGMGSTSSPOLRPLHTLRCAITITIEHOKENAYPGNITDTWVCASVQEGGKDCSQG 180
XX
XX RESULT 15
XX AAB11712

Db 174 CLISGWSTSPQLRLPHTLRCAITIIHQKCNAYPCNITDTWVCASVQEGCKSCQG 233
QY 181 DSGGPLVCNQSJQGIISKGQDPCAITRKPGVYTKVCKYVDWIQETMKN 229
Db 234 DSGGPLVCNQSJQGIISKGQDPCAITRKPGVYTKVCKYVDWIQETMKN 282

Search completed: October 22, 2003, 15:51:34
Job time : 35.0587 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 22, 2003, 15:50:17 ; Search time 21.9589 Seconds
(without alignments)

1746.375 Million cell updates/sec

Title: us-09-856-320a-2_copy_54_282

Perfect score: 1258

Sequence: 1 11KGECFPHQPCQAAALFS.....GVYTRVKYVWIDQETHKN 229

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 629382 seqs, 167460630 residues

Total number of hits satisfying chosen parameters: 629382

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
17: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1258	100.0	250	11	US-09-946-374-170
2	1258	100.0	250	12	Sequence 170, App
3	1258	100.0	250	12	Sequence 170, App
4	1258	100.0	250	12	Sequence 506, App
5	1258	100.0	250	12	Sequence 506, App
6	1258	100.0	250	12	Sequence 506, App
7	1258	100.0	250	12	Sequence 506, App
8	1258	100.0	250	12	Sequence 506, App
9	1258	100.0	250	12	Sequence 506, App
10	1258	100.0	250	12	Sequence 506, App
11	1258	100.0	250	12	Sequence 506, App
12	1258	100.0	250	12	Sequence 506, App
13	1258	100.0	250	12	Sequence 506, App
14	1258	100.0	250	12	Sequence 506, App
15	1258	100.0	250	12	Sequence 506, App

16 1258 100.0 250 12 US-10-142-432-506
17 1258 100.0 250 12 US-10-142-767-506
18 1258 100.0 250 12 US-10-143-033-506
19 1258 100.0 250 12 US-10-144-994-506
20 1258 100.0 250 12 US-10-145-828-506
21 1258 100.0 250 12 US-10-145-831-506
22 1258 100.0 250 12 US-10-145-833-506
23 1258 100.0 250 12 US-10-145-746-506
24 1258 100.0 250 12 US-10-145-748-506
25 1258 100.0 250 12 US-10-145-823-506
26 1258 100.0 250 12 US-10-145-826-506
27 1258 100.0 250 12 US-10-145-870-506
28 1258 100.0 250 12 US-10-145-876-506
29 1258 100.0 250 12 US-10-145-959-506
30 1258 100.0 250 12 US-10-146-724-506
31 1258 100.0 250 12 US-10-146-125-506
32 1258 100.0 250 12 US-10-146-195-506
33 1258 100.0 250 12 US-10-147-185-506
34 1258 100.0 250 12 US-10-147-501-506
35 1258 100.0 250 12 US-10-147-506-506
36 1258 100.0 250 12 US-10-147-509-506
37 1258 100.0 250 12 US-10-147-510-506
38 1258 100.0 250 12 US-10-147-511-506
39 1258 100.0 250 12 US-10-147-529-506
40 1258 100.0 250 12 US-10-153-397-506
41 1258 100.0 250 12 US-10-153-586-506
42 1258 100.0 250 12 US-10-158-783-506
43 1258 100.0 250 12 US-10-158-786-506
44 1258 100.0 250 12 US-10-006-130A-170
45 1258 100.0 250 12 US-10-006-130A-170

ALIGNMENTS

RESULT 1

US-09-946-374-170
; Sequence 170, Application US/09946374
; Publication No. US20030073129A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCES: P2830P1C1
; CURRENT APPLICATION NUMBER: US/09/945,374
; CURRENT FILING DATE: 2001-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750

PRIOR APPLICATION NUMBER: 60/101472	PRIOR FILING DATE: 1998-09-23	PRIOR APPLICATION NUMBER: 60/101473	PRIOR FILING DATE: 1998-09-23	PRIOR APPLICATION NUMBER: 60/101474	PRIOR FILING DATE: 1998-09-23	PRIOR APPLICATION NUMBER: 60/101475	PRIOR FILING DATE: 1998-09-23	PRIOR APPLICATION NUMBER: 60/101476	PRIOR FILING DATE: 1998-09-23	PRIOR APPLICATION NUMBER: 60/101477	PRIOR FILING DATE: 1998-09-23	PRIOR APPLICATION NUMBER: 60/101478	PRIOR FILING DATE: 1998-09-23	PRIOR APPLICATION NUMBER: 60/101479	PRIOR FILING DATE: 1998-09-23	PRIOR APPLICATION NUMBER: 60/101738	PRIOR FILING DATE: 1998-09-24	PRIOR APPLICATION NUMBER: 60/101741	PRIOR FILING DATE: 1998-09-24	PRIOR APPLICATION NUMBER: 60/101743	PRIOR FILING DATE: 1998-09-24	PRIOR APPLICATION NUMBER: 60/101915	PRIOR FILING DATE: 1998-09-24	PRIOR APPLICATION NUMBER: 60/101916	PRIOR FILING DATE: 1998-09-24	PRIOR APPLICATION NUMBER: 60/102207	PRIOR FILING DATE: 1998-09-29	PRIOR APPLICATION NUMBER: 60/102240	PRIOR FILING DATE: 1998-09-29	PRIOR APPLICATION NUMBER: 60/102307	PRIOR FILING DATE: 1998-09-29	PRIOR APPLICATION NUMBER: 60/102330	PRIOR FILING DATE: 1998-09-29	PRIOR APPLICATION NUMBER: 60/102331	PRIOR FILING DATE: 1998-09-29	PRIOR APPLICATION NUMBER: 60/102484	PRIOR FILING DATE: 1998-09-30	PRIOR APPLICATION NUMBER: 60/102487	PRIOR FILING DATE: 1998-09-30	PRIOR APPLICATION NUMBER: 60/102570	PRIOR FILING DATE: 1998-09-30	PRIOR APPLICATION NUMBER: 60/102571	PRIOR FILING DATE: 1998-09-30	PRIOR APPLICATION NUMBER: 60/102684	PRIOR FILING DATE: 1998-10-01	PRIOR APPLICATION NUMBER: 60/102687	PRIOR FILING DATE: 1998-10-01	PRIOR APPLICATION NUMBER: 60/102965	PRIOR FILING DATE: 1998-10-02	PRIOR APPLICATION NUMBER: 60/103256	PRIOR FILING DATE: 1998-10-06	PRIOR APPLICATION NUMBER: 60/103314	PRIOR FILING DATE: 1998-10-07	PRIOR APPLICATION NUMBER: 60/103315	PRIOR FILING DATE: 1998-10-07	PRIOR APPLICATION NUMBER: 60/103328	PRIOR FILING DATE: 1998-10-07	PRIOR APPLICATION NUMBER: 60/103395	PRIOR FILING DATE: 1998-10-07	PRIOR APPLICATION NUMBER: 60/103396	PRIOR FILING DATE: 1998-10-07	PRIOR APPLICATION NUMBER: 60/103401	PRIOR FILING DATE: 1998-10-07	PRIOR APPLICATION NUMBER: 60/103449	PRIOR FILING DATE: 1998-10-06	PRIOR APPLICATION NUMBER: 60/103633	PRIOR FILING DATE: 1998-10-08	PRIOR APPLICATION NUMBER: 60/103678	PRIOR FILING DATE: 1998-10-08	PRIOR APPLICATION NUMBER: 60/103679	PRIOR FILING DATE: 1998-10-08	PRIOR APPLICATION NUMBER: 60/103711	PRIOR FILING DATE: 1998-10-08	PRIOR APPLICATION NUMBER: 60/104257	PRIOR FILING DATE: 1998-10-08
-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------	-------------------------------------	-------------------------------

PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105907

Query Match 100.0%; Score 1258; DB 11; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAHCLKERYIVHLGQHNLOKEE 81
QY 61 GCQTRTATESPPHGFNNSLPNKDHRNDIMLVKASPVSIWAVRPLTLSSRCVTAAGTS 120
DB 82 GCQTRTATESPPHGFNNSLPNKDHRNDIMLVKASPVSIWAVRPLTLSSRCVTAAGTS 141
QY 121 CLISGMGSTSSPOLRPLPHTLRCAITIIIEHOKCENAYPGNITDTMVCASVOEGGKDSQCG 180
DB 142 CLISGMGSTSSPOLRPLPHTLRCAITIIIEHOKCENAYPGNITDTMVCASVOEGGKDSQCG 201
QY 181 DSGGPLVCNQSLOGIISWGQDPCAITRKPGVTVCKYVDWIOETMKN 229
DB 202 DSGGPLVCNQSLOGIISWGQDPCAITRKPGVTVCKYVDWIOETMKN 250

RESULT 2
US-10-015-387A-170
Sequence 170, Application US/10015387A
Publication No. US20030135034A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Pacini, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2810P1C54
CURRENT APPLICATION NUMBER: US/10/015,387A
CURRENT FILING DATE: 2001-12-12
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 170
LENGTH: 250
TYPE: PRT
ORGANISM: Homo sapiens
US-10-015-387A-170
Query Match 100.0%; Score 1258; DB 12; Length 250;

Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 81
QY 61 GCQTRTATESPPHGFNNSLPNKDHRNDIMLVKASPVSIWAVRPLTLSSRCVTAAGTS 120
DB 82 GCQTRTATESPPHGFNNSLPNKDHRNDIMLVKASPVSIWAVRPLTLSSRCVTAAGTS 141
QY 121 CLISGMGSTSSPOLRPLPHTLRCAITIIIEHOKCENAYPGNITDTMVCASVOEGGKDSQCG 180
DB 142 CLISGMGSTSSPOLRPLPHTLRCAITIIIEHOKCENAYPGNITDTMVCASVOEGGKDSQCG 201
QY 181 DSGGPLVCNQSLOGIISWGQDPCAITRKPGVTVCKYVDWIOETMKN 229
DB 202 DSGGPLVCNQSLOGIISWGQDPCAITRKPGVTVCKYVDWIOETMKN 250

RESULT 3
US-10-137-870-506
Sequence 506, Application US/10137870
Publication No. US2003013883A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Bersini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnovers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C155
CURRENT APPLICATION NUMBER: US/10/137,870
CURRENT FILING DATE: 2002-05-03
Prior Application removed - See Palm or File Wrapper
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 506
LENGTH: 250
TYPE: PRT
ORGANISM: Homo Sapien
US-10-137-870-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 81
QY 61 GCQTRTATESPPHGFNNSLPNKDHRNDIMLVKASPVSIWAVRPLTLSSRCVTAAGTS 120
DB 82 GCQTRTATESPPHGFNNSLPNKDHRNDIMLVKASPVSIWAVRPLTLSSRCVTAAGTS 141
QY 121 CLISGMGSTSSPOLRPLPHTLRCAITIIIEHOKCENAYPGNITDTMVCASVOEGGKDSQCG 180
DB 142 CLISGMGSTSSPOLRPLPHTLRCAITIIIEHOKCENAYPGNITDTMVCASVOEGGKDSQCG 201
QY 181 DSGGPLVCNQSLOGIISWGQDPCAITRKPGVTVCKYVDWIOETMKN 229

Db 202 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVKYVDWMIQETMKN 250

RESULT 4

US-10-140-018-506
; Sequence 506, Application US/10140018

; Publication No. US2003013885A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C158

; CURRENT APPLICATION NUMBER: US/10/140,018

; CURRENT FILING DATE: 2002-05-06

; Prior Application removed - See Palm or File Wrapper

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 506

; LENGTH: 250

; TYPE: PRT

; ORGANISM: Homo Sapien

US-10-140-018-506

Query Match 100.0%; Score 1258; DB 12; Length 250;

Best Local Similarity 100.0%; Pred. No. 1.4e-118;

Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
Db 22 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAACHLKPRYIVHLGQHNLOKEE 81
Qy 61 GCQOTRTATESPPHGFNNSLPNKHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 120
Db 82 GCQOTRTATESPPHGFNNSLPNKHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 141
Qy 121 CLISGWSSTSSPOLRPLHTLRCAITIIIEHOKCENAYPGNITDTMYCASVQEGGKDSQCG 180
Db 142 CLISGWSSTSSPOLRPLHTLRCAITIIIEHOKCENAYPGNITDTMYCASVQEGGKDSQCG 201
Qy 181 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVKYVDWMIQETMKN 229
Db 202 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVKYVDWMIQETMKN 250

RESULT 5

US-10-140-021-506

; Sequence 506, Application US/10140021

; Publication No. US2003013886A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C167
; CURRENT APPLICATION NUMBER: US/10/140,021
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-021-506

Query Match 100.0%; Score 1258; DB 12; Length 250;

Best Local Similarity 100.0%; Pred. No. 1.4e-118;

Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
Db 22 IIKGFECKPHSQWQAALFEKTRLLCGATLIAPRWLLTAACHLKPRYIVHLGQHNLOKEE 81
Qy 61 GCQOTRTATESPPHGFNNSLPNKHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 120
Db 82 GCQOTRTATESPPHGFNNSLPNKHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 141
Qy 121 CLISGWSSTSSPOLRPLHTLRCAITIIIEHOKCENAYPGNITDTMYCASVQEGGKDSQCG 180
Db 142 CLISGWSSTSSPOLRPLHTLRCAITIIIEHOKCENAYPGNITDTMYCASVQEGGKDSQCG 201
Qy 181 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVKYVDWMIQETMKN 229
Db 202 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVKYVDWMIQETMKN 250

RESULT 6

US-10-140-274-506

; Sequence 506, Application US/10140274

; Publication No. US2003014367A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C161

; CURRENT APPLICATION NUMBER: US/10/140, 274

; CURRENT FILING DATE: 2002-05-06

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 506

; LENGTH: 250

TYPE: PRT
ORGANISM: Homo Sapien
US-10-140-274-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFECKPHSQPWAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHGLQHNLOKEE 60
DB 22 IIKGFECKPHSQPWAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHGLQHNLOKEE 81
QY 61 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 120
DB 82 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 141
QY 121 CLISGWSTSSPOLRPLPHTLRCAITIEHOKCENAYPGNITDTMVCASVQEGKDCSCQ 180
DB 142 CLISGWSTSSPOLRPLPHTLRCAITIEHOKCENAYPGNITDTMVCASVQEGKDCSCQ 201

QY 181 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVCKYVDWIOETMKN 229
DB 202 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVCKYVDWIOETMKN 250

RESULT 7
US-10-140-471-506
Sequence 506, Application US/10140471
Publication No. US20030138897A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C163
CURRENT APPLICATION NUMBER: US/10/140,471
CURRENT FILING DATE: 2002-05-06
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 506
LENGTH 250
TYPE: PRT
ORGANISM: Homo Sapien
US-10-140-471-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFECKPHSQPWAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHGLQHNLOKEE 60
DB 22 IIKGFECKPHSQPWAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHGLQHNLOKEE 81
QY 61 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 120
DB 82 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 141
QY 121 CLISGWSTSSPOLRPLPHTLRCAITIEHOKCENAYPGNITDTMVCASVQEGKDCSCQ 180
DB 142 CLISGWSTSSPOLRPLPHTLRCAITIEHOKCENAYPGNITDTMVCASVQEGKDCSCQ 201

DB 142 CLISGWSTSSPOLRPLPHTLRCAITIEHOKCENAYPGNITDTMVCASVQEGKDCSCQ 201
QY 181 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVCKYVDWIOETMKN 229
DB 202 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVCKYVDWIOETMKN 250

RESULT 8
US-10-140-807-506
Sequence 506, Application US/10140807
Publication No. US20030134354A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C174
CURRENT APPLICATION NUMBER: US/10/140,807
CURRENT FILING DATE: 2002-05-07
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 506
LENGTH 250
TYPE: PRT
ORGANISM: Homo Sapien
US-10-140-807-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFECKPHSQPWAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHGLQHNLOKEE 60
DB 22 IIKGFECKPHSQPWAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHGLQHNLOKEE 81
QY 61 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 120
DB 82 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKASPVSIITWAVRPLTLSSRCVTAGTS 141
QY 121 CLISGWSTSSPOLRPLPHTLRCAITIEHOKCENAYPGNITDTMVCASVQEGKDCSCQ 180
DB 142 CLISGWSTSSPOLRPLPHTLRCAITIEHOKCENAYPGNITDTMVCASVQEGKDCSCQ 201

QY 181 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVCKYVDWIOETMKN 229
DB 202 DSGGPLVNCNLSQGIISWGQDPCAITRKPGVYTKVCKYVDWIOETMKN 250

RESULT 9
US-10-140-922-506
Sequence 506, Application US/10140922
Publication No. US2003013889A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc

```
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C177
; CURRENT APPLICATION NUMBER: US/10/140,922
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-922-506

Query Match      100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFCKPHSQPQQAALFEKTRLLCGATLIAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFCKPHSQPQQAALFEKTRLLCGATLIAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 81
QY 61 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKMASPVSIITWAVRPLTSSRCVTAGTS 120
DB 82 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKMASPVSIITWAVRPLTSSRCVTAGTS 141
QY 121 CLISGWSSTSPQLRPLHTLRCAITIEHOKCENAYPGNITDTWVCASVQEGKDSGCG 180
DB 142 CLISGWSSTSPQLRPLHTLRCAITIEHOKCENAYPGNITDTWVCASVQEGKDSGCG 201
QY 181 DSGGPLVCNCSLQGIISWGQDPCAITRKPGVYTKVCKYVDMIOETMKN 229
DB 202 DSGGPLVCNCSLQGIISWGQDPCAITRKPGVYTKVCKYVDMIOETMKN 250

RESULT 10
US-10-140-924-506
; Sequence 506, Application US/10140924
; Publication No. US20030134355A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C177
; CURRENT APPLICATION NUMBER: US/10/140,924
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-924-506

Query Match      100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFCKPHSQPQQAALFEKTRLLCGATLIAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFCKPHSQPQQAALFEKTRLLCGATLIAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 81
QY 61 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKMASPVSIITWAVRPLTSSRCVTAGTS 120
DB 82 GCEQTRTATESFPHPGFNNSLPNKDHNDIMLVKMASPVSIITWAVRPLTSSRCVTAGTS 141
QY 121 CLISGWSSTSPQLRPLHTLRCAITIEHOKCENAYPGNITDTWVCASVQEGKDSGCG 180
DB 142 CLISGWSSTSPQLRPLHTLRCAITIEHOKCENAYPGNITDTWVCASVQEGKDSGCG 201
QY 181 DSGGPLVCNCSLQGIISWGQDPCAITRKPGVYTKVCKYVDMIOETMKN 229
DB 202 DSGGPLVCNCSLQGIISWGQDPCAITRKPGVYTKVCKYVDMIOETMKN 250

RESULT 11
US-10-140-926-506
; Sequence 506, Application US/10140926
; Publication No. US20030134356A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C187
; CURRENT APPLICATION NUMBER: US/10/140,926
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 506
; LENGTH: 250
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-926-506

Query Match      100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFCKPHSQPQQAALFEKTRLLCGATLIAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFCKPHSQPQQAALFEKTRLLCGATLIAAPRWLLTAACHLKPRYIVHLGQHNLOKEE 81
```

```
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C177
; CURRENT APPLICATION NUMBER: US/10/140,924
```

QY 61 GCQTRTATESFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 120
DB 82 GCQTRTATESFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 141
QY 121 CLISGWGTSFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 180
DB 142 CLISGWGTSFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 201
QY 181 DSGGLVNCVQSLGIIISWGQDPCALTRKPGVYTKVKYVDWIQETMKN 229
DB 202 DSGGLVNCVQSLGIIISWGQDPCALTRKPGVYTKVKYVDWIQETMKN 250

RESULT 12

US-10-141-698-506
; Sequence 506, Application US/10141698
; Publication No. US20030134357A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.

APPLICANT: Beresini, Maureen

APPLICANT: DeForge, Laura

APPLICANT: Desnoyers, Luc

APPLICANT: Filvaroff, Ellen

APPLICANT: Gao, Wei-Qiang

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Gurney, Austin L.

APPLICANT: Sherwood, Steven

APPLICANT: Smith, Victoria

APPLICANT: Stewart, Timothy A.

APPLICANT: Tamas, Daniel

APPLICANT: Watanabe, Colin K

APPLICANT: Wood, William

APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

FILE REFERENCE: P3330R1C206

CURRENT APPLICATION NUMBER: US/10/141,698

CURRENT FILING DATE: 2002-05-08

Prior Application removed - See Palm or File Wrapper

NUMBER OF SEQ ID NOS: 550

SEQ ID NO 506

LENGTH: 250

TYPE: PRT

ORGANISM: Homo Sapien

US-10-141-698-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFCKPHSQPQWQAALFEKTRLLCGATLIAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFCKPHSQPQWQAALFEKTRLLCGATLIAPRWLLTAACHLKPRYIVHLGQHNLOKEE 81
QY 61 GCQTRTATESFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 120
DB 82 GCQTRTATESFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 141
QY 121 CLISGWGTSFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 180
DB 142 CLISGWGTSFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 201
QY 181 DSGGLVNCVQSLGIIISWGQDPCALTRKPGVYTKVKYVDWIQETMKN 229
DB 202 DSGGLVNCVQSLGIIISWGQDPCALTRKPGVYTKVKYVDWIQETMKN 250

RESULT 13

US-10-141-702-506
; Sequence 506, Application US/10141702
; Publication No. US20030134358A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.

APPLICANT: Beresini, Maureen

APPLICANT: DeForge, Laura

APPLICANT: Desnoyers, Luc

APPLICANT: Filvaroff, Ellen

APPLICANT: Gao, Wei-Qiang

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Gurney, Austin L.

APPLICANT: Sherwood, Steven

APPLICANT: Smith, Victoria

APPLICANT: Stewart, Timothy A.

APPLICANT: Tamas, Daniel

APPLICANT: Watanabe, Colin K

APPLICANT: Wood, William

APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

FILE REFERENCE: P3330R1C208

CURRENT APPLICATION NUMBER: US/10/141,702

CURRENT FILING DATE: 2002-05-08

Prior Application removed - See Palm or File Wrapper

NUMBER OF SEQ ID NOS: 550

SEQ ID NO 506

LENGTH: 250

TYPE: PRT

ORGANISM: Homo Sapien

US-10-141-702-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFCKPHSQPQWQAALFEKTRLLCGATLIAPRWLLTAACHLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFCKPHSQPQWQAALFEKTRLLCGATLIAPRWLLTAACHLKPRYIVHLGQHNLOKEE 81
QY 61 GCQTRTATESFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 120
DB 82 GCQTRTATESFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 141
QY 121 CLISGWGTSFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 180
DB 142 CLISGWGTSFPHGPFNNLSLNKDHNDIMLVQASPVSIITWVRPLTLSSRCVTAAGTS 201
QY 181 DSGGLVNCVQSLGIIISWGQDPCALTRKPGVYTKVKYVDWIQETMKN 229
DB 202 DSGGLVNCVQSLGIIISWGQDPCALTRKPGVYTKVKYVDWIQETMKN 250

RESULT 14

US-10-141-704-506
; Sequence 506, Application US/10141704
; Publication No. US20030134359A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.

APPLICANT: Beresini, Maureen

APPLICANT: DeForge, Laura

APPLICANT: Desnoyers, Luc

APPLICANT: Filvaroff, Ellen

APPLICANT: Gao, Wei-Qiang

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Gurney, Austin L.

APPLICANT: Sherwood, Steven

APPLICANT: Smith, Victoria

APPLICANT: Stewart, Timothy A.

APPLICANT: Tamas, Daniel

APPLICANT: Watanabe, Colin K

APPLICANT: Wood, William

Fri Oct 24 14:08:12 2003

APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C209
CURRENT APPLICATION NUMBER: US/10/141,704
PRIOR APPLICATION DATE: 2002-05-08
Prior Application removed - See Palm or File Wrapper
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 506
LENGTH: 250
TYPE: PRT
ORGANISM: Homo Sapien
US-10-141-704-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFECKPHSQPQQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFECKPHSQPQQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 81
QY 61 GCQOTRTATESPPHGFNNSLPNKHNDIMLVKMASPVSIITWAVRPLTLSSRCVTAGTS 120
DB 82 GCQOTRTATESPPHGFNNSLPNKHNDIMLVKMASPVSIITWAVRPLTLSSRCVTAGTS 141
QY 121 CLISGWSSTSPQLRPLHPTLRCANITIIIEHOKCENAYPGNITDTMVCASVQEGGKDCSCG 180
DB 142 CLISGWSSTSPQLRPLHPTLRCANITIIIEHOKCENAYPGNITDTMVCASVQEGGKDCSCG 201
QY 181 DSGGPLVNCNQSLOGIISWGQDPCAITRKPGYTKVCKYVDNIQETMKN 229
DB 202 DSGGPLVNCNQSLOGIISWGQDPCAITRKPGYTKVCKYVDNIQETMKN 250

Search completed: October 22, 2003, 15:54:44
Job time : 22.9589 secs

APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C209
CURRENT APPLICATION NUMBER: US/10/141,704
PRIOR APPLICATION DATE: 2002-05-08
Prior Application removed - See Palm or File Wrapper
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 506
LENGTH: 250
TYPE: PRT
ORGANISM: Homo Sapien
US-10-141-704-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IIKGFECKPHSQPQQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 60
DB 22 IIKGFECKPHSQPQQAALFEKTRLLCGATLIAPRWLLTAHCLKPRYIVHLGQHNLOKEE 81
QY 61 GCQOTRTATESPPHGFNNSLPNKHNDIMLVKMASPVSIITWAVRPLTLSSRCVTAGTS 120
DB 82 GCQOTRTATESPPHGFNNSLPNKHNDIMLVKMASPVSIITWAVRPLTLSSRCVTAGTS 141
QY 121 CLISGWSSTSPQLRPLHPTLRCANITIIIEHOKCENAYPGNITDTMVCASVQEGGKDCSCG 180
DB 142 CLISGWSSTSPQLRPLHPTLRCANITIIIEHOKCENAYPGNITDTMVCASVQEGGKDCSCG 201
QY 181 DSGGPLVNCNQSLOGIISWGQDPCAITRKPGYTKVCKYVDNIQETMKN 229
DB 202 DSGGPLVNCNQSLOGIISWGQDPCAITRKPGYTKVCKYVDNIQETMKN 250

RESULT 15
US-10-142-421-506
Sequence 506, Application US/10142421
Publication No. US20030134360A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3330R1C218
CURRENT APPLICATION NUMBER: US/10/142,421
CURRENT FILING DATE: 2002-05-09
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 506
LENGTH: 250
TYPE: PRT
ORGANISM: Homo Sapien
US-10-142-421-506

Query Match 100.0%; Score 1258; DB 12; Length 250;
Best Local Similarity 100.0%; Pred. No. 1.4e-118;
Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

GenCore version 5.1.6
Copyright (C) 1993 - 2003 CompuGen Ltd.

OM protein - nucleic search, using frame_plus_p3n model

Run on: October 23, 2003, 14:08:00 / Search time 3410.8 Seconds
(without alignments)
2746.659 Million cell updates/sec

Title: us-09-856-320a-2_copy_54_282

Perfect score: 1258
Sequence: 1 IIKGFECKPHSQPMQALFE.....GVYTKYCKYVDWIQETMKNN 229

Scoring table: BLOSUM62

Xgapop 10.0, Xgapext 0.5
Ygapop 10.0, Ygapext 0.5
Fgapop 6.0, Fgapext 7.0
Delop 6.0, Delext 7.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlh
-Q=/cgn2_1/USPTO.spool/US09856320/runat_22102003_121414_25661/app.query.fasta_1.846
-DB=GenEmbl -QFMT=fastp -SUFFIX=rge -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0
-UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45
-DOCALIGN=200 -THR SCORE=oct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=200000000
-USER=US09856320 @CGN_1_1_4326 @runat_22102003_121414_25661 -NCPU=6 -ICPU=3
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREDS=1 -XGAPOP=10 -XGAPEXT=0.5 -Fgapop=6
-FGAPEXT=7 -Ygapop=10 -Ygapext=0.5 -DSELP=6 -DELEXT=7

Database :

GenEmbl:
1: gb_ba:
2: gb_hcg:
3: gb_in:
4: gb_om:
5: gb_ov:
6: gb_pat:
7: gb_ph:
8: gb_pl:
9: gb_pr:
10: gb_ro:
11: gb_scs:
12: gb_sy:
13: gb_un:
14: gb_vi:
15: em_ba:
16: em_fun:
17: em_hum:
18: em_in:
19: em_mu:
20: em_on:
21: em_or:
22: em_ov:
23: em_pat:
24: em_ph:
25: em_pl:
26: em_ro:
27: em_scs:
28: em_un:

29: em_vi:
30: em_hcg_hum:
31: em_hcg_inv:
32: em_hcg_other:
33: em_hcg_mus:
34: em_hcg_pln:
35: em_hcg_rdd:
36: em_hcg_mam:
37: em_hcg_vrt:
38: em_sy:
39: em_hcg_hum:
40: em_hcg_mus:
41: em_hcg_other:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1258	100.0	1106	6	AX016287 Sequence
2	1258	100.0	1106	6	BD137019 Human CAS
3	1258	100.0	1158	6	AX016289 Sequence
4	1258	100.0	1158	6	BD137020 Human CAS
5	1258	100.0	1181	9	AB013730 Homo sapi
6	1258	100.0	1186	9	AB013917 Homo sapi
7	1258	100.0	1192	6	AR152174 Sequence
8	1258	100.0	1204	6	AX358932 Sequence
9	1258	100.0	1204	6	AX362425 Sequence
10	1258	100.0	1204	6	AX454622 Sequence
11	1258	100.0	1204	6	AX464372 Sequence
12	1258	100.0	1204	6	AX491100 Sequence
13	1258	100.0	1204	6	AX697101 Sequence
14	1258	100.0	1213	9	BC022068 Homo sapi
15	1258	100.0	1301	6	BD091587 Novel ser
16	1258	100.0	1301	6	AB041036 Homo sapi
17	1258	100.0	1314	6	AR098430 Sequence
18	1258	100.0	1314	6	BD130920 Serine pr
19	1246	99.0	1166	6	AR152173 Sequence
20	1235.5	98.2	930	9	AB078780 Homo sapi
21	1235.5	98.2	934	6	BD091589
22	1228	97.6	1191	6	BD139483 Extended
23	1219.5	96.9	1052	6	AR19287 Sequence
24	1213	96.4	833	6	AR060847 Sequence
25	1213	96.4	833	6	BD082136 Novel pro
26	1062	84.4	1213	10	AB016226 Mus muscu
27	1062	84.4	1256	10	AB016227 Mus muscu
28	1062	84.4	1323	6	BD091588
29	1014.5	80.6	1154	6	AX661915 Sequence
30	956	76.0	9120	9	AF164623 Homo sapi
31	956	76.0	132323	9	AC011473 Homo sapi
32	943	75.0	230000	9	AF243527 Homo sapi
33	943	75.0	142334	2	AC073185 Homo sapi
34	916.5	72.9	618	6	AR263825 Sequence
35	897.5	71.3	178504	2	AC140096 Pan trogl
36	897.5	71.3	200792	2	AC130782 Pan trogl
37	885.5	70.4	176647	2	AC130188 Papio anu
38	782.5	62.2	226890	2	AC135541 Rattus no
39	782.5	62.2	228413	2	AC127853 Rattus no
40	782.5	62.2	243655	2	AC099172 Rattus no
41	687	54.6	974	10	RA05641 Rattus ra
42	684	54.4	759	6	BD080531 Novel ext
43	684	54.4	1322	6	AX305781 Sequence
44	684	54.4	1322	10	MUSNEU
45	684	54.4	1333	6	E12348 cDNA encodi

ALIGNMENTS

RESULT 1

AX016287 AX016287 1106 bp DNA linear PAT 07-SEP-2000
LOCUS
DEFINITION Sequence 1 from Patent W09949055.
ACCESSION AX016287
VERSION AX016287.1 GI:10041854
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE
1 Bruck,C.E., Coche,T., Cassart,J.P. and Vinals-Bassols,C.
Human casb12 polypeptide, a serine protease
Patent: WO 9949055-A 1 30-SEP-1999.
TITLE BRUCK CLAUDE ELVIRE MARIE (BE); SMITHKLINE BEECHAM BIOLOG (BE);
JOURNAL COCHE THIERRY (BE); CASSART JEAN POL (BE); VINALS BASSOLS CARLOTTA
(BE)
FEATURES
source
1..1106
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 247 a 348 c 287 g 224 t
ORIGIN
Alignment Scores:
Pred. No.: 4,14e-97 Length: 1106
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
Gaps: 6
US-09-856-320A-2_COPY_54_282 (1-229) x AX016287 (1-1106)
Qy 1 IletleLysGlyPheGluCysLeuProHisSerGlnProTTPGlnAlaLeuPheGlu 20
Db 173 ATCATCAAGGGTTTCAGTGAAGCCCTCACTCCAGCCCTGCGAGGAGGAGGAG 232
Qy 21 LysThrArgLeuLeuGlyAlaThrLeuLeuAlaProArgTTPLeuThrAlaAla 40
Db 233 AAGACGGGCTACTCTGTGGGGGAGCCCTCATCGCCCGCCAGATGCTCTGCACAGC 292
Qy 41 HisCysLeuLeuProArgTTPLeuValHisGluGlyGlnHisAsnLeuGlyGlu 60
Db 293 CACTGGCTCAAGCCCGCTCATAGTTCACTGGGGGAGCAGACACCTCCAGAGGAGGAG 352
Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnSer 80
Db 353 GGCTGTGAGCAGACCGGAGCAGCCACTGAGTCTCTCCCGCCCGGCTTCAACACAGC 412
Qy 81 LeuProAsnLysAspHisArgAsnAspIleValLeuValLysMetAlaSerProValSer 100
Db 413 CTCCCCCAAGAGACCCGCAATGACATCATCTGTCGAGATGCGATCGCCAGTCTCC 472
Qy 101 IletThrTTPAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db 473 ATCACTGGGCTGTGGGACCCCTCACCTCTCTCCAGCTGTGTCTGTCGACGACGAGC 532
Qy 121 CysLeuIleSerGlyTTPGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
Db 533 TGCTCATTTCCGGCTGGGGGAGCAGCAGCTCCAGCCCGCCAGTACGCTCCCTCACACCTTG 592
Qy 141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
Db 593 CGATGCGCAACATCACCATCATTTGAGCAGCAGCAGAGTGTGAGAGCGCTACCCCGGCAAC 652
Qy 161 IletThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
Db 653 ATCAGACACCATGTTGTGTCAGGCTGTGAGGAGGAGGAGGAGGAGTCTCTGCGAGGT 712
Qy 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTTPGlyGln 200

Db 713 GACTCGGGGGCCCTCTGTCTGTAAACCAAGTCTCTTCAAGGCATTATCTCTCGGGCCAG 772
Qy 201 AspProCysValIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
Db 773 GATCCGTGTGCGATCAACCGAAAGCCCTGTGTCTTACAGGAAGTCTGTGCAATATGTGCAC 832
Qy 221 TTPleGlnGluThrMetLysAsnAsn 229
Db 833 TGGATCCAGGAGACGATGAAGAACAT 859
RESULT 2
LOCUS BD137019 1106 bp DNA linear PAT 18-SEP-2002
DEFINITION Human CASB 12 polypeptide, a serine protease.
ACCESSION BD137019
VERSION BD137019.1 GI:23231964
KEYWORDS JP 2002507425-A/1.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
1 (Bases 1 to 1106)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Bruck,C.E.M., Cassart,J.P., Coche,T. and Bassols,C.V.
TITLE Human CASB 12 polypeptide, a serine protease
JOURNAL Patent: JP 2002507425-A 1 12-MAR-2002;
SMITHKLINE BEECHAM BIOLOGICALS SA
COMMENT OS Homo sapiens (human)
PN JP 2002507425-A/1
PD 12-MAR-2002
PF 17-MAR-1999 JP 2000538015
PR 20-MAR-1998 GB 9806095.7
PI CLAUDE ELVIRE MARIE BRUCK,JEAN POL CASSART,THIERRY COCHE, PI
CARLOTTA VINALS BASSOLS
PC C12N15/09,A61K31/70,A61K38/00,A61P35/00,A61P37/02,C07K16/40,
PC C12N1/15,C12N1/21,C12N5/10,C12N9/64,C12P21/02,C12Q1/02,C12Q1/15,
PC 68,G01N33/15,PC
PC G01N33/50,G01N33/50,G01N33/574,G01N33/68,C12N15/00,A61K37/02,
PC C12N5/00
CC Human CASB 12 polypeptide, a serine protease. FH Key
Location/Qualifiers
FT source 1..1106
/organism="Homo sapiens (human)"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 247 a 348 c 287 g 224 t
ORIGIN
Alignment Scores:
Pred. No.: 4,14e-97 Length: 1106
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
Gaps: 6
US-09-856-320A-2_COPY_54_282 (1-229) x BD137019 (1-1106)
Qy 1 IletleLysGlyPheGluCysLeuProHisSerGlnProTTPGlnAlaLeuPheGlu 20
Db 173 ATCATCAAGGGTTTCAGTGAAGCCCTCACTCCAGCCCTGCGAGGAGGAGGAG 232
Qy 21 LysThrArgLeuLeuGlyAlaThrLeuLeuAlaProArgTTPLeuThrAlaAla 40
Db 233 AAGACGGGCTACTCTGTGGGGGAGCCCTCATCGCCCGCCAGATGCTCTGCACAGC 292
Qy 41 HisCysLeuLeuProArgTTPLeuValHisGluGlyGlnHisAsnLeuGlyGlu 60
Db 293 CACTGGCTCAAGCCCGCTCATAGTTCACTGGGGGAGCAGACACCTCCAGAGGAGGAG 352

PC 68.G01N33/15,
 PC G01N33/50,G01N33/50,G01N33/574,G01N33/68,C12N15/00,A61K37/02,
 CC C12N5/00
 Human CASB 12 polypeptide, a serine protease. PH Key
 Location/Qualifiers
 FT source 1..1158
 /organism="Homo sapiens (human)"

FEATURES
 source
 1..1158
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 274 a 359 c 306 g 219 t
 ORIGIN

Alignment Scores:
 Pred. No.: 4,356-97 Length: 1158
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservatives: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 6 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x BD137020 (1-1158)

Qy 1 IleIleLysGlyPheGluCysLeuProHisSerGlnProTrpGlnAlaLeuPheGlu 20
 Db 243 ATCATCAAGGGGTTCGAGTGAAGCCCTCACTCCAGCCCTGGCAGGAGCCCTGTTCCGAG 302
 Qy 21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuThrAlaAla 40
 Db 303 AAGACGCGGCTACTCTGTGGGGGACGCTCATGCCCCCGAGTGCTCTCGACAGCAGCC 362
 Qy 41 HisCysLeuLeuProArgTrpIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
 Db 363 CACTGCTCCAGCCCGCTACATAGTTCACTTGGGGCAGCAACCTCCAGAGGAGGAG 422
 Qy 61 GlyCysGluGlnThrArgThrAlaThrGlnSerPheProHisProGlyPheAsnSer 80
 Db 423 GCGTGTGACGACCCGACGACGACCTGAGTCTCTCCACCCCGCTTCAACACAGC 482
 Qy 81 LeuProAsnLysAspHisArgAspIleMetLeuValLysMetAlaSerProValSer 100
 Db 483 CTCCTCCCAACAAAGACCCGCAATGACATCATCTGTTGAAGATGGCATGCCAGTCTCC 542
 Qy 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
 Db 543 ATCACCTGGGCTGTGGACCCCTCACCTCTCTCAGCGCTGTGTCACCTGTGACCCAGC 602
 Qy 121 CysLeuIleSerGlyTrpGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
 Db 603 TGCTTCATTTCCGGTGGGGGACGACGCTCCAGCCCGCTTACGCTTGCCTCACCTTG 662
 Qy 141 ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluAsnAlaTyProGlyAsn 160
 Db 663 CGATGGCCCAACATCACCATCATTTGACACACAGAGTGTGAAGCGCTACCCCGCAAC 722
 Qy 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyLysAspSerCysGlnGly 180
 Db 723 ATCAGACACACCATGTTGTGTGGCAGCGTGCAGAGAGGGGCGAGGACTCTCCAGGCT 782
 Qy 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
 Db 783 GACTCCGGGGGCTCTGGTCTGTACCATGCTCTCTCAAGGCATTATCTCTGGGGCCAG 842
 Qy 201 AspProCysAlaIleThrArgLysProGlyValTyThrLysValCysLysTyValAsp 220
 Db 843 GATCGGTGTGGGATCACCCGAAAGCTGGTGTCTACAGAAAGTCTGCAATATATGTGGAC 902
 Qy 221 TrpIleGlnGluThrMetLysAsnAsn 229
 Db 903 TGGATCCAGGAGACCATGAACAAAT 929

RESULT 5
 AB013730
 LOCUS
 DEFINITION
 ACCESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM

AB013730 Homo sapiens mRNA for Hippostasin, complete cds. PRI 20-JUN-2000
 AB013730
 AB013730.1 GI:6681453
 Hippostasin.
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1. (sites)
 Yamaguchi,S., Yamada,T., Okui,A., Kominami,K., Uemura,H. and
 Mitsuhashi,N.
 A novel isoform of a kallikrein-like protease, TLSP/hippocastasin,
 (PRSS20), is expressed in the human brain and prostate
 Biochem. Biophys. Res. Commun. 272 (1), 205-211 (2000)

JOURNAL
 MEDLINE
 PUBMED
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL

2 (bases 1 to 1181)
 Yamaguchi,S. and Mitsuhashi,N.
 Direct Submission
 Submitted (09-MAY-1998) Nozomi Yamaguchi, Kyoto Prefectural
 University of Medicine, Res. Ins. Geriatrics, Kawaramachi Hirokoji,
 Kyoto, Kyoto 602-8566, Japan (E-mail:nozomi@koto.kpu-m.ac.jp).
 Tel:81-75-251-5848, Fax:81-75-251-5848

FEATURES
 source

1..1181
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /tissue_type="Hippocampus and Prostate"
 121..873
 /codon_start=1
 /product="Hippocastasin"
 /protein_id="BA88713.1"
 /db_xref="GI:6681454"

CDS

/translation="MRILQLLLALATGLVGGSETRIIKGFCKPHSQWQALFEKTR
 LIGCATLAPRLWLTAAHCLPKRYIVLGHNLQKEEGCEQYRTATSEFPHPGPNNSU
 PNKDRNDIMLYKASPSVITWAVPLTSSRCVTAGTSLGSGSTSSPOLRLPHT
 LRCANITIEHOKCENAYPGNITDTMVCAVSGVQEGKSCQSGSGPLVCNOSLOGIIS
 WGGDPICATIRKPGYTVKCYKVDWIQETWKN"

polya_site

BASE COUNT 271 a 375 c 287 g 248 t
 ORIGIN

Alignment Scores:
 Pred. No.: 4,446-97 Length: 1181
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservatives: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 9 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x AB013730 (1-1181)

Qy 1 IleIleLysGlyPheGluCysLeuProHisSerGlnProTrpGlnAlaLeuPheGlu 20
 Db 184 ATCATCAAGGGGTTCGAGTGAAGCCCTCACTCCAGCCCTGGCAGGAGCCCTGTTCCGAG 243
 Qy 21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuThrAlaAla 40
 Db 244 AAGACGCGGCTACTCTGTGGGGGACGCTCATGCCCCCGAGTGGCTCTCGACAGCAGCC 303
 Qy 41 HisCysLeuLeuProArgTrpIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
 Db 304 CACTGCTCCAGCCCGCTTACATAGTTCACTCCGGGCGACGACCAACCTCCAGAGGAGGAG 363
 Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
 Db 364 GGCTGTGAGCAGACCCGACAGCCAGCTGAGTCTCTTCCCCACCCCGGCTTCAACACAGC 423

```

QY 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
DB 424 CTCCCAACAAAGACCAACGCAATGACATCATGCTGGTGAAGATGGCATGCCAGTCTCC 483
QY 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
DB 484 ATCACTGGCTGTGGACCCCTCACCTCTCTCCAGCTGTGTGCTGCTGCTGCTGCTGCTG 543
QY 121 CysLeuLeuSerGlyTyrGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
DB 544 TGCTCTCAATTCGGGTGGGGGAGCAGCAGCTCCAGGCCCCAGTACGCTGCTCCACACCTTG 603
QY 141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
DB 604 CGATGGCCCAACATCACCATCATTTGAGCAGCAGAAAGTGTGAGAACGCTACCCCGGCAAC 663
QY 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyCysLysAspSerCysGlnGly 180
DB 664 ATCAAGACACCATCGTGTGCTCCAGCTGCAGAGAGGGGGGAGAGATCTCTGTCAGGGT 723
QY 181 AspSerGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
DB 724 GACTCCGGGGCCCTCTGCTGTGTAAACAGTCTCTTCAAGGCATTATCTCTGGGGCCAG 783
QY 201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
DB 784 GATCGGTGTGCATCACCCGAAAGCCTGGTGTCTACAGAAAGTCTGCAAAATATGTGGAC 843
QY 221 TrpIleGlnGluThrMetLysAsnAsn 229
DB 844 TGGATCCAGGAGCAGCATGAAGCAAT 870

RESULT 6
AB012917. 1186 bp mRNA linear PRI 31-JAN-2003
LOCUS Homo sapiens mRNA for serine protease (TUSP), complete cds.
DEFINITION AB012917
ACCESSION AB012917.1 GI:3649790
VERSION TUSP; serine protease (TUSP).
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
Yoshida,S., Taniguchi,M., Suemoto,T., Oka,T., He,X. and Shioesaka,S.
cDNA cloning and expression of a novel serine protease, TUSP
Biochim. Biophys. Acta 1399 (2-3), 225-228 (1998)
98438738
Hokkaido 078-8510, Japan [E-mail: syoehida@asahikawa-med.ac.jp].
Tel:81-156-68-2300, Fax:81-156-68-2309)
PUBMED 9765601
Direct Submission
Yoshida,S.
TUSP
SUBMITTED (10-Apr-1998) Shigetaka Yoshida, Department of Anatomy 1,
Asahikawa Medical College, Midorigaoka Higashi 2-1-1, Asahikawa,
Hokkaido 078-8510, Japan [E-mail: syoehida@asahikawa-med.ac.jp].
Tel:81-156-68-2300, Fax:81-156-68-2309)
JOURNAL
FEATURES
Location/Qualifiers
1..1186
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
26..874
/codon_start=1
/product="serine protease (TUSP)"
/protein_id="BA033404.1"
/db_xref="GI:3649791"
/translation="MORLRWLRDWKSSGRGLTAKEFGARSSPLQARILQLILALA
TGLVGGETRIIKGPECKPHSPQWQALFEKTRLLCGATLIAPRWLLTAHCKLPRIY
HLGQHNQKEEGCEQTRTATESPPHPGFNNSLPNKDHNDIMLVKASPVSLTWVRP
LTLSSRCVYAGTSLGISGWSSTSPCLSLPHTLSCANITIEHQKCNAYRGNITDM
VCASVQSGGRKDSQSGSGPLVCNOSLOGISWGGDFCATITRPGVYTKVYKIVDWIQ
ETMKN"
185..871
mat_peptide

```

```

/product="TUSP"
polyA_signal 1164..1169
polyA_site 1186
BASE COUNT 271 a 368 c 303 g 244 t
ORIGIN
Alignment Scores:
Pred. No.: 4,46e-97 Length: 1186
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 9 Gaps: 0
US-09-856-320A-2_COPY_54_282 (1-229) x AB012917 (1-1186)
QY 1 IleIleIleGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
DB 185 ATCATCAAGGGTTCAGTGCAGGCTCTACCCAGCCCTGGCAGGCGCCCTGTTTCGAG 244
QY 21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
DB 245 AAGACGCGGCTACTCTGTGGGGCGAGCGCTCATCGCCCCCAGATGGCTCTCTGACAGCAGCC 304
QY 41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
DB 305 CACTGCTCTCAAGCCCCGCTACATAGTTCACTTGGGGCAGCACAACCTCCAGAGAGGAGGAG 364
QY 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
DB 365 GCGTGTGAGCAGAGCCCGACAGCCACTGAGTCTCTCCACCACCCCGGCTTCAACAACAGC 424
QY 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
DB 425 CTCCCAACAAAGACCAACGCAATGACATCATGCTGGTGAAGATGGCATGCCAGTCTCC 484
QY 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
DB 485 ATCACTGGCTGTGGAGCCCTCACTCCCTCTCTCACGCTGTGTCACTGCTGCGCACCCAGC 544
QY 121 CysLeuLeuSerGlyTyrGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
DB 545 TGCTCTCAATTCGGGTGGGGGAGCAGCAGCTCCAGGCCCCAGTTCGCTGCTCTACACCTTG 604
QY 141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
DB 605 CGATGGCCCAACATCACCATCATTTGAGCAGCAGAAAGTGTGAGAACGCTACCCCGGCAAC 664
QY 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyCysLysAspSerCysGlnGly 180
DB 665 ATCAAGACACCATCGTGTGCTCCAGCTGCAGGAGGGGGCAAGGACTCTCTGCGCAGGGT 724
QY 181 AspSerGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
DB 725 GACTCCGGGGCCCTCTGCTGTGTAAACAGTCTCTTCAAGGCATTATCTCTGGGGCCAG 784
QY 201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
DB 785 GATCGGTGTGCATCACCCGAAAGCCTGGTGTCTACAGAAAGTCTGCAAAATATGTGGAC 844
QY 221 TrpIleGlnGluThrMetLysAsnAsn 229
DB 845 TGGATCCAGGAGCAGCATGAAGCAAT 871
RESULT 7
AB012917
LOCUS Sequence 8 from patent US 6232456.
DEFINITION AR152174
ACCESSION AR152174
VERSION AR152174.1 GI:15118224
KEYWORDS Unknown.
SOURCE

```

```

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1192)
AUTHORS Cohen, M., Colpitts, T.L., Friedman, P.N., Granados, B., Klass, M.R.,
TITLE Serine protease reagents and methods useful for detecting and
JOURNAL treating diseases of the prostate
FEATURES
SOURCE Patent: US 6232456-A 8 15-MAY-2001;
Location/Qualifiers
1..1192
/organism="unknown"
BASE COUNT 279 a 385 c 290 g 238 t
ORIGIN
Alignment Scores:
Pred. No.: 4,48e-97 Length: 1192
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6
US-09-856-320A-2_COPY_54_282 (1-229) x AR152174 (1-1192)
Qy 1 IleIleLeuGlyPheGluCysLeuProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
Db 170 ATCATCAAGGGGTTTCAGTGGAGCCCTCACTCCAGCCCTGGAGGAGCCCTGTCGAG 229
Qy 21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTTPLeuLeuThrAlaAla 40
Db 230 AAGACCGCGCTACTCTGTTGGGGCGAGCCTCATCGCCCCAGATGCTCTTCACAGCAGCC 289
Qy 41 HisCysLeuLeuProArgTyrIleValHisLeuGlyGlnHisLeuGlnLeuGluGlu 60
Db 290 CACTGCTCAAGCCCGCTACATAGTTCACTTGGGGCAGCAACCTCCAGAGGAGGAG 349
Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
Db 350 GACTGTGAGCAGACCGGAGCAGCAGTCACTGCTCTTCCCGCCCGGCTTCACACAGC 409
Qy 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
Db 410 CTCCTCCAAAGAACCCAGGCAATGATCATCTGTTGGTGAAGATGGCATGCCAGTCTCC 469
Qy 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db 470 ATCACCTGGGCTGTGGACCCCTCACCTCTCTCCAGCTGTGTCACTGTGGCACCAGC 529
Qy 121 CysLeuIleSerGlyTyrGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
Db 530 TGCTCTATTTCGGGTGGGGCAGCAGCTCCAGCCCGAGTTACGCTTCACACCTTG 589
Qy 141 ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
Db 590 CGATGGCCCAATCATCACCCTTTGAGCCACCAAGAGTGTGAGAGCGCTACCCCGGCAAC 649
Qy 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
Db 650 ATCACAGACACCATGGTGTGGCCAGCGTGCAGGAAGGGGGGCAAGGACTCTCTGCCAGGGT 709
Qy 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTyrGlyGln 200
Db 710 GACTCCGGGGGCGCTCTGCTGTGTAAACAGTCTCTTCAAGGCATTATCTCTCTGGGCCAG 769
Qy 201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
Db 770 GATCCGTGTGCATCACCCTGAAAGCCCTGTGTACACGAAGTCTGCAATATGTGGAC 829
Qy 221 TrpIleGlnGluThrMetLysAsnAsn 229
Db 830 TGGATCCAGGAGACATGAAGAAACAAT 856
RESULT 8.

```

```

AX358932
LOCUS AX358932 1204 bp DNA linear PAT 13-FEB-2002
DEFINITION Sequence 185 from Patent WO0193983.
ACCESSION AX358932
VERSION AX358932.1 GI:18675367
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Baker, K.P., Deanoyers, L., Gerritsen, M.E., Goddard, A.,
Godowski, P.J., Grimaldi, J.C., Gurney, A.L., Smith, V., Stephan, J.P.,
Watanabe, C.K., and Wood, W.I.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
JOURNAL the same
JOURNAL Patent: WO 0193983-A 185 13-DEC-2001;
Genentech Inc. (US)
FEATURES
SOURCE Location/Qualifiers
1..1204
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 306 a 364 c 294 g 240 t
ORIGIN
Alignment Scores:
Pred. No.: 4,53e-97 Length: 1204
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6
US-09-856-320A-2_COPY_54_282 (1-229) x AX358932 (1-1204)
Qy 1 IleIleLeuGlyPheGluCysLeuProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
Db 169 ATCATCAAGGGGTTTCAGTGGAGCCCTCACTCCAGCCCTGGAGGAGCCCTGTCGAG 228
Qy 21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTTPLeuLeuThrAlaAla 40
Db 229 AAGACCGCGCTACTCTGTTGGGGCGAGCCTCATCGCCCCAGATGCTCTTCACAGCAGCC 288
Qy 41 HisCysLeuLeuProArgTyrIleValHisLeuGlyGlnHisLeuGlnLeuGluGlu 60
Db 289 CACTGCTCAAGCCCGCTACATAGTTCACTTGGGGCAGCAACCTCCAGAGGAGGAG 348
Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
Db 349 GCTGTGAGCAGACCGGAGCAGCAGTCACTGAGTCTTCCCGCCCGGCTTCACACAGC 408
Qy 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
Db 409 CTCCTCCAAAGAACCCAGGCAATGATCATCTGTTGGTGAAGATGGCATGCCAGTCTCC 468
Qy 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db 469 ATCACCTGGGCTGTGGACCCCTCACCTCTCTCCAGCTGTGTCACTGTGGCACCAGC 528
Qy 121 CysLeuIleSerGlyTyrGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
Db 529 TGCTCTATTTCGGGTGGGGCAGCAGCTCCAGCCCGAGTTACGCTTCACACCTTG 588
Qy 141 ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
Db 589 CGATGGCCCAATCATCACCCTTTGAGCCACCAAGAGTGTGAGAGCGCTACCCCGGCAAC 648
Qy 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
Db 649 ATCACAGACACCATGGTGTGGCCAGCGTGCAGGAAGGGGGGCAAGGACTCTCTGCCAGGGT 708
Qy 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTyrGlyGln 200

```

Db	529	TCCTCAATTCCTGGCTGGGACAGCATGTCCAGCCCTTACCTGCTTACACCTTG	588
Qy	141	ATGCVSAlaAenillethrllelGluHleGlnLysCysGluAsnAlaTyPrSGLyAsn	160
Db	589	CGATCGGCAACATCAACCATCATTTAGACACCAAGAGTGTGAAGACGCTACCCGGCAAC	648
Qy	161	ileThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly	180
Db	649	ATCAGAGACACATGTGTGTGTGCACGCTGCAGAGGAGGGGCAAGGATCTCTGCGAGGT	708
Qy	181	AppSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyLleIleSerTrpGlyGln	200
Db	709	GACTCGGGGGCCCTCTGGTCTGTACCAAGTCTCTCAAGGCATATTATCTCTCGGGCCAG	768
Qy	201	AppProCysAlaIleThrArgLysProGlyValThrLysValCysLysValAsp	220
Db	769	GATCGTGTGGATCATCCCGAAGCCTGTGTCTACAGCAAGTCTGCAATATATGAC	828
Qy	221	TrpIleGlnGluThrMetLysAsnAsn	229
Db	829	TGATCCAGGAGCGATGAAGACAAAT	855
RESULT 10			
LOCUS	AX454622	1204 bp	DNA linear PAT 06-JUL-2002
DEFINITION	Sequence 207 from Patent WO0208284.		
ACCESSION	AX454622		
VERSION	AX454622.1	GI:21713935	
KEYWORDS			
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
	1		
TITLE	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis		
JOURNAL	Patent: WO 0208284-A 207 31-JAN-2002;		
	Genentech, Inc. (US); Baker, Kevin P. (US); Ferrara, Napoleone		
	(US); Gerber, Hanspeter (US); Gerritsen, Mary E. (US); Goddard,		
	Audrey (US); Godowski, Paul J. (US); Gurney, Austin L. (US);		
	Hillan, Kenneth J. (US); Marsters, Scot A. (US); Pan, James (US)		
	; Paoni, Nicholas F. (US); Stephan, Jean-Philippe F. (US);		
	Watanabe, Colin K. (US); Williams, P. Mickey (US); Wood, William		
	I. (US)		
FEATURES	Location/Qualifiers		
source	1..1204		
	/organism="Homo sapiens"		
	/mol_type="genomic DNA"		
	/db_xref="taxon:9606"		
BASE COUNT	306 a 364 c 294 g 240 t		
ORIGIN			
Alignment Scores:			
Pred. No.:	4,53e-97	Length:	1204
Score:	1258.00	Matches:	229
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	5	Gaps:	0
US-09-856-320A-2_COPY_54_282 (1-229) x AX454622 (1-1204)			
Qy	1	IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu	20
Db	169	ATCATCAAGGGTTCGAGTGCAGCCCTACTCCAGCCCTGGCAGGACGCCCTGTTCCAG	228
Qy	21	LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProAaGTrpLeuLeuThrAlaAla	40

```

Db      229  AAGACGGCGCTACTCTGTGGGGGCGACGCTCATCGCCCCCAGATGGCTCTCTGACAGCAGCC 288
Qy      41   HisCysLeuLeuProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
Db      289  CACTGCTCAAGCCCGCTACATAGTTCACTCTGGGCGACGACCACTCCAGAGGAGGAG 348
Qy      61   GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
Db      349  GGCTGTGACGACGACCGGACGACGACCTAGTGTCTTCCCTCCACCCCGGCTTCAACAACAGC 408
Qy      81   LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
Db      409  CTCCCAACAAGACACCGCATGATCATCTCTGGTGAATGGCATGCCAGTCTCC 468
Qy      101  IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db      469  ATCACCCTGGCTGTGGACCCCTCACCTCTCTCAGCTGTGTCACTGCTGGCACCAGC 528
Qy      121  CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
Db      529  TGCTCTCATTTCCGGCTGGGGGAGCAGCTCCAGCCCTCAGTTACGCTCTCCCTCACACCTTG 588
Qy      141  ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
Db      589  CGATGCGCCCAACATCACCATCATTTGAGCACCAGAGTGTGAGAACCTTACCCCGGCAAC 648
Qy      161  IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyValAspSerCysGlnGly 180
Db      649  ATCAGACAGCACCATTGGTGTGGCAGGCTGCAGGAAGGGGCGAAGACTCTCTCCAGGGT 708
Qy      181  AspSerGlyCysProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
Db      709  GACTCCGGGGGCGCTCTGTCTGAACCGACTCTTCAAGGCAATTTATCTCTGGGGCCAG 768
Qy      201  AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
Db      769  GATCCGTGTGCATCACCAGAAAGCTGTGTCTACACGAAGTCTGCAATATGTGGAC 828
Qy      221  TrpIleGlnGlnThrMetLysAsnAsn 229
Db      829  TGGATCCAGGAGCATGAAGAACAAAT 855

RESULT 11
AX464372      1204 bp      DNA      linear      PAT 16-JUL-2002
LOCUS      Sequence 505 from Patent WO0140466.
DEFINITION      AX464372
ACCESSION      AX464372
VERSION      AX464372.1 GI:21899202
KEYWORDS      Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM      Homo sapiens
REFERENCE      Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Baker, K.P., Baresini, M., Deforge, L., Desnoyers, L., Filvaroff, E.,
Gao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L.,
Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K.,
Wood, W.L. and Zhang, Z.
Secrated and transmembrane polypeptides and nucleic acids encoding
same
JOURNAL      Patent: WO 0140466-A 505 07-JUN-2001;
Genentech Inc. (US)
FEATURES      Location/Qualifiers
source      1..1204
            /organism="Homo sapiens"
            /molecule="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      306 a 364 c 294 g 240 t
ORIGIN
Alignment Scores:      4.53e-97      Length:      1204
Pred. No.:      1258.00      Matches:      229
Score:

```

```

Percent Similarity: 100.00%      Conservative: 0
Best Local Similarity: 100.00%      Mismatches: 0
Query Match: 100.00%      Indels: 0
DB: 6      Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x AX464372 (1-1204)

Qy      1   IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaAlaLeuPheGlu 20
Db      169  ATATCAAGGGTTCAGTGTCAAGCTCTCACTCCACGAGCTTGGCAGGCAGCCCTGTTCGAG 228
Qy      21   LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
Db      229  AAGACGGCTACTCTGTGGGCGACGCTCATCGCCCCCAGATGGCTCTCTGACAGCAGCC 288
Qy      41   HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
Db      289  CACTGCTCAAGCCCGCTACATAGTTCACTCTGGGCGACGACCACTCCAGAGGAGGAG 348
Qy      61   GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
Db      349  GGCTGTGACGACGACCGGACGACGCTAGTGTCTTCCCTCCACCCCGGCTTCAACAACAGC 408
Qy      81   LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
Db      409  CTCCCAACAAGACACCGCATGATCATCTCTGGTGAATGGCATGCCAGTCTCC 468
Qy      101  IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db      469  ATCACCCTGGCTGTGGACCCCTCACCTCTCTCAGCTGTGTCACTGCTGGCACCAGC 528
Qy      121  CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
Db      529  TGCTCTCATTTCCGGCTGGGGGAGCAGCTCCAGCCCTCAGTTACGCTCTCCCTCACACCTTG 588
Qy      141  ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
Db      589  CGATGCGCCCAACATCACCATCATTTGAGCACCAGAGTGTGAGAACCTTACCCCGGCAAC 648
Qy      161  IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyValAspSerCysGlnGly 180
Db      649  ATCAGACAGCACCATTGGTGTGGCAGGCTGCAGGAAGGGGCGAAGACTCTCTCCAGGGT 708
Qy      181  AspSerGlyCysProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
Db      709  GACTCCGGGGGCGCTCTGTCTGAACCGACTCTTCAAGGCAATTTATCTCTGGGGCCAG 768
Qy      201  AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
Db      769  GATCCGTGTGCATCACCAGAAAGCTGTGTCTACACGAAGTCTGCAATATGTGGAC 828
Qy      221  TrpIleGlnGlnThrMetLysAsnAsn 229
Db      829  TGGATCCAGGAGCATGAAGAACAAAT 855

RESULT 12
AX491100      1204 bp      DNA      linear      PAT 16-AUG-2002
LOCUS      Sequence 207 from Patent WO0200690.
DEFINITION      AX491100
ACCESSION      AX491100
VERSION      AX491100.1 GI:22323887
KEYWORDS      Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM      Homo sapiens
REFERENCE      Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Baker, K.P., Ferrara, N., Gerber, H., Gerritsen, M.E., Goddard, A.,
Godowski, P.J., Gurney, A.L., Hillan, K.J., Marsters, S.A., Pan, J.,
Paoni, N.F., Stephen, J.P., Watanabe, C.K., Williams, P.M., Wood, W.L.
and Ye, W.
Compositions and methods for the diagnosis and treatment of
disorders involving angiogenesis
TITLE

```

JOURNAL Patent: WO 0200690-A 207 03-JAN-2002;
Genentech, Inc. (US)
FEATURES
SOURCE
1. .1204
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 306 a 364 c 294 g 240 t
ORIGIN

Alignment Scores:
Pred. No.: 4,53e-97 Length: 1204
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x AX491100 (1-1204)

Oy 1 IletlelysglypheglucyvalysprohisserglnprotrpGlnAlaLeuPheGlu 20
Db 169 ATCATCAAGGGTTCAGTGCAGGCTCACTCCAGCCCTGGCAGGAGCCCTGTTCGAG 228
Oy 21 LysThrArgLeuLeuLeuGlyAlaThrLeuLeuAlaProArgTrpLeuLeuThraAla 40
Db 229 AAGACCGGCTACTCTGTGGGCGAGCTCATCGCCGCCAGATGGCTCTGACAGCAGCC 288
Oy 41 HisCysLeuLeuProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnIlysglu 60
Db 289 CACTGCTCAAGCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAGGAGGAG 348
Oy 61 GlyCysGluGlnThrArgThrAlaThrLeuLeuSerPheProHisProGlyPheAsnSer 80
Db 349 GGCTGTGACGACACCGGACGACCTAGTGTCTTCCCCCAGCCCGCTTCAACAGCAGC 408
Oy 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
Db 409 CTCCCCAACAAAGACACCGCAATGACATCATGTGTGTGAAGATGGCATGCCAGTCTCC 468
Oy 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db 469 ATCACCTGGGCTGTGGACCCCTCACCTCTCTCAGCTGTGTACTGCTGGCAGCAGC 528
Oy 121 CysLeuLeuSerGlyTrpGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
Db 529 TGCTCTATTTCGGCTGTGGGCGAGCAGCTCCAGCCCGCTAGCTAGCTGCTCCAGCCTTG 588
Oy 141 ArgCysAlaAsnIleThrIleleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
Db 589 CGATGGCCCAACATCACCATCATTTGAGCAGCAGCAGAGTGTGAGAAGCCCTACCCCGCAAC 648
Oy 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyIleValAspSerCysGlnGly 180
Db 649 ATCACAGACACCATGTGTGTGCCAGGTGCAGAGGGGGCAAGGACTCTCTGCCAGGGT 708
Oy 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleleSerTrpGlyGln 200
Db 709 GACTCCGGGGCCCTCTGTGTGAACAGTCTCTTCAAGGCATTATCTCTGGGGCCAG 768
Oy 201 AspProCysAlaIleThrArgLysProGlyValIleThrValCysLeuValAsp 220
Db 769 GATCCGTGTGCCATCACCCGAAAGCCCTGGTGTCTACACGAAAGTCTGCAATATGTGGAC 828
Oy 221 TrpIleGlnGlyThrMetLysAsn 229
Db 829 TGGATCCAGGACGATGAAGAACAAT 855

RESULT 13
AX697101
LOCUS
DEFINITION Sequence 169 from Patent WO0078961.
ACCESSION AX697101

AX697101.1 GI:29498066
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM

REFERENCE
AUTHORS
Ferrara, N., Stewart, T.A., Williams, P.M., Baker, K.P., Deanoyers, L.,
Sutton, D.L., Gao, W.Q., Pan, J., Botstein, D., Fong, S., Goddard, A.,
Godowski, P.J., Gurney, A.L., Smith, V., Tumas, D., Wood, W.I.,
Grimaldi, C.J., Hillan, K.J., Paoni, N.F., Roy, M.A. and Watanabe, C.K.
Secreted and transmembrane polypeptides and nucleic acids encoding
the same

JOURNAL Patent: WO 0078961-A 169 28-DEC-2000;

Genentech Inc. (US)
FEATURES
Location/Qualifiers
1. .1204
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

BASE COUNT 306 a 364 c 294 g 240 t
ORIGIN

Alignment Scores:
Pred. No.: 4,53e-97 Length: 1204
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x AX697101 (1-1204)

Oy 1 IletlelysglypheglucyvalysprohisserglnprotrpGlnAlaLeuPheGlu 20
Db 169 ATCATCAAGGGTTCAGTGCAGGCTCACTCCAGCCCTGGCAGGAGCCCTGTTCGAG 228
Oy 21 LysThrArgLeuLeuGlyAlaThrLeuLeuAlaProArgTrpLeuLeuThraAla 40
Db 229 AAGACCGGCTACTCTGTGGGCGAGCTCATCGCCGCCAGATGGCTCTGACAGCAGCC 288
Oy 41 HisCysLeuLeuProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnIlysglu 60
Db 289 CACTGCTCAAGCCCGCTACATAGTTCACCTGGGGCAGCACAACCTCCAGAGGAGGAG 348
Oy 61 GlyCysGluGlnThrArgThrAlaThrLeuLeuSerPheProHisProGlyPheAsnSer 80
Db 349 GGCTGTGACGACACCGGACGACCTAGTGTCTTCCCCCAGCCCGCTTCAACAGCAGC 408
Oy 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
Db 409 CTCCCCAACAAAGACACCGCAATGACATCATGTGTGTGAAGATGGCATGCCAGTCTCC 468
Oy 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db 469 ATCACCTGGGCTGTGGACCCCTCACCTCTCTCAGCTGTGTACTGCTGGCAGCAGC 528
Oy 121 CysLeuLeuSerGlyTrpGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
Db 529 TGCTCTATTTCGGCTGTGGGCGAGCAGCTCCAGCCCGCTAGCTAGCTGCTCCAGCCTTG 588
Oy 141 ArgCysAlaAsnIleThrIleleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
Db 589 CGATGGCCCAACATCACCATCATTTGAGCAGCAGCAGAGTGTGAGAAGCCCTACCCCGCAAC 648
Oy 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyIleValAspSerCysGlnGly 180
Db 649 ATCACAGACACCATGTGTGTGCCAGGTGCAGAGGGGGCAAGGACTCTCTGCCAGGGT 708
Oy 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleleSerTrpGlyGln 200
Db 709 GACTCCGGGGCCCTCTGTGTGAACAGTCTCTTCAAGGCATTATCTCTGGGGCCAG 768


```

Qy 201 AppProCyAlaIleThrArglyProGlyVallyThrlyValCyAllyTyValasp 220
Db 769 GATCCGTGTGGATCACCGGAAGCGTGTGTCTACAGGAAGTCTGCATAATATGTGCAC 828

Qy 221 TptileGlnGluThrMetlyAsnAsn 229
Db 829 TGGATCCAGGACGATGAAGAACAA 855

RESULT 14
BC022068 1213 bp mRNA linear PRI 24-JAN-2002
LOCUS Homo sapiens, kallikrein 11, clone MGC:33060 IMAGE:4824387, mRNA,
DEFINITION complete cds.
ACCESSION BC022068
VERSION 1 GI:18314497
KEYWORDS MGC
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 1213)
AUTHORS Strausberg R.
TITLE Direct Submission
JOURNAL Submitted (22-JAN-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT Contact: MGC help desk
Email: cgapbs@mail.nih.gov
Tissue Procurement: Miklos Palkovits, M.D., Ph.D.
CDNA Library Preparation: Michael J. Brownstein (NHGRI) & Shiraki
Toshiyuki and Piero Carninci (RIKEN)
CDNA Library Arrayed by: the I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
http://www.isysbiology.org
contact: amadan@systemsbiology.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Kettelman, Anuradha
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAC Plate: 46 Row: n Column: 6
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 5803198.
Location/Qualifiers
1..1213
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="LOCUSID:11012"
/db_xref="taxon:9606"
/clone="MGC:33060 IMAGE:4824387"
/tissue_type="Testis"
/clone_lib="NIH_MGC_97"
/lab_host="DH10B"
/notes="Vector: pBluescript"
133..885
/codon_start=1
/product="Kallikrein 11"
/protein_id="AAH22088.1"
/db_xref="GI:18314498"
/translation="MRILQILALATGLVGGTIRIKGFCKPHSQPQQAALFKTR
LUCGATLAPWLTAAHCUKPRVIVLQHNLOKEGCEQTRTATESPHGFNNSL
PKNHRNDIMLVKASPVSTWAVRELTLSRCVPTAGTSCLSIGWSTSSPOLRPH
LRCANITIEHQKNEAYPGNITDITWVCASVOEGGKSCQDSDSGPLVNCNLSQGIIS
WQDPCATIRFQYTKVYKVDWIOETMKN"
BASE COUNT 290 a 376 c 296 g 251 t
ORIGIN

Alignment Scores: 4,57e-97 Length: 1213
Pred. No.: 1258.00 Matches: 229
Score: 100.00% Conservative: 0
Percent Similarity: "

```

```

Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 5 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x BC022068 (1-1213)

Qy 1 IletlelysglyPheglucyslyspromisserglnProtrpGlnAlaAlaLeuPheGlu 20
Db 196 ATCATCAAGGGTTTCAGTTCGAAGCTCTCACTCCAGGCGCTGGCAGGCGAGCCCTGTTTCGAG 255

Qy 21 LysThrArgLeuLeuCyGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
Db 256 AAGACGGCGGTACTCTGTGGGGGAGCGCTCATCGCCCCAGATGGCTCTCTGACAGCAGCC 315

Qy 41 HisCysLeuLysProArgTyrIleValHisCysGlyGlnHisLeuGlnLysGluGlu 60
Db 316 CACTGCTTCAAGCCCCGCTACATAGTTCACTGGGGGAGCACAACCTCCAGAGGAGGAG 375

Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
Db 376 GGCTGTGAGCAGACCCGAGCAGCCACTGAGTCTTCCGCCACCCCGGCTTCAACACAGC 435

Qy 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
Db 436 CTCGCCAACAAAGACCAACCGCAATCATCATCTGCTGAAGATGGCATCGCCAGTCTCC 495

Qy 101 IletThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db 496 ATCACTGGGCTGTGCGACCCCTCACTCCCTCTCTGCTCACTGCTGGCCACCAGC 555

Qy 121 CysLeuIleSerGlyTrpGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
Db 556 TGCTCATTTCCCGCTGGGGGAGCAGCGTCCAGCCCCCAGTTAGCTGCTCTCACACCTTG 615

Qy 141 ArgCysAlaHisIleThrIleIleGluHisGlnLysCysGluHisAlaIleTrpGlyAsn 160
Db 616 CGATGGCCCAACATCACTACCATTCATTGAGCAGCAGAGTGTGAGAACGCTTACCCGCGCAAC 675

Qy 161 IletThrAspThrMetValCysAlaSerValGlnGluGlyCysGlyValSerCysGlnGly 180
Db 676 ATCACAGACACCATGTGTGTGCGCAGCGTGGAGAGGGGCGAAGCACTCTCTGCCAGGGT 735

Qy 181 AspSerGlyCysProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
Db 736 GACTCCGGGGGCGCTCTGTCTGTAAACGAGTCTTCAAGGCATTATCTCTCGGGGCGAG 795

Qy 201 AspProCysAlaIleThrArglyspProGlyVallyThrlyValCyslyspTyValasp 220
Db 796 GATCCGTGTCCGATCACCGGAAGCGTGTCTTACAGGAAGTCTGCAAAATATGTGCAC 855

Qy 221 TptileGlnGluThrMetlyAsnAsn 229
Db 856 TGGATCCAGGACGATGAAGAACAA 882

RESULT 15
LOCUS BD091587 1301 bp DNA linear PAT 27-AUG-2002
DEFINITION Novel serine protease BSSP6.
ACCESSION BD091587
VERSION BD091587.1 GI:22637198
KEYWORDS WO 0031257-A/1.
SOURCE Homo sapiens
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 1301)
AUTHORS Uemura, H., Okui, A., Kominami, K., Yamaguchi, N. and Mitsui, S.
TITLE Novel serine protease BSSP6
JOURNAL Patent: WO 0031257-A 1 02-JUN-2000;
FUSO PHARMACEUTICAL INDUSTRIES LTD, HIDETOHSHI UEMURA, AKIRA OKUI,
KATSUYA KOMINAMI, NOZOMI YAMAGUCHI, SHINICHI MITSUI
COMMENT OS Homo sapiens (human)
PN WO 0031257-A/1

```


PD 02-JUN-2000
 PF 19-NOV-1999 WO 1999JP006476
 PR 20-NOV-1998 JP 98P 347802
 PI HIDETOSHI UEMURA,AKIRA OKUI,KATSUYA KOMINAMI,NOZOMI YAMAGUCHI,
 SHINICHI MITSUI
 PC C12N15/12,C12N9/64,C12N5/06,C12N1/21,C07K16/40,C12P21/08,PC
 A01K67/027,
 PC G01N33/543

FEATURES

source
 1. .1301
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 BASE COUNT 332 a 397 c 330 g 252 t
 ORIGIN

Alignment Scores:
 Pred. NO.: 4.92e-97 Length: 1301
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 6 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x BD091587 (1-1301)

Qy	1	IleIleIleGlyPheGlnCysIleProHisSerGlnProTrrGlnAlaAlaLeuPheGlu	20
Db	272	ATCATCAAGGGTTTGAGTGGAGCCCTCCTCCAGCCCTGGCAGGAGCCCTGTTTGAG	331
Qy	21	LythArgLeuLeuGlyAlaThrLeuIleAlaProArgTrrLeuThrAlaAla	40
Db	332	AGACCGGCTACTCTGTGGGGCAGCCCTCATGCCCCGAGATGCTCTGCACAGCAGCC	391
Qy	41	HisCysLeuLeuProArgTrrIleValHisLeuGlyGlnHisAsnLeuGlnGluGlu	60
Db	392	CACCTGCTCAAGCCCGCTACATAGTTACCTCGGGCAGCACAACCTCCAGAGGAGGAG	451
Qy	61	GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer	80
Db	452	GGCTGTGACGACCCGAGCAGCCACTGAGTCTCTCCCGCCCGGGTTCAACACAGC	511
Qy	81	LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer	100
Db	512	CTCCCCAACAAAGACCAACCGCAATGACATCATGCTGGTGAAGATGGCATGCCAGTCTCC	571
Qy	101	IleThrTrrAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer	120
Db	572	ATCAGCTGGGCTGTGGACCCCTCACCCTCTCTCAGCTGTGTCTGCTGGCAGCCAGC	631
Qy	121	CysLeuIleSerGlyTrrGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu	140
Db	632	TGCTCATTTCCGGCTGGGGCAGCAGCTCCAGCCCCAGTTAAGCTGCTCCTCACACCTTG	691
Qy	141	ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn	160
Db	692	CGATCGCCCAACATCACCATCATTTAGCACCAGAGTGTGAGAACGCCCTACCCCGGCAAC	751
Qy	161	IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly	180
Db	752	ATCACAGACACCATGGTGTGTGGCCAGGTGCAGAGAGGGGCGAGGACTCTCTGCCAGGGT	811
Qy	181	AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrrGlyGln	200
Db	812	GACTCGGGGGCCCTCTGGTCTGAACCACTCTCTTCAGAGGCATTATCTCTGGGGCCAG	871
Qy	201	AspProCysAlaIleThrArgLysProGlyValTrrThrLysValCysLysTrrValAsp	220
Db	872	GATCGGTGGCATCACCCGAAAGCCCTGGTGTCTACACGAAAGTCTGCAAAATATGTGGAC	931
Qy	221	TrrIleGlnGluThrMetLysAsnAsn	229

Db 932 TGGATCCAGGAGACGATGAAGACAAT 958
 Search completed: October 23, 2003, 18:05:25
 Job time : 3420.8 secs

THIS PAGE BLANK (uspto)

and is derived by analysis of the total score distribution.

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: October 23, 2003, 14:05:42 ; Search time 251.855 Seconds
(without alignments)
2454.471 Million cell updates/sec

Title: US-09-856-320A-2_COPY_54_282

Perfect score: 1258

Sequence: 1 IIKTECKPHSQPMQALPE.....GVYTKVCKYVDWQIETMKN 229

Scoring table:
BLOSUM62
Xgapop 10.0 ; Xgapext 0.5
Ygapop 10.0 ; Ygapext 0.5
Zgapop 6.0 ; Zgapext 7.0
Delop -6.0 ; Delext 7.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODE=frame+pn.model -DB=xlh
-O=/cgn2_1/USPTO.spool/US09856320/runat_22102003_121413_25652/app_query.fasta_1.846
-DB=N_Geneseq_19Jun03 -OFT=fastap -SUFFIX=ring -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -LOCAL -OUTFT=ptc -THR_SCORE=ptc -THR_MAX=100 -THR_MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US09856320 @CGN 1.1 401 @runat_22102003_121413_25652 -NCPU=3
-NO_MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -DSBLOCK=100 -LONGLOC
-DEV_TIMEOUT=120 -WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N_Geneseq_19Jun03.:

- 1: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
- 2: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
- 3: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
- 4: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
- 5: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
- 6: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
- 7: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
- 8: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
- 9: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
- 10: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
- 11: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
- 12: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
- 13: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
- 14: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
- 15: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
- 16: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
- 17: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
- 18: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
- 19: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
- 20: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
- 21: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
- 22: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
- 23: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
- 24: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*
- 25: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1258	100.0	1106	20	AA222638	CASB12 nucleotide
2	1258	100.0	1158	20	AA222639	CASB12 derived fro
3	1258	100.0	1186	24	ABK92131	Prostate cancer-as
4	1258	100.0	1186	25	ABX76468	Lung cancer-associ
5	1258	100.0	1192	22	AA114842	Human PS133 gene c
6	1258	100.0	1204	21	AAA37072	Human PRO1279 (UNQ
7	1258	100.0	1204	22	AAG21496	Human cDNA sequenc
8	1258	100.0	1204	22	AAG21496	Human cDNA sequenc
9	1258	100.0	1204	24	ABU88175	Human angiotensin
10	1258	100.0	1204	24	ABU88175	Human PRO1279 cDNA
11	1258	100.0	1204	24	ABK31328	cDNA encoding huma
12	1258	100.0	1204	25	AC303355	cDNA encoding huma
13	1258	100.0	1204	25	AC303376	Human cDNA encodin
14	1258	100.0	1204	25	AC303376	Human cDNA encodin
15	1258	100.0	1292	22	ABA83372	Human secreted pro
16	1258	100.0	1301	21	AA611763	cDNA encoding huma
17	1258	100.0	1314	21	AA230222	cDNA encoding huma
18	1248	99.2	1146	20	AAV84589	Human secreted pro
19	1248	99.2	1146	22	ABA83430	Human secreted pro
20	1246	99.0	1166	22	AA114841	Human PS133 consen
21	1235.5	98.2	934	21	AA611765	cDNA encoding huma
22	1228	97.6	1191	20	AA297777	Extended human sec
23	1227.5	97.6	1335	21	AA245572	Nucleotide sequenc
24	1219.5	96.9	1052	21	AA287798	Activation constru
25	1219.5	96.9	1052	22	AA287798	Nucleotide sequenc
26	1213	96.4	833	19	AAV42525	DNA encoding a hum
27	1042	84.4	1323	21	AA611764	cDNA encoding mous
28	1014.5	80.6	1164	24	AA551883	DNA encoding huma
29	916.5	72.9	618	24	ABK30233	Human G-protein-co
30	829	65.9	762	21	AAH31050	Human colon cancer
31	829	65.9	762	21	AAH31061	Human colon cancer
32	736	58.5	1375	22	AA268766	Human cDNA encodin
33	736	58.5	1438	22	ABQ93555	Human coding seque
34	734	58.3	1365	22	AA541087	cDNA encoding nove
35	716	56.9	924	22	AA541522	cDNA encoding nove
36	716	56.9	924	22	AA526346	Human cDNA encodin
37	716	56.9	924	23	ABK41355	cDNA encoding nove
38	684	54.4	1322	24	AB199534	Mouse ischaemic co
39	684	54.4	1333	17	AA148519	Human neuropilin-9
40	684	54.4	1333	18	AA163251	Mouse neuropilin-9
41	683	54.3	942	20	AA211030	Human serine prote
42	682	54.2	963	24	AA305070	Human protease, PR
43	682	54.2	963	24	ABK31774	DNA encoding novel
44	682	54.2	1278	24	ABK48347	cDNA encoding nove
45	681	54.1	809	23	AA587560	DNA encoding novel

ALIGNMENTS

RESULT 1
AA222638
ID AA222638 standard; cDNA; 1106 BP.
XX AA222638;
AC AA222638;
DT 08-DEC-1999 (first entry)
DE CASB12 nucleotide sequence.
XX CASB12 nucleotide sequence.
XX neuropilin; cancer; assay; inhibitor; serine protease; immunogenic;
KW ds.
XX Homo sapiens.
XX Key Location/Qualifiers
FH 14..862
FT

CC homology with neuropilin and the encoded protein AYA4239 is structurally
 CC related to other proteins of the serine protease family, having homology
 CC and/or structural similarity with neuropilin. It is expected that as well
 CC as similar structure, these proteins will also share similar biological
 CC functions and properties.
 CC The CASB12 polypeptides and polynucleotides can be used to develop
 CC methods for identifying agonists and antagonists/inhibitors of these
 CC molecules, and thereby treating conditions associated with CASB12
 CC polypeptide imbalance. The invention also provides for diagnostic assays
 CC for detecting diseases associated with inappropriate CASB12 polypeptide
 CC activity or levels.
 CC Since CASB12 is either specifically expressed or highly over-expressed
 CC in tumors compared to normal cells, the polypeptides and polynucleotides
 CC of the invention are believed to be important immunogens for specific
 CC prophylactic or therapeutic immunization against tumors. The
 CC polypeptides and polynucleotides can therefore be targeted by antigen
 CC specific immune reactions (which result in the destruction of the tumor
 CC cell) or they can be used to diagnose the occurrence of tumor cells
 XX
 SQ Sequence 1158 BP; 274 A; 359 C; 306 G; 219 T; 0 other;

Alignment Scores:

Pred. No.: 4, 8e-105 Length: 1158
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservativity: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 20 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x AA222639 (1-1158)

QY 1 ILeileYsGlyPheGluCysLeuProHisSerGlnProTgAlaAlaLeuPheGlu 20
 DB 243 ATCATCAAGGGTTTCAGTGAAGCTTCACTCCAGCCCTGCGAGGAGCCCTGTCGAG 302
 QY 21 LysThrArgLeuLeuGlyGluValAlaThrLeuLeuAlaAlaProArgTgPheLeuThrAlaAla 40
 DB 303 AAGACGGCTACTCTGAGGCGCAGCTATCTCCCGCAGATGCTCTCTGACGAGCC 362
 QY 41 HisCysLeuLeuProArgTgYileValHisLeuGlyGlnHisAsnLeuGlyGlu 60
 DB 363 CACTGCTCAAGCCCGCTACATAGTTCACTGGGCGAGCACAACCTCAGAGGAGGAG 422
 QY 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer 80
 DB 423 GGCTGTGAGCAGACCCGAGCAGCCACTGAGTCTCTTCCCGCCCGGCTTCAACACAGC 482
 QY 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValIleMetAlaSerProValSer 100
 DB 483 CTCCCAACACAGACCCAGCAGCATCATGCTGTGAGATGGATGCCAGCTCTCC 542
 QY 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
 DB 543 ATCAGCTGGGCTGTGGACCCCTCCCTCTCTCAGCTGTGTGCTGCTGGCAGCAGC 602
 QY 121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
 DB 603 TGCCCTCATTTCCGGTGGGCGAGCAGCTCCAGCCCGCCAGTTCAGCTGCTCCACACCTTG 662
 QY 141 ArgCysAlaAsnIleThrIleGluGluHisGlyCysGluAsnAlaGlyProGlyAsn 160
 DB 663 CGATGGCCCACTTCCATCTATTGACACCAAGGTGTGAGAGCTCTCCCGGAC 722
 QY 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyIleYAspSerCysGlnGly 180
 DB 723 ATCAGACAGACCATGTTGTGCGAGGCTGACGAGAGGGGGGAGGAGTCTCCGAGGGT 782
 QY 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
 DB 783 GACTCCGGGGGGCCCTCTGCTGTAAACAGTCTCTTCAAGGCATTATCTCTCGGGCCAG 842
 QY 201 AspProCysAlaIleThrArgLeuProGlyValThrThrValCysLeuValValAsp 220

Db 843 GATCCCTGTGCGATCACCAGGAGCTGTGTCTACACGAAAGTCTGCAAAATATGTGGAC 902
 QY 221 TptlleGlnGluThrMetLysAsnAsn 229
 DB 903 TGGATCCAGGAGACGATGAAGAACAAT 929
 RESULT 3
 ABK92131
 ID ABK92131 standard; DNA; 1186 BP.
 XX
 AC ABK92131;
 XX
 DT 15-AUG-2002 (first entry)
 XX
 DE Prostate cancer-associated DNA sequence #17.
 XX
 KW Prostate cancer; prostate tumour tissue; human; mammal; cytostatic;
 KW Gene therapy; Gene; ds.
 XX
 OS Mammalia.
 XX
 PN WO200230258-A2.
 XX
 PD 18-APR-2002.
 XX
 PP 12-OCT-2001; 2001WO-US2045.
 XX
 PR 13-OCT-2000; 2000US-0687576.
 PR 08-DEC-2000; 2000US-0733288.
 PR 08-DEC-2000; 2000US-0733742.
 PR 24-JAN-2001; 2001US-263957P.
 PR 16-MAR-2001; 2001US-276791P.
 PR 16-MAR-2001; 2001US-276888P.
 PR 08-APR-2001; 2001US-281922P.
 PR 24-APR-2001; 2001US-285214P.
 PR 30-APR-2001; 2001US-0847046.
 PR 04-MAY-2001; 2001US-289599P.
 XX
 PA (EOSB-) EOS BIOTECHNOLOGY INC.
 XX
 PI Gish KC, Mack DH, Wilson KE, Afar D, Hevezi P;
 XX
 DR P-PSDB; ABG61816.
 XX
 DR WPI; 2002-471335/50.
 XX
 PT Detecting a prostate cancer-associated transcript in a cell in a
 PT patient, useful for diagnosing prostate cancer (PC) or screening
 PT modulators of PC, by determining if prostate cancer-associated genes
 PT are expressed in a prostate tissue.
 XX
 PS Claim 22; Page 313; 436pp; English.
 XX
 CC The present invention relates to methods of detecting a prostate
 CC cancer-associated transcript in a cell from a patient. The method
 CC comprises contacting a biological sample from the patient with
 CC prostate cancer-associated polynucleotides (designated PC genes) that
 CC selectively hybridize to a sequence that is at least 80% identical
 CC to them. The prostate cancer-associated polynucleotide sequences
 CC are differentially expressed in prostate tumour tissue or in
 CC prostate cancer and are derived from the tissues of various
 CC organisms such as humans or other mammals (e.g. mice, sheep and dogs).
 CC The methods of the invention are useful for diagnosing and treating
 CC prostate cancer in mammals. The prostate cancer-associated genes are
 CC useful for diagnosing or treating prostate cancer, as well as for
 CC identifying modulators of prostate cancer or agents that inhibit
 CC prostate cancer. The nucleic acid sequences are particularly useful
 CC in gene therapy, as a vaccine or in antisense applications.
 CC ABK92115-ABK92263 represent prostate cancer-associated polynucleotide
 CC sequences.
 XX
 SQ Sequence 1186 BP; 272 A; 368 C; 302 G; 244 T; 0 other;

Alignment Scores:

Pred. No.: 4,95e-105 Length: 1186
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 24 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x ABK92131 (1-1186)

QY 1 IlelelysclyPheGluCysLysProHisSerGlnProTropGlnAlaLeuPheGlu 20
 DB 185 ATCATCAAGGGGTTTCAGTGAACCTCACTCCAGCCCTGGCAGCAGCCCTGTTCGAG 244
 QY 21 LysThrArgLeuLeuCysGlyAlaThrLeuLeuAlaProArgTrpLeuLeuThraAla 40
 DB 245 AAGACCGGCTACTCTGTGGGGCGACGCTCATCGCCCGCAGATGGCTCTGACAGCAGCC 304
 QY 41 HisCysLeuLysProArgTyrlleValHisLeuGlyGlnHisAsnLeuGlyGluGlu 60
 DB 305 CACTGCCTCAAGCCCGCTACATAGTTCACCTGGGGCAGCAACCTCCAGAGGAGGAG 364
 QY 61 GlyCysGluGlnThrArgThrAlaThrCluserPheProHisProGlyPheAsnSer 80
 DB 365 GGCTGTGAGCAGCCGACAGCAGCAGTGTCTTCCCAACCCCGCTTCAACAGC 424
 QY 81 LeuProAsnLysAspHisArgAsnAspIleuLeuValLysMetAlaSerProValSer 100
 DB 425 CTCCCAACAAGACCCGCAATGATCATGTGTGAAGATGGCATGCCAGTCTCC 484
 QY 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
 DB 485 ATCACTGGGCTGTGCGACCCCTCACTCTCTCTCACTGCTGTGTCTGCGACAGC 544
 QY 121 CysLeuLeuSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
 DB 545 TGCTCTCATTTCCGCTGGGGCAGCAGCTCCAGCCCGCAGTACGCTGCTCCACACTTG 604
 QY 141 ArgCysAlaAsnIleThrIleleGluHisGlnLysCysGluAsnAlaTyProGlyAsn 160
 DB 605 CGATGGCCCAACATCACCATCATTTGAGCAGCAGAGTGTGAGAGCGCTACCCCGCAAC 664
 QY 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
 DB 665 ATCAGACACCATCGTGTGTGCGAGCGTGCAGGAGGGGGCAAGGACTCTCTGCGAGGT 724
 QY 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleleSerTrpGlyGln 200
 DB 725 GACTCCGGGGCCCTCTGCTGTGAACGCTCTTCAAGGCTATCTCTGCGGGCCAG 784
 QY 201 AspProCysAlaIleThrArgLysProGlyValTyThrLysValCysLysTyValAsp 220
 DB 785 GATCCGTGTGCGATCACCAGGAGCCCTGCTGTCTACAGGAAAGTCTGCAAAATATGTGGAC 844
 QY 221 TrpIleGlnGlnThrMetLysAsnAsn 229
 DB 845 TGGATCCAGGAGCAGTGAAGAAAT 871

RESULT 4
 ABX76468
 ID ABX76468 standard; DNA; 1186 BP.
 AC ABX76468;
 XX
 DT 02-APR-2003 (first entry)
 XX
 DE Lung cancer-associated polynucleotide #332.
 XX
 KW Lung cancer-associated polynucleotide; gene; ds; cytostatic; emphysema;
 KW antiinflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;
 KW small cell lung cancer; benign lesion; precancerous lesion; bronchitis;
 KW chronic obstructive pulmonary disease; hypersensitivity pneumonitis;
 KW interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis.
 XX

OS Unidentified.
 XX WO200286443-A2.
 XX 31-OCT-2002.
 XX
 XX 18-APR-2002; 2002WO-US12476.
 XX
 XX 18-APR-2001; 2001US-284770P.
 PR 10-MAY-2001; 2001US-290492P.
 PR 09-NOV-2001; 2001US-339245P.
 PR 13-NOV-2001; 2001US-350686P.
 PR 29-NOV-2001; 2001US-334370P.
 PR 12-APR-2002; 2002US-372246P.
 XX
 XX (E05B-) EOS BIOTECHNOLOGY INC.
 XX
 XX Aziz N, Murray R;
 XX WPI; 2003-093161/08.
 XX P-PSDB; ABUS6739.
 XX
 XX Detecting a lung cancer-associated transcript in a cell from a patient
 XX for treating lung cancer, by contacting a biological sample from the
 XX patient with a polynucleotide that exhibits increased or decreased
 XX expression in lung cancer.
 XX
 XX Claim 22; Page 443; 453pp; English.
 XX
 XX The invention relates to a method for detecting a lung cancer-associated
 XX transcript in a cell from a patient, comprising contacting a biological
 XX sample from the patient with a polynucleotide that selectively hybridizes
 XX to a sequence that is at least 80% identical to a gene that exhibits
 XX increased or decreased expression in lung cancer samples. Lung
 XX cancer-associated polynucleotides and polypeptides are used for
 XX identifying a compound that modulates a lung cancer-associated
 XX polypeptide, for inhibiting proliferation of a lung cancer-associated
 XX cell to treat lung cancer in a patient and for treating a mammal having
 XX lung cancer by administering a modulatory compound identified. The
 XX methods are useful for treating lung cancer, such as small cell lung
 XX cancer, non-small cell lung cancer or other benign or precancerous
 XX lesions, e.g. atelectasis, emphysema, bronchitis, chronic obstructive
 XX pulmonary disease, fibrosis, hypersensitivity pneumonitis, interstitial
 XX pulmonary fibrosis, asthma and bronchiectasis. The genes, polynucleotides
 XX and polypeptides are useful for diagnostic purposes and as targets for
 XX screening for therapeutic compounds that modulate lung cancer, such as
 XX antibodies. Sequences ABX76124-ABX76174 represent lung cancer-associated
 XX polynucleotides of the invention.
 XX
 XX Sequence 1186 BP; 272 A; 368 C; 302 G; 244 T; 0 other;
 SQ

Alignment Scores:
 Pred. No.: 4,95e-105 Length: 1186
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 25 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x ABX76468 (1-1186)

QY 1 IlelelysclyPheGluCysLysProHisSerGlnProTropGlnAlaLeuPheGlu 20
 DB 185 ATCATCAAGGGGTTTCAGTGAACCTCACTCCAGCCCTGGCAGCAGCCCTGTTCGAG 244
 QY 21 LysThrArgLeuLeuCysGlyAlaThrLeuLeuAlaProArgTrpLeuLeuThraAla 40
 DB 245 AAGACCGGCTACTCTGTGGGGCGACGCTCATCGCCCGCAGATGGCTCTGACAGCAGCC 304
 QY 41 HisCysLeuLysProArgTyrlleValHisLeuGlyGlnHisAsnLeuGlyGluGlu 60
 DB 305 CACTGCCTCAAGCCCGCTACATAGTTCACCTGGGGCAGCAACCTCCAGAGGAGGAG 364

QY 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAenSer 80
 DB 365 GGTGTGAGCAGACCCGGACAGCACTGAGTCTTCCCTCCACCCGCTTCAACACAGC 424
 QY 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValIleValMetAlaSerProValSer 100
 DB 425 CTCCCAACAAACACCAACCGCATGACATCATCTGTGTGAATGGCATGCCAGTCTCC 484
 QY 101 IleThrTrpAlaValArgProLeuThrIleuSerSerArgCysValThrAlaGlyThrSer 120
 DB 485 ATCACCCTGGGCTGTGGACCCCTCAACCTCTCTCCAGCTGTGTCACTCTGGACACAGC 544
 QY 121 CysLeuIleSerGlyTrpGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
 DB 545 TGCCTCATTTCCGGCTGGGGGACAGCAGTCCAGCCGCCCATGTTAGCGCTGCCTCACACCTTG 604
 QY 141 ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluSerAlaThrProGlyAsn 160
 DB 605 CGATGGCCCAACATCATCATCATGAGCAGCAGAGTGTGAGAACCTTACCCCGGCCAAC 664
 QY 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
 DB 665 ATCAGACACCATGTGTGTGCCAGCTGCAGAGAGGGGCAAGGACTCTCTGCCAGGT 724
 QY 181 AspSerGlyCysProLeuValCysAsnGlnSerLeuGlnIleIleIleSerTrpGlyGln 200
 DB 725 GACTCCGGGGCCCTCTGTCTGTAAACAGTCTCTTCAAGGCATATTCTCTGGGGCCAG 784
 QY 201 AspProCysAlaIleThrArgLysProGlyValIleThrLysValCysLysValValAsp 220
 DB 785 GATCCGTGTGGATCACCAGGAGCTGTGTCTACAGGAGTCTGCANATATGTGGAC 844
 QY 221 TrpIleGlnGluThrMetLysAsnAsn 229
 DB 845 TGGATCAGAGACGATGAGAACAT 871

RESULT 5
 AAD14842
 ID AAD14842 standard; DNA; 1192 BP.
 XX AC AAD14842;
 XX
 XX
 DT 01-NOV-2001 (first entry)
 XX
 DE Human PS133 gene contig.
 XX
 KW Human; PS133; prostate disease; cancer; immunogen; gene therapy; EST;
 KW expressed sequence tag; cytostatic; ds.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 XX CDS 107..859
 FT /*tag= a
 FT /product= "Human PS133 protein"
 FT /transl_except= (pos:198..196, aa:Cys-Pro)
 FT /transl_except= (pos:224..232, aa:Phe-Lys)
 XX
 XX US6232456-B1.
 XX
 XX PD 15-MAY-2001.
 XX
 XX PF 06-OCT-1997; 97US-0944483.
 XX
 XX PR 06-OCT-1997; 97US-0944483.
 XX
 XX (ABBO) ABBOTT LAB.
 XX
 XX Cohen M, Colpitts TV, Friedman PN, Granados E, Klass MR,
 XX Russell JC, Stewart KD, Stroupe SD;
 XX MPI; 2001-366357/38.
 XX P-PSDB; AA308017.

XX New PS133 polynucleotides, useful for detecting, diagnosing, staging,
 PT monitoring, progressing, preventing, treating or determining the
 PT predisposition of an individual to a prostate disease, e.g. cancer -
 XX
 XX Claim 1; Column 71-74; 93pp; English.
 CC The patent discloses PS133 polynucleotides and polypeptides which
 CC are indicative of prostate disease. The patent also provides a method
 CC for detecting PS133 protein in a test sample. The polynucleotides of
 CC the invention are useful for detecting, diagnosing, staging, monitoring,
 CC prognosing, preventing, treating or determining the predisposition of
 CC an individual to prostate diseases such as cancer. PS133-derived
 CC polynucleotides are used for the detection of normal or altered gene
 CC expression in assays for detecting, amplifying or quantifying genes
 CC or nucleic acids relating to prostate tissue diseases and conditions,
 CC and to produce probes which can be used in the detection of nucleic
 CC acids in a sample. PS133 proteins are used as immunogens for the
 CC production of antibodies. PS133 sequences are also used in gene
 CC therapy. The present sequence is human PS133 gene contig.
 XX
 SQ Sequence 1192 BP; 279 A; 385 C; 290 G; 238 T; 0 other;
 Alignment Scores:
 Pred. No.: 4.98e-105 Length: 1192
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 22 Gaps: 0
 US-09-856-320A-2_COPY_54_282 (1-229) x AAD14842 (1-1192)
 QY 1 IleIleLysGlyPheGluCysLysProHisSerGlnProTrpGlnAlaLeuPheGlu 20
 DB 170 ATCATCAAGGGTTCGAGTGCAGCCTCACTCCAGCCCTGGCAGGCGCTGTTCCGAG 229
 QY 21 LysThrArgLeuLeuGlyGlyAlaThrIleuIleAlaProArgTrpLeuLeuThrAlaAla 40
 DB 230 AAGACCGCGTACTCTGTGGGGCGAGCTCATCGCCCCCAGATGGCTCTCTGACGAGGCC 289
 QY 41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
 DB 290 CACTGCTCAAGCCCGCTACATAGTTCACCTGGGGCAGACACACCTCCAGAGGAGGAG 349
 QY 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAenSer 80
 DB 350 GGTGTGAGCAGACCCGGACAGCAGTGTGCTTCCCTCCACCCCGCTTCAACACAGC 409
 QY 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValIleValMetAlaSerProValSer 100
 DB 410 CTCCCAACAAACACCAACCGCATGACATCATCTGTGTGAATGGCATGCCAGTCTCC 459
 QY 101 IleThrTrpAlaValArgProLeuThrIleuSerSerArgCysValThrAlaGlyThrSer 120
 DB 470 ATCACCCTGGGCTGTGGACCCCTCAACCTCTCTCCAGCTGTGTCACTCTGGACACAGC 529
 QY 121 CysLeuIleSerGlyTrpGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
 DB 530 TGCCTCATTTCCGGCTGGGGGACAGCAGTCCAGCCGCCCATGTTAGCGCTGCCTCACACCTTG 589
 QY 141 ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluSerAlaThrProGlyAsn 160
 DB 590 CGATGGCCCAACATCATCATCATGAGCAGCAGAGTGTGAGAACCTTACCCCGGCCAAC 649
 QY 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
 DB 650 ATCAGACACCATGTGTGTGCCAGCTGTGAGAACCTTACCCCGGCCAAC 709
 QY 181 AspSerGlyCysProLeuValCysAsnGlnSerLeuGlnIleIleIleSerTrpGlyGln 200
 DB 710 GACTCCGGGGCCCTCTGTGTTAAACAGTCTCTTCAAGGCATATTATCTCTGGGGCCAG 769

```
OY 201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
Db |||||
OY 221 TrpIleGlnGluThrMetLysAsn 229
Db 830 TGAATCCAGGACGATGAAGACAAT 856

RESULT 6
AAA37072
ID AAA37072 standard; cDNA, 1204 BP.
XX AC AAA37072;
XX DT 08-AUG-2000 (first entry)
XX DE Human PRG1279 (UNQ649) cDNA sequence SEQ ID NO:169.
XX KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
XX KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening;
XX KW ss.
XX OS Homo sapiens.
XX PN WO200012708-A2.
XX PD 09-MAR-2000.
XX PF 01-SEP-1999; 99WO-US20111.
XX PR 01-SEP-1998; 98US-0098716.
XX PR 01-SEP-1998; 98US-0098749.
XX PR 01-SEP-1998; 98US-0098750.
XX PR 02-SEP-1998; 98US-0098803.
XX PR 02-SEP-1998; 98US-0098821.
XX PR 02-SEP-1998; 98US-0098843.
XX PR 02-SEP-1998; 98US-0098936.
XX PR 02-SEP-1998; 98US-0099596.
XX PR 02-SEP-1998; 98US-0099598.
XX PR 02-SEP-1998; 98US-0099602.
XX PR 02-SEP-1998; 98US-0099642.
XX PR 02-SEP-1998; 98US-0099741.
XX PR 02-SEP-1998; 98US-0099754.
XX PR 02-SEP-1998; 98US-0099763.
XX PR 02-SEP-1998; 98US-0099792.
XX PR 02-SEP-1998; 98US-0099808.
XX PR 02-SEP-1998; 98US-0099812.
XX PR 02-SEP-1998; 98US-0099815.
XX PR 02-SEP-1998; 98US-0099816.
XX PR 02-SEP-1998; 98US-0100385.
XX PR 02-SEP-1998; 98US-0100390.
XX PR 02-SEP-1998; 98US-0100398.
XX PR 02-SEP-1998; 98US-0100584.
XX PR 02-SEP-1998; 98US-0100627.
XX PR 02-SEP-1998; 98US-0100651.
XX PR 02-SEP-1998; 98US-0100682.
XX PR 02-SEP-1998; 98US-0100684.
XX PR 02-SEP-1998; 98US-0100683.
XX PR 02-SEP-1998; 98US-0100710.
XX PR 02-SEP-1998; 98US-0100711.
XX PR 02-SEP-1998; 98US-0100919.
XX PR 02-SEP-1998; 98US-0100930.
XX PR 02-SEP-1998; 98US-0100948.
XX PR 02-SEP-1998; 98US-0100849.
XX PR 02-SEP-1998; 98US-0101014.
XX PR 02-SEP-1998; 98US-0101068.
XX PR 02-SEP-1998; 98US-0101071.
XX PR 02-SEP-1998; 98US-0101279.
XX PR 02-SEP-1998; 98US-0101471.
XX PR 02-SEP-1998; 98US-0101472.
XX PR 02-SEP-1998; 98US-0101474.
XX PR 02-SEP-1998; 98US-0101475.
XX PR 02-SEP-1998; 98US-0101476.
XX PR 02-SEP-1998; 98US-0101477.
XX PR 02-SEP-1998; 98US-0101479.
XX PR 02-SEP-1998; 98US-0101738.
XX PR 02-SEP-1998; 98US-0101741.
XX PR 02-SEP-1998; 98US-0101743.
XX PR 02-SEP-1998; 98US-0101915.
XX PR 02-SEP-1998; 98US-0101916.
XX PR 02-SEP-1998; 98US-0102207.
XX PR 02-SEP-1998; 98US-0102240.
XX PR 02-SEP-1998; 98US-0102307.
XX PR 02-SEP-1998; 98US-0102330.
XX PR 02-SEP-1998; 98US-0102331.
XX PR 02-SEP-1998; 98US-0102484.
XX PR 02-SEP-1998; 98US-0102487.
XX PR 02-SEP-1998; 98US-0102570.
XX PR 02-SEP-1998; 98US-0102571.
XX PR 02-SEP-1998; 98US-0102634.
XX PR 02-SEP-1998; 98US-0102687.
XX PR 02-SEP-1998; 98US-0102965.
XX PR 02-SEP-1998; 98US-0103258.
XX PR 02-SEP-1998; 98US-0103449.
XX PR 02-SEP-1998; 98US-0103314.
XX PR 02-SEP-1998; 98US-0103315.
XX PR 02-SEP-1998; 98US-0103328.
XX PR 02-SEP-1998; 98US-0103395.
XX PR 02-SEP-1998; 98US-0103396.
XX PR 02-SEP-1998; 98US-0103401.
XX PR 02-SEP-1998; 98US-0103633.
XX PR 02-SEP-1998; 98US-0103678.
XX PR 02-SEP-1998; 98US-0103679.
XX PR 02-SEP-1998; 98US-0103711.
XX PR 02-SEP-1998; 98US-0104257.
XX PR 02-SEP-1998; 98US-0104987.
XX PR 02-SEP-1998; 98US-0105000.
XX PR 02-SEP-1998; 98US-0105002.
XX PR 02-SEP-1998; 98US-0105104.
XX PR 02-SEP-1998; 98US-0105159.
XX PR 02-SEP-1998; 98US-0105266.
XX PR 02-SEP-1998; 98US-0105693.
XX PR 02-SEP-1998; 98US-0105694.
XX PR 02-SEP-1998; 98US-0105807.
XX PR 02-SEP-1998; 98US-0105881.
XX PR 02-SEP-1998; 98US-0105882.
XX PR 02-SEP-1998; 98US-0106062.
XX PR 02-SEP-1998; 98US-0106023.
XX PR 02-SEP-1998; 98US-0106029.
XX PR 02-SEP-1998; 98US-0106030.
XX PR 02-SEP-1998; 98US-0106032.
XX PR 02-SEP-1998; 98US-0106033.
XX PR 02-SEP-1998; 98US-0106178.
XX PR 02-SEP-1998; 98US-0106248.
XX PR 02-SEP-1998; 98US-0106384.
XX PR 02-SEP-1998; 98US-0106500.
XX PR 02-SEP-1998; 98US-0106464.
XX PR 02-SEP-1998; 98US-0106466.
XX PR 02-SEP-1998; 98US-0106502.
XX PR 02-SEP-1998; 98US-0106505.
XX PR 02-SEP-1998; 98US-0106919.
XX PR 02-SEP-1998; 98US-0106932.
XX PR 02-SEP-1998; 98US-0106934.
XX PR 02-SEP-1998; 98US-0107783.
XX PR 02-SEP-1998; 98US-0108775.
XX PR 02-SEP-1998; 98US-0108779.
XX PR 02-SEP-1998; 98US-0108787.
XX PR 02-SEP-1998; 98US-0108788.
XX PR 02-SEP-1998; 98US-0108801.
XX PR 02-SEP-1998; 98US-0108802.
XX PR 02-SEP-1998; 98US-0108806.
XX PR 02-SEP-1998; 98US-0108807.
XX PR 02-SEP-1998; 98US-0108867.
XX PR 02-SEP-1998; 98US-0108925.
XX PR 02-SEP-1998; 98US-0108948.
```


PR 18-NOV-1998; 98US-0108849.
PR 18-NOV-1998; 98US-0108850.
PR 18-NOV-1998; 98US-0108851.
PR 18-NOV-1998; 98US-0108852.
PR 18-NOV-1998; 98US-0108856.
PR 18-NOV-1998; 98US-0108904.
XX (GETH) GENENTECH INC.
PA Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
PI WPI; 2000-237871/20.
XX P-PSDB; AAY99390.
DR New mammalian DNA sequences encoding transmembrane, receptor or
XX secreted PRO polypeptides, useful for screening of potential peptide or
PT small molecule inhibitors of the relevant receptor/ligand interactions
XX Claim 2; Fig 101; 773pp; English.
XX CC- AAA37022 to AAA37144 encode the new isolated human transmembrane,
CC receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The
CC transmembrane and receptor PRO proteins can be used for screening of
CC potential peptide or small molecule inhibitors of the relevant
CC receptor/ligand interactions. The polypeptides and nucleotide sequences
CC encoding then have various industrial applications, including uses as
CC pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent
CC PCR primers and hybridisation probes used in the isolation of the PRO
CC polypeptides from the present invention.
XX SQ Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;
Alignment Scores:
Pred. No.: 5,04e-105 Length: 1204
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 21 Gaps: 0
US-09-856-320A-2_COPY_54_282 (1-229) x AAA37072 (1-1204)
Qy 1 IleThrArgLeuValCysGlyValThrProHisSerGlnProTyrGlnAlaLeuPheGlu 20
Db 169 ATCATCAGGGGTTCGAGTGAAGCCCTCACTCCAGCCCTGGCAGCAGCCCTGTTGAG 228
Qy 21 LysThrArgLeuValCysGlyValThrLeuAlaProArgTyrLeuThrAlaAla 40
Db 229 AAGACCGGCTACTCTGTGGGGCGCAGCTCATCGCCCGCCAGATGGCTCTGCACAGCAGCC 288
Qy 41 HisCysLeuValProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGlu 60
Db 289 CACTGCTCAAGCCCGCTACATAGTTTCACTTGGGGCAGCAGCACTCCAGAGAGAGAG 348
Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnSer 80
Db 349 GGTGTGTGACGACAGCCGACAGCCACTGTGTTCTTCCCGCCCGGCTTCAACACAGC 408
Qy 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
Db 409 CTCCTCCAAAGAGACCCGCAATGACATCATCTGTTGAAGATGGCATGCCAGTCTCC 468
Qy 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db 469 ATCACCTGGGCTGTGGCAGCCCTCACCTCTCTCCACCTGTGTCTGCTGGCAGCAGC 528
Qy 121 CysLeuIleSerGlyTyrProGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
Db 529 TGCCTCATTTCCGGTGTGGGGCAGCAGCTCCAGCCCGCCAGTTACGCTGCCTCACCTTG 588
Qy 141 ArgCysAlaAsnIleThrIleGlnHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
Db 589 CGATGGCCCAACATCACCATTGAGCAGCAGAGAGTGTGAGACAGCCCTACCCCGGCAAC 648

Qy 161 IleThrAspThrMetValCysAlaSerValGlnGlnGlyGlyLysAspSerCysGlnGly 180
Db 649 ATCAGAGACACCATGGTGTGTGCGAGGTGCGAGGAGGGGCAAGGACTCTCTCCAGGT 708
Qy 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTyrGlyGln 200
Db 709 GACTCCGGGGCCCTCTGGTCTGTAAACCAAGCTCTTCAAGGCATTATCTCTCTGGGGCCAG 768
Qy 201 AspProCysAlaIleThrArgLysProGlyValThrLysValCysLysTyrValAsp 220
Db 769 GATCCGTGTGGGATCACCCGAAAGCCTGGTGTCTACAGCAAGTCTCAATATGTGAC 828
Qy 221 TrrIleGlnGluThrMetLysAsnAsn 229
Db 829 TGGATCCAGGAGACGTGAAGAACAT 855
RESULT 7
AAS21496
ID AAS21496 standard: cDNA; 1204 BP.
XX AAS21496;
AC AAS21496;
DT 24-OCT-2001 (first entry)
XX Human cDNA sequence encoding for PRO1279 polypeptide.
DB Human secretory and transmembrane; PRO, mammalian; cancer; lung;
KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW adipocyte; A-peptide; factor VIIa; gene therapy; ss.
XX Homo sapiens.
OS
XX WO20010466-A2.
XX 07-JUN-2001.
XX 01-DEC-2000; 2000WO-US32678.
XX 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 09-DEC-1999; 99US-0170262.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 30-DEC-1999; 99WO-US31243.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04311.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 01-MAR-2000; 2000WO-US05004.
PR 20-MAR-2000; 2000WO-US05601.
PR 21-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 10-NOV-2000; 2000WO-US10873.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumes D, Watanabe CK, Wood WI, Zhang Z;

Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores: 5.04e-105 Length: 1204
 Pred. No.: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 22 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x AAF54320 (1-1204)

Qy 1 IleIleIleGlyPheGluCysLeuArgProHisSerGlnProTIPGlnAlaLeuPheGlu 20
 Db 169 ATCATCAAGGGTTCGAGTGCAGCCCTCACTCCAGCCCTTCGAGAGCCCTTCGAG 228
 Qy 21 LysThrArgLeuLeuGlyAlaThrIleuIleAlaProArgTIPLeuThrAlaAla 40
 Db 229 AAGACGGCTACTCTGTGGGGGACGCTCATCGCCCGAGATGCTCTCCACAGCAGCC 288
 Qy 41 HisCysLeuLeuProArgTyrIleValHisLeuGlyGlnHisAsnLeuGluGlu 60
 Db 289 CATGCTCAAGCCCGCTCATAGTTCATCTGGGCGAGCAGCACTCCAGAGGAGGAG 348
 Qy 61 GlyCysGluGlnThrArgThrAlaThrGlnSerPheProHisProGlyPheAsnSer 80
 Db 349 GGCTGTGAGCAGACCGGACGACGACCTGAGTCTCTCCCGCCCGGCTTCAACACAGC 408
 Qy 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
 Db 409 CTCCCAACAAAGACCCCGCAATGACATCATCTGTGTAAGATGCGCATGCCAGTCTCC 468
 Qy 101 IleThrTIPAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
 Db 469 ATCACTGTGGCTGTGGACCCCTCATCTCTCTCAGCTGTGCTCAGTCTGGCAGCAGC 528
 Qy 121 CysLeuIleSerGlyTIPGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
 Db 529 TGCTCATTTCCGGTGTGGGCGAGCAGCTCCAGCCCGCCAGTTACGCTCTCCACACCTTG 588
 Qy 141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
 Db 589 CGATCGCCCAACATCACCATTGAGCAGCAGCAAGTGTGAGAACGCTTACCCCGGCAAC 648
 Qy 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyValAspSerCysGlnGly 180
 Db 649 ATCAGACAGACCATGCTGTGCCAGCTGTCAGGAGGGGGGCAAGGATCTCTGCCAGGCT 708
 Qy 181 AspSerGlyCysProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTIPGlyGln 200
 Db 709 GACTCCGGGGGCGCTCTGTCTGTAACAGCTCTTCAAGGCAATATCTCTGGGGCCAG 768
 Qy 201 AspProCysAlaIleThrArgLeuProGlyValThrThrValCysLeuTyrValAsp 220
 Db 769 GATCCGTGTGGATCACCCGAAAGCTGTGTCTACACGAAAGTCTGCAAAATATGTGGAC 828
 Qy 221 TTPileGlnGluThrMetLysAsnAsn 229
 Db 829 TGGATCCAGGACCATGATGAGACAT 855

RESULT 9

ABL95664
 ID ABL95664 standard; cDNA; 1204 BP.
 XX AC ABL95664;
 XX DT 19-JUL-2002 (first entry)
 XX DE Human angiogenesis related cDNA PRO1279 SEQ ID NO: 207.
 XX KW Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
 XX KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
 KW cardiant; cyostatic; antiangiogenic; hypotensive; vulnerary;

KW antiarteriosclerotic; gene; ss.
 XX Homo sapiens.
 XX WO200208284-A2.
 XX 31-JAN-2002.
 XX 09-JUL-2001; 2001WO-US21735.
 XX 20-JUL-2000; 2000US-219556P.
 XX 25-JUL-2000; 2000US-22064P.
 XX 28-JUL-2000; 2000WO-US20710.
 XX 02-AUG-2000; 2000US-222695P.
 XX 17-AUG-2000; 2000US-0643657.
 XX 23-AUG-2000; 2000WO-US23322.
 XX 24-AUG-2000; 2000WO-US23328.
 XX 07-SEP-2000; 2000US-230978P.
 XX 15-SEP-2000; 2000US-000000P.
 XX 18-SEP-2000; 2000US-0654610.
 XX 24-OCT-2000; 2000US-0853350.
 XX 08-NOV-2000; 2000US-242922P.
 XX 08-NOV-2000; 2000US-0709238.
 XX 10-NOV-2000; 2000WO-US30952.
 XX 01-DEC-2000; 2000WO-US30873.
 XX 20-DEC-2000; 2000US-074259.
 XX 20-DEC-2000; 2000WO-US34956.
 XX 22-JAN-2001; 2001US-0767609.
 XX 28-FEB-2001; 2001US-0796498.
 XX 28-FEB-2001; 2001WO-US06520.
 XX 01-MAR-2001; 2001WO-US06666.
 XX 09-MAR-2001; 2001US-0802706.
 XX 14-MAR-2001; 2001US-0808689.
 XX 05-APR-2001; 2001US-0816744.
 XX 10-MAY-2001; 2001US-0828366.
 XX 10-MAY-2001; 2001US-0854208.
 XX 25-MAY-2001; 2001US-0866028.
 XX 25-MAY-2001; 2001US-0866034.
 XX 30-MAY-2001; 2001US-0870574.
 XX 30-MAY-2001; 2001WO-US17443.
 XX 01-JUN-2001; 2001WO-US17800.
 XX 20-JUN-2001; 2001WO-US19592.
 XX 28-JUN-2001; 2001WO-US00000.
 XX (GETH) GENENTECH INC.
 PA (BAKE) BAKER K P.
 PA (FERR) FERRARA N.
 PA (GERB) GERBER H.
 PA (GERR) GERRITSEN M E.
 PA (GODD) GODDARD A.
 PA (GODO) GODOWSKI P J.
 PA (GURN) GURNEY A L.
 PA (HILL) HILLAN K J.
 PA (MARS) MARSTERS S A.
 PA (PANJ) PAN J.
 PA (PAON) PAONI N P.
 PA (STEP) STEPHAN J P.
 PA (WATR) WATKINS C K.
 PA (WILL) WILLIAMS P M.
 PA (WOOD) WOOD W I.
 PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A,
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF,
 PI Stephan JP, Watanabe CK, Williams PM, Wood WI, Ye W;
 WPI: 2002-171999/22.
 DR P-PSDB; ABB95526.
 XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 PT

PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
XX infarction), endothelial or angiogenic disorders in a mammal -
PS Claim 1: Fig 207; 567pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration, atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis, angina, myocardial infarction, thrombophlebitis, lymphangitis, tumor angiogenesis (such as breast carcinoma and liver carcinoma) and wound healing. The present sequence is a coding sequence of the invention.
XX
SQ Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;
Alignment Scores:
Pred. No.: 5,046-105 Length: 1204
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 24 Gaps: 0
US-09-856-320A-2_COPY_54_282 (1-229) x ABL95664 (1-1204)
QY 1 IleIleValGlyPheGluCysValProHisSerClnProTrpGlnAlaAlaLeuPheGlu 20
DB 169 ATCATCAAGGGTTTGAGTGAGCCCTCACTCCAGCCCTGGCAGCAGCCCTGTCGAG 228
QY 21 LysThrArgLeuLeuGlyAlaThrLeuLeuAlaProArgTrpLeuThrAlaAla 40
DB 229 AAGACCGCGCTACTCTGTGGCGACGCTCATTCGCCCGCCAGATGCTCTGACAGCAGCC 288
QY 41 HisCysLeuLeuProArgTrpIleValHisLeuGlyGlnHisAsnLeuGlyLeuGlu 60
DB 289 CACTGCTCAAGCCCGCTACATAGTTTCACTTGGGCGACGACCACTCCAGAGGAGGAG 348
QY 61 GlyCysGlnGluThrArgThrAlaThrClnSerPheProHisProGlyPheAsnSer 80
DB 349 GGTGTGACACACCGGACGACGACCTGAGTCTTCCCTCCACCCCGGCTTCAACACAGC 408
QY 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
DB 409 CTCCTCCAAACAAAGACACCGCAATGACATCATCTGTTGAAGATGGCATCCCAAGTCTCC 468
QY 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
DB 469 ATCACCCTGGGCTGTGCGACCCCTCACCCTCTCTCCACGCTGTGTCACCTGCGCACCAGC 528
QY 121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
DB 529 TGCTCTCATTTCCGGCTGGGCGAGCGCTCCAGCCCTTACGCTGCTGCTCACCTTG 588
QY 141 ArgCysAlaAsnIleThrIleGluHisGlnLysCysGluAsnAlaTyProGlyAsn 160
DB 589 CGATGCCCAACATCACCATTTGACGACCAAGATGTGAGACGCTTACCCCGGCAAC 648
QY 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly 180
DB 649 ATCAGACGACCATGTTGTGTCAGGCTGTGACGAGGCGGCGGCAAGGACTCTGTCAGGGT 708
QY 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
DB 709 GACTCCGGGGCCCTCTGTTGTAACAGTCTCTTCAAGGCATTATCTCTGCGGGCCAG 768
QY 201 AspProCysAlaIleThrArgLysProGlyValThrThrValValCysValValAsp 220
DB 769 GATCCGTTGCGATCACCGAAGCCCTGGTGTCTACAGAAAGTCTGCAAAATATGTGGAC 828
QY 221 TrpIleGlnGluThrMetLysAsnAsn 229
DB 829 TGGATCCAGGAGCATGAAGCAAT 855

RESULT 10
ABL88175
ID ABL88175 standard; cDNA; 1204 BP.
XX
XX ABL88175;
XX AC
XX DT 16-MAY-2002 (first entry)
XX DE Human PRO1279 cDNA sequence SEQ ID NO:207.
XX KW Human; angiogenesis; cardiant; cytosolic; antiangiogenic; hypotensive;
XX KW vulnary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
XX KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;
XX KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
XX KW age-related macular degeneration; arterial restenosis; angina;
XX KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;
XX KW lymphangitis; tumor angiogenesis; breast carcinoma; liver carcinoma;
XX KW wound healing; chromosome mapping; Gene mapping; Gene; ss.
XX
XX CS Homo sapiens.
XX PN WO200200690-A2.
XX
XX PD 03-JAN-2002.
XX
XX PF 20-JUN-2001; 2001WO-US19692.
XX
XX PR 23-JUN-2000; 2000US-213637P.
XX PR 20-JUL-2000; 2000US-219556P.
XX PR 25-JUL-2000; 2000US-220634P.
XX PR 25-JUL-2000; 2000US-220664P.
XX PR 28-JUL-2000; 2000WO-US20710.
XX PR 02-AUG-2000; 2000US-222695P.
XX PR 17-AUG-2000; 2000US-0643657.
XX PR 23-AUG-2000; 2000WO-US23322.
XX PR 24-AUG-2000; 2000WO-US23328.
XX PR 07-SEP-2000; 2000US-210978P.
XX PR 18-SEP-2000; 2000US-0654610.
XX PR 18-SEP-2000; 2000US-065350.
XX PR 24-OCT-2000; 2000US-242922P.
XX PR 08-NOV-2000; 2000US-0709238.
XX PR 08-NOV-2000; 2000WO-US30952.
XX PR 10-NOV-2000; 2000WO-US30973.
XX PR 01-DEC-2000; 2000WO-US32678.
XX PR 20-DEC-2000; 2000US-0747259.
XX PR 20-DEC-2000; 2000WO-US34956.
XX PR 22-JAN-2001; 2001US-0767609.
XX PR 28-FEB-2001; 2001US-0796498.
XX PR 28-FEB-2001; 2001WO-US06520.
XX PR 01-MAR-2001; 2001WO-US06666.
XX PR 09-MAR-2001; 2001US-0802706.
XX PR 14-MAR-2001; 2001US-0806689.
XX PR 22-MAR-2001; 2001US-0816744.
XX PR 05-APR-2001; 2001US-0828366.
XX PR 10-MAY-2001; 2001US-0854208.
XX PR 25-MAY-2001; 2001US-0856028.
XX PR 25-MAY-2001; 2001US-0856034.
XX PR 30-MAY-2001; 2001WO-US17092.
XX PR 30-MAY-2001; 2001US-0870574.
XX PR 01-JUN-2001; 2001WO-US17443.
XX PR 01-JUN-2001; 2001WO-US17800.
XX
XX PA (GETH) GENENTECH INC.
XX
XX PI Baker KP, Ferrara N, Gerber H, Gerttsen ME, Goddard A;
XX PI Godowski PI, Gurney AL, Hillan XJ, Marssters SA, Pan J, Paoni NF;
XX PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W,
XX WPI; 2002-090516/12.
XX DR P-PSDB; ABB84920.
XX

PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 PT infarction), endothelial or angiogenic disorders in a mammal -
 XX
 PS Claim 2; Fig 207; 565pp; English.

CC AB188072 to AB188258 encode the PRO proteins given in AB18817 to
 CC AB188003. The PRO proteins and polynucleotides have cardiant, cytostatic,
 CC antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
 CC activities, and can be used in gene therapy. The PRO polynucleotides,
 CC proteins, agonists and antagonists are useful for treating or diagnosing
 CC a cardiovascular, endothelial or angiogenic disorder in a mammal,
 CC e.g. cardiac hypertrophy, trauma, cancer, age-related macular
 CC degeneration, atherosclerosis, hypertension, arterial restenosis,
 CC rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,
 CC lymphangitis, tumour angiogenesis (such as breast carcinoma and liver
 CC carcinoma) and wound healing. The PRO polynucleotides have applications
 CC in molecular biology, including use as hybridisation probes, and in
 CC chromosome and gene mapping. AB188259 to AB188267 represent primers and
 CC probes used in the exemplification of the present invention.

XX Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores: Pred. NO.: 5,04e-105 Length: 1204
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 24 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x AB188175 (1-1204)

Qy 1 IleIleGlyGlyPheGluCysGlyProHisSerGlnProTrpGlnAlaAlaPheGlu 20
 Db 169 ATCATCAAGGGGTCGAGTGAAGCCTCACTCCAGCGCTGGCAGCGCCCTGTCGAG 228
 Qy 21 LysThrArgLeuLeuCysGlyAlaThrLeuIleAlaProArgTrpLeuLeuThrAlaAla 40
 Db 229 AACACGGCGCTACTCTGTGGGGCGACCGCTCATCGCCCCAGATGCTCTGACAGCGCC 288
 Qy 41 HisCysLeuLeuProArgTyrIleValHisGlyGlnHisAsnLeuGlnGlyGlu 60
 Db 289 CACTGCTCAAGCCCGCTCATAGTATCACTCGGGGAGCAGCAACCTCCAGAGGAGGAG 348
 Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisSerProGlyPheAsnSer 80
 Db 349 GGCTGTGAGCAGACCGGACGACCTGAGTCTTCCCGCCAGCGGCTTCAACACAGC 408
 Qy 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
 Db 409 CTCCCAACAAAGACCCGCAATGATCATCTGTGTGAAGATGGCATGCCAGTCTCC 468
 Qy 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
 Db 469 ATCACTGGCTGTGCGACCCCTCACCCTCTCTCAGCTGTCTCACTGTGGCAGCAGC 528
 Qy 121 CysLeuIleSerGlyTrpGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
 Db 529 TGCTCATTTCCGGTGGGGGAGCAGCCTCCAGCGCCCGCTACGCTCGCTCAACCTTG 588
 Qy 141 ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyrProGlyAsn 160
 Db 589 CGATGGCGCAACATCACCATTGAGCAGCAGAGTGTGAGAGCGCTACCCCGGCAC 648
 Qy 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyIleAsnSerCysGlnGly 180
 Db 649 ATCAGAGACCATGTGTGTGTGCGGCTGCAGAGGGGGGAGGAGCTCTCCAGGGT 708
 Qy 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200
 Db 709 GACTCCGGGGGCGCTCTGGTCTGTGAACCAAGTCTCTTCAGGCGATTATCTCTCGGGCCAG 768

Qy 201 AspProCysAlaIleThrArgLysProGlyValThrLysValCysLysValValAsp 220
 Db 769 GATCGGTGTGGATCACCAGAGCGCTGTGTCTACAGAAAGCTGCAAAATATGTGAC 828
 Qy 221 TrpIleGlnGluThrMetLysAsnAsn 229
 Db 829 TGGATCCAGGAGACGATGAAGAACAAT 855
 RESULT 11
 ABK33628
 ID ABK33628 standard; cDNA; 1204 BP.
 AC ABK33628;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE cDNA encoding human PRO protein, Seq ID No 185.
 XX
 KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
 KW breast cancer; prostate tumour; rectal tumour; liver tumour;
 KW pericyte cell proliferation; chondrocyte cell proliferation;
 KW tumour necrosis factor-alpha; gene; ss.
 XX
 OS Homo sapiens.
 XX
 DN WO200208288-A2.
 XX
 ED 31-JAN-2002.
 XX
 PF 29-JUN-2001; 2001WO-US21066.
 XX
 PR 20-JUL-2000; 2000US-219556P.
 PR 25-JUL-2000; 2000US-220585P.
 PR 25-JUL-2000; 2000US-220605P.
 PR 25-JUL-2000; 2000US-220607P.
 PR 25-JUL-2000; 2000US-220624P.
 PR 25-JUL-2000; 2000US-220638P.
 PR 25-JUL-2000; 2000US-220644P.
 PR 25-JUL-2000; 2000US-220666P.
 PR 28-JUL-2000; 2000US-220893P.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 15-SEP-2000; 2000US-000000P.
 PR 10-NOV-2000; 2000WO-US30873.
 PR 28-NOV-2000; 2000US-253646P.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 20-DEC-2000; 2000US-0747259.
 PR 20-DEC-2000; 2000WO-US34956.
 PR 26-FEB-2001; 2001WO-US06520.
 PR 10-MAY-2001; 2001US-0854280.
 PR 23-MAY-2001; 2001WO-US17092.
 XX
 (GETH) GENENTECH INC.
 XX
 Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2002-172001/22.
 DR P-PSDB; AAU83684.
 XX
 PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for treating a PRO related disorder and for diagnosing tumours
 PT such as lung cancer, colon cancer, breast tumour, prostate tumour, rectal
 PT tumour or liver tumour -
 XX
 PS Claim 2, Figure 195; 359pp; English.
 XX
 CC The invention relates to one hundred and twenty two nucleic acids
 CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
 CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
 CC agonists and antagonists are useful for treating a PRO related disorder.
 CC The PRO polypeptides are useful for diagnosing tumours, especially lung

CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. The PRO polypeptides are useful for stimulating the
 CC proliferation of, or gene expression, in pericyte cells, for stimulating
 CC the proliferation or differentiation of chondrocyte cells, for
 CC stimulating the release of tumour necrosis factor-alpha from human blood,
 CC for stimulating or inhibiting the proliferation of normal human dermal
 CC fibroblast cells. The PRO polypeptide may also be used as molecular
 CC weight markers and for tissue typing. The PRO nucleic acids have
 CC applications in molecular biology, including use as hybridisation probes,
 CC and in chromosome and gene mapping. ABK336-ABK33657 represent human
 CC PRO protein coding sequences of the invention.

XX SQ Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:

Pred. No.:	5,048-105	Length:	1204
Score:	1258.00	Matches:	229
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	2%	Gaps:	0

US-09-856-320A-2_COPY_54_282 (1-229) x ABK33628 (1-1204)

Qy	1	IleileLysGlyPheGluCysLysProHisSerGlnProTTPGlnAlaLeuPheGlu	20
Db	169	ATCATCAAGGGGTTCCAGTCAAGCCTCACTCCAGCCCTGGCAGGCGAGCTGTTCGAG	228
Qy	21	LysThrArgLeuLeuCysGlyValaThrLeuIleAlaProArgTTPLeuLeuThrAlaAla	40
Db	229	AAGACGGCGCTACTCTGTGGGGCGAGCCTCATCGCCCGCCAGATGCTCTTGACAGCAGCC	288
Qy	41	HisCysLeuLysProArgTTPLeuValHisGlyGlnHisAsnLeuLysGluGlu	60
Db	289	CACCTGCTCAAGCCCGCTCATAGTTCACCTGGGCGAGCAACCTCCAGAGGGAGGAG	348
Qy	61	GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnAsnSer	80
Db	349	GGCTGTGAGCAGACCGGACAGCCACTGAGTCTTCTCCCGCCGGCTTCAACACAGC	408
Qy	81	LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer	100
Db	409	CTCCCAACAAAGACCCCGCAATGACATCATCTGTGTGAAGATGGCATGCCAGTCTCC	468
Qy	101	IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer	120
Db	469	ATCACCTGGGCTGTGGACCCCTCACCTCTCTCAGCTGTGTACCTGTGGCAGCAGC	528
Qy	121	CysLeuIleSerGlyTTPGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu	140
Db	529	TGCCTCATTTCCGGTGGGCGAGCAGCTCCAGCCCGCCAGTTAGCGTGGCTTCACCTTG	588
Qy	141	ArgCysAlaAsnIleThrIleIleGluHisGlnLysCysGluAsnAlaTyProGlyAsn	160
Db	589	CGATGGCCCAACATCACCATCATTTGAGCAGCAGAGGTGTGAGAACGCTTACCCCGCAAC	648
Qy	161	IleThrAspThrMetValCysAlaSerValGlnGluGlyGlyLysAspSerCysGlnGly	180
Db	649	ATCACAGACACCATGGTGTGTGGCAGCTGCAGAGAGGGGGCAGGACTCTCTCCAGGGT	708
Qy	181	AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln	200
Db	709	GACTCCGGGGGCGCTCTGGTCTGTAAACAGTCTCTTCAAGGCATTATCTCTGGGGCCAG	768
Qy	201	AspProCysAlaIleThrArgLysProGlyValTyThrLysValCysLysTyValAsp	220
Db	769	GATCCGTGTGGCATCACCCGAAAGCCCTGGTGTCTACACGAAAGTCTGCAATATGTGGAC	828
Qy	221	TrpIleGlnGluThrMetLysAsnAsn	229
Db	829	TGGATCCAGAGACGATGAAGAACAT	855

RESULT 12..

ACA03855
 ID ACA03855 standard; cDNA; 1204 BP.
 AC ACA03855;
 XX ACA03855;
 DT 23-MAY-2003 (first entry)
 XX cDNA encoding human PRO polypeptide #253.
 DE Human; PRO polypeptide; secreted and transmembrane protein;
 XX tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
 KW differentiation; chondrocyte; tumour; genetic disorder;
 KW cytotstatic; gene; ss.
 XX Homo sapiens.
 OS Homo sapiens.
 XX US2003036180-A1.
 XX 20-FEB-2003.
 XX 09-MAY-2002; 2002US-0143114.
 XX 31-MAR-1987; 97MO-US05230.
 PR 12-JUN-1988; 98MO-US12456.
 PR 14-JUL-1988; 98MO-US14552.
 PR 28-AUG-1988; 98MO-US17888.
 PR 10-SEP-1988; 98MO-US18824.
 PR 14-SEP-1988; 98MO-US19093.
 PR 14-SEP-1988; 98MO-US19094.
 PR 14-SEP-1988; 98MO-US19177.
 PR 16-SEP-1988; 98MO-US19330.
 PR 17-SEP-1988; 98MO-US19437.
 PR 07-OCT-1988; 98MO-US21141.
 PR 29-OCT-1988; 98MO-US22391.
 PR 20-NOV-1988; 98MO-US24955.
 PR 01-DEC-1988; 98MO-US25108.
 PR 05-JAN-1989; 99MO-US00106.
 PR 08-MAR-1989; 99MO-US05028.
 PR 10-MAR-1989; 99MO-US05190.
 PR 20-APR-1989; 99MO-US08615.
 PR 14-MAY-1989; 99MO-US10733.
 PR 02-JUN-1989; 99MO-US12252.
 PR 01-SEP-1989; 99MO-US20111.
 PR 08-SEP-1989; 99MO-US20594.
 PR 13-SEP-1989; 99MO-US20944.
 PR 15-SEP-1989; 99MO-US21090.
 PR 13-SEP-1989; 99MO-US21547.
 PR 05-OCT-1989; 99MO-US23089.
 PR 29-NOV-1989; 99MO-US28214.
 PR 30-NOV-1989; 99MO-US28313.
 PR 30-NOV-1989; 99MO-US28409.
 PR 01-DEC-1989; 99MO-US28301.
 PR 02-DEC-1989; 99MO-US28534.
 PR 02-DEC-1989; 99MO-US28551.
 PR 02-DEC-1989; 99MO-US28564.
 PR 16-DEC-1989; 99MO-US28565.
 PR 20-DEC-1989; 99MO-US30095.
 PR 20-DEC-1989; 99MO-US30911.
 PR 20-DEC-1989; 99MO-US30999.
 PR 22-DEC-1989; 99MO-US30720.
 PR 30-DEC-1989; 99MO-US31243.
 PR 30-DEC-1989; 99MO-US31274.
 PR 05-JAN-2000; 2000MO-US00219.
 PR 06-JAN-2000; 2000MO-US00277.
 PR 06-JAN-2000; 2000MO-US00376.
 PR 11-FEB-2000; 2000MO-US03565.
 PR 18-FEB-2000; 2000MO-US04341.
 PR 18-FEB-2000; 2000MO-US04342.
 PR 22-FEB-2000; 2000MO-US04414.
 PR 24-FEB-2000; 2000MO-US04914.
 PR 24-FEB-2000; 2000MO-US05004.
 PR 01-MAR-2000; 2000MO-US05601.

PR 02-MAR-2000; 2000WO-US05746.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US05319.
 PR 15-MAR-2000; 2000WO-US05684.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 21-MAR-2000; 2000WO-US07532.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 10-NOV-2000; 2000WO-US30873.
 PR 01-DEC-2000; 2000WO-US33678.
 PR 20-DEC-2000; 2000WO-US34956.
 PR 28-FEB-2001; 2001WO-US05820.
 PR 01-MAR-2001; 2001WO-US05666.
 PR 25-MAY-2001; 2001WO-US17092.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 22-JUN-2001; 2001WO-US20116.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 20-DEC-2000; 2000US-0747259.
 PR 28-FEB-2001; 2001US-0796498.
 PR 09-MAR-2001; 2001US-0803706.
 PR 14-MAR-2001; 2001US-0803689.
 PR 22-MAR-2001; 2001US-0816744.
 PR 05-APR-2001; 2001US-0823366.
 PR 10-MAY-2001; 2001US-0854208.
 PR 18-MAY-2001; 2001US-0860216.
 PR 25-MAY-2001; 2001US-0866028.
 PR 25-MAY-2001; 2001US-0865034.
 PR 01-JUN-2001; 2001US-0878035.
 PR 05-JUN-2001; 2001US-0874503.
 PR 14-JUN-2001; 2001US-0882636.
 PR 19-JUN-2001; 2001US-0886342.
 PR 21-JUN-2001; 2001US-0887879.
 PR 18-JUL-2001; 2001US-0908827.
 PR 06-AUG-2001; 2001US-0924419.
 PR 09-AUG-2001; 2001US-0927795.
 PR 16-AUG-2001; 2001US-0931836.
 PR 19-DEC-2001; 2001US-0028072.
 XX
 PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI, 2003-132040/31.
 DR P-PSDB, ABUS6822.

PT New secreted and transmembrane PRO nucleic acids, useful for gene
 PT therapy, in chromosome and gene mapping, as chromosome markers, in
 PT tissue typing, and in chromosome identification
 XX
 PS Claim 2; Fig 505; 660pp; English.

XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The
 CC PRO polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for
 CC linking bioactive molecules to cells expressing PRO polypeptides,
 CC for modulating biological activities of cells expressing PRO
 CC polypeptides, and for identifying agonists or antagonists.
 CC The PRO polypeptides are useful for stimulating the release of
 CC tumour necrosis factor (TNF)-alpha from human blood, for stimulating

CC the proliferation or differentiation of chondrocytes, and detecting the
 CC presence of tumours. The polynucleotide sequences encoding PRO
 CC polypeptides are useful as hybridisation probes, in chromosome and
 CC gene mapping, in the generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptides, for generating transgenic animals or
 CC knockout animals, for the genetic analysis of individuals with genetic
 CC disorders, and in gene therapy. ACA03603-ACA03877 represent cDNAs
 CC encoding the human PRO polypeptides of the invention.
 CC Note: The sequence data for this patent was obtained in electronic
 CC format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdIDEntry.html.
 XX

SQ Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
 Pred. No.: 5,04e-105 Length: 1204
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 25 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x ACA03955 (1-1204)

Qy 1 ILEILEYSGLYPHEGLUCYVLSERPROHISERGLNPROTRPGINLAALALEUPHEGLU 20
 Db 169 ATCATCAAGGGGTTTCAGTGCAGAGCTTACTCCAGCCCTGGCAGGCGCCCTTCGAG 228
 Qy 21 LYSNHRARGLEULEUCYSGLYALATHRLEULEALAPROARGTRPLeuLeuThrAlaAla 40
 Db 229 AAGACGGCGCTACTCTGTGGGCGAGCGCTCATCGCCCGCCAGATGGCTCTCGACGAGCC 388
 Qy 41 HISCYLSLEULYSPROARGTYRILEVALHISLEUGLYGLNHISASNLEULINLYSGLU 60
 Db 289 CACTGCTCAAGCCCGCTACATAGTTTCACTGGGGCAGCAACAACCTCCAGAGAGGAG 348
 Qy 61 GLYCYSGLEULINHRARGTHRATHRGLUSERPHEPROHISPROGLYPHEASNANSER 80
 Db 349 GGCTGTGAGCAGACCGGAGCCAGCCACTGAGTCTTCCCCACCCCGCTTCAACACAGC 408
 Qy 81 LEUPROASNLYSASPHEHISARGASNAPLLEMETLEUVALLYSMETALASERPROVALSER 100
 Db 409 CTCCCAACCAAGACCCACCGCATCATGCTGTGGTGAAGATGGCATCGCCAGTCTCC 468
 Qy 101 ILETHRTPALAVALARPROLEUTHRLEUSERSERARGCYVALTHRAlaGlyThrSer 120
 Db 469 ATCACTGGGCTGTGGACCCCTCACTCCCTCCTCAGCGTGTGTCTGCTGACCTGAC 528
 Qy 121 CYSEULEISERGITYRPGLYSERTHRSESRERPROGLINLEUARGLEUPROHISThrLeu 140
 Db 529 TCCCTCATTTCCGGCTGGGCGACGCTCCAGCCCGCCAGTTTACCCCTTCCCTCACACTTG 588
 Qy 141 ARGCYSAALASNLLETHRLEULEGLNHISGLINLYSCYSGLUASNALATYRPROGLYASN 160
 Db 589 CGATCGGCCAACATCACTCCATTCATTGAGCACCAGAGTGTGAGAACGGCTTACCCCGCAAC 648
 Qy 161 ILETHRASPETHRMETVALCYSLASERVALGLINGLYGLYLYSASPSERCYSGINGLY 180
 Db 649 ATCACAGACACCATGGTGTGTGCGCGTGCAGGAAGGGGCAAGGACTCTCTCCAGAGGT 708
 Qy 181 ASPSERGLYGLYPROLEUVALCYSAENGLINSERLINLEULINLYSGLYILELLESLERTRPGLYGLIN 200
 Db 709 GACTCCGGGGGCGCTCTGTGTCTGTAAACAGTCTCTTCAAGGCATTATCTCTCTGGGCCAG 768
 Qy 201 APPPROCYSAALALLETHRARGLYSPROGLYVALTYRTHRILYSLVALCYSLYSTRVALASP 220
 Db 769 GATCGTGTGGATTCACCCGAAAGCTGGTGTCTACACGAAGTCTGCAATATGTGGAC 828
 Qy 221 TRPILGLINGLUTHRMETLYSAENASN 229
 Db 829 TGGATCCAGGAGCAGTCAAGAACAAAT 855

RESULT 13

ACA04276
ID ACA04276 standard; cDNA; 1204 BP.

XX AC ACA04276;

XX DT 27-MAY-2001 (first entry)

XX DE Human cDNA encoding a secreted/transmembrane protein, SEQ ID 505.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
XX inflammatory disease; organ failure; atherosclerosis; cardiac injury;
XX infertility; birth defects; premature aging; AIDS; biosensor;
XX acquired immunodeficiency syndrome; cancer; diabetic complication;
XX bioreactor; tumour.

XX OS Homo sapiens.

XX PN US2003032155-A1.

XX PD 13-FEB-2003.

XX PF 03-MAY-2002; 2002US-0137865.

XX PR 31-MAR-1997; 97NO-US05230.

XX PR 12-JUN-1998; 98NO-US12456.

XX PR 14-JUL-1998; 98NO-US14552.

XX PR 28-AUG-1998; 98NO-US17888.

XX PR 10-SEP-1998; 98NO-US18824.

XX PR 14-SEP-1998; 98NO-US19094.

XX PR 14-SEP-1998; 98NO-US19177.

XX PR 16-SEP-1998; 98NO-US19330.

XX PR 17-SEP-1998; 98NO-US19437.

XX PR 07-OCT-1998; 98NO-US21141.

XX PR 29-OCT-1998; 98NO-US22991.

XX PR 29-OCT-1998; 98NO-US23892.

XX PR 20-NOV-1998; 98NO-US24855.

XX PR 01-DEC-1998; 98NO-US25108.

XX PR 05-JAN-1999; 99NO-US00106.

XX PR 08-MAR-1999; 99NO-US05028.

XX PR 10-MAR-1999; 99NO-US05190.

XX PR 20-APR-1999; 99NO-US08615.

XX PR 14-MAY-1999; 99NO-US10733.

XX PR 02-JUN-1999; 99NO-US12252.

XX PR 01-SEP-1999; 99NO-US20111.

XX PR 08-SEP-1999; 99NO-US20594.

XX PR 13-SEP-1999; 99NO-US20944.

XX PR 15-SEP-1999; 99NO-US21090.

XX PR 15-SEP-1999; 99NO-US21547.

XX PR 05-OCT-1999; 99NO-US23089.

XX PR 29-NOV-1999; 99NO-US28214.

XX PR 30-NOV-1999; 99NO-US28313.

XX PR 01-DEC-1999; 99NO-US28409.

XX PR 01-DEC-1999; 99NO-US28301.

XX PR 02-DEC-1999; 99NO-US28634.

XX PR 02-DEC-1999; 99NO-US28551.

XX PR 02-DEC-1999; 99NO-US28564.

XX PR 16-DEC-1999; 99NO-US28565.

XX PR 20-DEC-1999; 99NO-US30095.

XX PR 20-DEC-1999; 99NO-US30911.

XX PR 20-DEC-1999; 99NO-US30939.

XX PR 22-DEC-1999; 99NO-US30720.

XX PR 30-DEC-1999; 99NO-US31243.

XX PR 30-DEC-1999; 99NO-US31274.

XX PR 05-JAN-2000; 2000WO-US00319.

XX PR 06-JAN-2000; 2000WO-US00377.

XX PR 06-JAN-2000; 2000WO-US00376.

XX PR 11-FEB-2000; 2000WO-US03565.

XX PR 18-FEB-2000; 2000WO-US04341.

XX PR 18-FEB-2000; 2000WO-US04342.

XX PR 22-FEB-2000; 2000WO-US04414.

XX PR 24-FEB-2000; 2000WO-US04914.

XX PR 24-FEB-2000; 2000WO-US05004.

PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19892.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 15-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-331925/31.

P-PSDB; ABU67098.

New secreted and transmembrane nucleic acids and polypeptides,
designated as PRO, useful for treating inflammation, organ failure,
atherosclerosis, cardiac injury, infertility, birth defects, premature
aging, AIDS, or cancer.

Claim 2; Fig 505; 659pp; English.

The invention relates to an isolated nucleic acid comprising, or which is
at least 80% identical to, or the full-length coding sequence of, any of
the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
(one of 275 secreted or transmembrane proteins). The nucleic acid
further comprises the full-length coding sequence of the DNA deposited
under American Type Culture Collection (ATCC) accession number in a list
given in the specification. Also included are vectors and host

cells for producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO extracellular domains and mature sequences, methods of detecting PRO proteins, methods for stimulating the release of TNF-alpha (tumour necrosis factor alpha) from human blood, (and the proliferation of differentiation of chondrocyte cells, the proliferation of, or gene expression in pericyte cells, the release or proteoglycans from cartilage, proliferation of T-lymphocyte cells, the release of a cytokine from peripheral blood mononuclear cells (PBMC), or the proliferation of endothelial cells), a method for modulating the uptake of glucose or free fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the binding of A-peptide to factor VIIa, or the differentiation of adipocyte cells, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the nucleotide sequences cited above. The nucleic acids and polypeptides are useful for treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or diabetic complications. The nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, and in generating antisense RNA or DNA. The polypeptides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both are useful in tissue typing.

CC The present sequence encodes a PRO protein of the invention.

XX Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
 Pred. NO.: 5.04e-105 Length: 1204
 Score: 1258.00 Matches: 229
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x ACA04276 (1-1204)

QY 1 IleIleIleGlyPheGluCysLysProHisSerGlnProTrpGlnAlaLeuPheGlu 20
 DB 169 ATCATCAAGGGGTTCAGTGCAGGCTCATCCAGCCCTGCGAGCGACCTGTTCGAG 228
 QY 21 LyeThrArgLeuLeuGlyAlaThrLeuLeuLeuAlaProArgTrpLeuThrAlaAla 40
 DB 229 AAGACCGGGCTACTCTGTGGGCGCAGCTCATCCGCCAGATGCTCTTCACAGCAGCC 288
 QY 41 HisCysLeuLeuProArgTrpIleValHisLeuGlyClnHisAlaLeuGlnGluGlu 60
 DB 289 CACTGGCTCAAGCCCGCTACATAGTTCACTTGGGCGCAGCACTTCAGAGAGGAGAG 348
 QY 61 GlyCysGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnSer 80
 DB 349 GGCTGTGAGCAGCCCGACAGCCACTGAGTCTTCCCCAGCCCGCTTCAACACAGC 408
 QY 81 LeuProAsnLysAspHisArgAsnAspIleMetLeuValLysMetAlaSerProValSer 100
 DB 409 CTCCCAACCAAGACCCAGCAATGACATCATCTGCTGAAGATGGCATGCCAGTCTCC 468
 QY 101 IleThrTrpAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
 DB 469 ATCACTGGGCTGTGGAGCCCTTCACTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 528
 QY 121 CysLeuLeuSerGlyTrpGlySerThrSerSerProGlyLeuArgProHisThrLeu 140
 DB 529 TGCTCTATTTCCGCTGGGCGAGCAGCTTCAGCCCGCCAGTTAGCTGCTTCACCTTG 588
 QY 141 ArgCysAlaAsnIleThrIleGlnHisGlnLysCysGlnAsnAlaTrpGlyValSer 160
 DB 589 CGATGGCCCAACATCATCATTTAGCAGCAGAGGTGTGAGAGCGCTATCCCGGCAAC 648
 QY 161 IleThrAspThrMetValCysAlaSerValGlnGluGlyCysLysAspSerCysGlnGly 180
 DB 649 ATCAGACACACCATGTGTGTGTCAGCGTGCAGGAGGGGCAAGGACTCTCTGCCAGGT 708
 QY 181 AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyIleIleSerTrpGlyGln 200

DB 709 GACTCCGGGGCCCTCTGGTCTGTATACCAAGTCTCTTCAAGGCATTATCTCTGGGCCAG 768
 QY 201 AppProCysAlaIleThrArgLysProGlyValTrpThrLysValCysLysValAsp 220
 DB 769 GATCCGTGTGGATCATCCACCCGAAAGCTGTGTCTACACAAAGTCTGCAATATGTGCAC 828
 QY 221 TrpIleGlnGluThrMetLysAsnAsn 229
 DB 829 TGGATCCAGGAGACGATGAGAACAT 855
 RESULT 14
 ABX89393
 ID ABX89393 standard; cDNA; 1204 BP.
 AC ABX89393;
 DT 13-MAY-2003 (first entry)
 DE DNA encoding novel secreted and transmembrane protein PRO1279.
 KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
 KW cardiac insufficiency disorder; cancer; tumor; immune response;
 KW adrenal cortical capillary endothelial growth; c-fos induction;
 KW vascular endothelial growth factor inhibition; VEGF inhibition;
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
 KW retinal neurons cell survival; rod photoreceptor cell survival;
 KW retinal disorder; retinitis pigmentosa; kidney disease;
 KW mammalian kidney mesangial cell proliferation; Berger disease;
 KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
 KW chondrocyte redifferentiation; sports injury; arthritis; gene; ss.
 OS Homo sapiens.
 XX US2003017563-A1.
 PN 23-JAN-2003.
 PD 07-MAY-2002; 2002US-0440808.
 PR 31-MAR-1997; 97WO-US05230.
 PR 12-JUN-1998; 98WO-US12456.
 PR 14-JUL-1998; 98WO-US14552.
 PR 28-AUG-1998; 98WO-US17888.
 PR 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19093.
 PR 14-SEP-1998; 98WO-US19094.
 PR 14-SEP-1998; 98WO-US19177.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 29-OCT-1998; 98WO-US22591.
 PR 29-OCT-1998; 98WO-US22592.
 PR 20-NOV-1998; 98WO-US24855.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 10-MAR-1999; 99WO-US05190.
 PR 20-APR-1999; 99WO-US08615.
 PR 02-JUN-1999; 99WO-US10713.
 PR 01-SEP-1999; 99WO-US20111.
 PR 08-SEP-1999; 99WO-US20594.
 PR 13-SEP-1999; 99WO-US20944.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 05-OCT-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US28313.
 PR 30-NOV-1999; 99WO-US28409.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 02-DEC-1999; 99WO-US28851.

PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 11-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US20311.
PR 21-AUG-2000; 2000WO-US23252.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30973.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAR-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 22-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802708.
PR 14-MAR-2001; 2001US-0805689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0884342.
PR 21-JUN-2001; 2001US-0885879.
PR 18-JUL-2001; 2001US-0908627.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927756.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deenoyers L, Filvaroff E, Gao W,
PI Gerritsen ME, Goldard A, Godewski PJ, Gurney AL, Sherwood S,
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-148238/14.
DR P-PSDB; ABUS9903.
XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
XX and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments
XX Claim 2; Fig 505; 659pp; English.

XX The invention describes an isolated human PRO polypeptide. The PRO
XX polypeptides are useful in detecting PRO polypeptides in a sample, in
XX linking a bioactive molecule to a cell expressing a PRO polypeptide, and
XX in modulating at least one biological activity of a cell expressing a PRO
XX polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
XX useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
XX stimulate adrenal cortical capillary endothelial growth, and PRO336,
XX PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
XX PRO1360 and PRO1387 induce e-fos in endothelial cells, and are thus
XX useful for treating conditions or disorders where angiogenesis would be
XX beneficial, e.g. wound healing and antagonist of this polypeptide are
XX useful for treating cancerous tumours. PRO812 inhibits vascular
XX endothelial growth factor (VEGF) stimulated proliferation of endothelial
XX cells and is thus useful for inhibiting endothelial cell growth in
XX mammals which would be beneficial in inhibiting tumour growth. PRO826,
XX PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
XX stimulated T-lymphocytes and are therapeutically useful for enhancing
XX immune response. PRO828, PRO826, PRO1068 or PRO132 enhance survival of
XX retinal neurons cells (PRO132 is also enhances survival/proliferation of
XX rod photoreceptor cells) and therefore are useful for treating retinal
XX disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
XX and PRO11066 induce proliferation of mammalian kidney mesangial cells,
XX and therefore are useful for treating kidney disorders associated with
XX decreased mesangial cell function such as Berger disease or other
XX nephropathies associated with dermatitis, herpetiformis or Crohn's
XX disease. PRO1310, PRO844, PRO1312, PRO1392 and PRO1387 induce the
XX proliferation and/or redifferentiation of chondrocytes in culture and
XX are thus useful for treating sports injuries, and arthritis. This
XX sequence encodes a novel human PRO protein.

XX Sequence 1204 BP; 306 A; 364 C; 294 G; 240 T; 0 other;

Alignment Scores:
Pred. No.: 5,04e-105 Length: 1204
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x ABX89393 (1-1204)

Qy 1 llellelysglypheglucyslyspromisserglnprotrpoinlaalaaleupheglu 20
Db 169 ATCATCAAGGGGTTTCGAGTCAAGCCTCCTCCAGCCCTGGCAGCAGCCCTGTTTCGAG 228
Qy 21 lvsrthrargleuleucysglyalathrleullealaalproargtrpLeuLeuthrAlaAla 40
Db 229 AAGACGGCGCTACTCTGTGGGGCGACGCTCATGCCCCAGATGGCTCTGCAGCAGC 288
Qy 41 HiscysleuysproargtrylevalhileuclglnhileanleuGlnlysgluGlu 60
Db 289 CACTGCTCAAGCCCGCTACATAGTTCACTGGGGCAGCACAACCTCCAGAGGAGGAG 348
Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProwisProGlyPheAenAenSer 80
Db 349 GCGTGTGAGCAGACCCGGACAGCCACTGAGTCTTCCCCCAGCCCGCTTCAACACAGC 408
Qy 81 LeuproAnlyspHisargAenAspIleMetLeuVallysmetAlaSerProValSer 100
Db 409 CTTCCCAACAAAGACCAACCCCAATGACATCATGTGTGAGATGGCATCGCCAGTCTCC 468
Qy 101 llethrtrpAlaValargProLeuthrLeuSerSerArgCysValThrAlaGlyThrSer 120

Db 469 ATCACTGGGCTGGAGCCCTCACCCTCTCTCAGCCTGTGTCTGCTGGACACAGC 528
Qy 121 CysLeuIleSerGlyTTPGlySerThrSerProGlnLeuArgLeuProHisThrLeu 140
Db 529 TGCCTCATTTTCGGCTGGGGGAGCAGCTCCAGCCGCCAGTTAGCCTGCTCACCACCTTG 588
Qy 141 ArgCysAlaSerIleThrIleLeuGluHisGlnLysCysGluHspAlaTyrProGlyAen 160
Db 589 CGATGCGCCCAACATCACTATTCAGGACCCAGAGTGTGAGAACCCCTACCCCGCAAC 648
Qy 161 IleThrAepThrMetValCysAlaSerValGlnGluGlyLysAspSerCysGlnGly 180
Db 649 ATCAGACACACCATGTGTGTCAGCTGCAGGAGCGGGGCAAGACCTCTGCGCGGT 708
Qy 181 AspSerGlyCysProLeuValCysGlnSerLeuGlnGlyIleLeuSerTTPGlyCln 200
Db 709 GACTTCGGGGGCTCTGCTGTATCAAGCTCTCTCAAGGCAATATCTCTGCGGGCCAG 768
Qy 201 AspProCysAlaIleThrArgLysProGlyValTyrThrLysValCysLysTyrValAsp 220
Db 769 GATCGGTGCGATCACCCGAAAGCTGTGTCTACACGAAGCTGTGCAATATGTGGAC 828
Qy 221 TriPileGlnGluThrMetLysAenAen 229
Db 829 TGGATCCAGGAGCAGATGAAGCAAT 855

RESULT 15
ABA83372
ID ABA83372 standard; cDNA; 1292 BP.
XX
AC ABA83372;
XX
DT 07-FEB-2002 (first entry)
XX
DE Human secreted protein gene 179 SEQ ID NO:189.
XX
KW Human; secreted protein; immunomodulatory; antisclerotic; anti-HIV;
KW dermatological; immunosuppressive; antiinflammatory; immunostimulant;
KW cytosolic; cardiac; vascular; anti-angiogenic; ophthalmological;
KW neuroprotective; nootropic; anticonvulsant; antialzheimer; vulnary;
KW antiparkinsonian; antimicrobial; gene therapy; vaccine; immune disorder;
KW multiple sclerosis; systemic lupus erythematosus; HIV infection; cancer;
KW human immunodeficiency virus; hyperproliferative disorder; wound healing;
KW Gaucher's disease; cardiovascular disease; Scimitar syndrome; chemotaxis;
KW Chaga's cardiomyopathy; coronary arteriosclerosis; angiogenic disorder;
KW corneal graft neovascularization; diabetic retinopathy; regeneration;
KW neurological disorder; Huntington's chorea; Alzheimer's disease;
KW Parkinson's disease; infectious disease; ss.
OS Homo sapiens.
XX
PN WO200162891-A2.
XX
PD 30-AUG-2001.
XX
PF 21-FEB-2001; 2001WO-US05614.
XX
PR 24-FEB-2000; 2000US-184836P.
XX
PR 29-MAR-2000; 2000US-193170P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ni J, Ebner R, Lafleur DW, Moore PA, Olsen HS, Rosen CA;
PI Ruben SM, Soppet DR, Young PE, Shi Y, Florence KA, Wei Y;
PI Florence C, Hu J, Li Y, Kyaw H, Fischer CL, Ferris AM, Fan P;
PI Feng P, Endress GM, Dillon FD, Carter KC, Brewer LA, Yu G;
XX Zeng Z, Greene JM;
XX WPI: 2001-625724/72.
DR P-PSDB; ABB50479.
XX
XX Nucleic acids encoding 207 human secreted polypeptides, useful for

PT preventing, diagnosing and/or treating, e.g. cancers, Parkinson's
PT disease and diabetic retinopathy -
XX
XX Claim 1; Page 1032; 153pp; English.
XX ABB50301 to ABB51287 and ABA83194 to ABA83441 represent human secreted
CC proteins (I) and polynucleotide (II) sequences. (I) and (II) have various
CC activities based on the tissues and cells the genes are expressed in.
CC Example of these activities include: immunomodulatory; antisclerotic;
CC dermatological; immunosuppressive; antiinflammatory; immunostimulant;
CC anti-HIV; cytostatic; cardiac; anti-angiogenic; ophthalmological;
CC neuroprotective; nootropic; anticonvulsant; antialzheimer; vascular;
CC antiparkinsonian; antimicrobial; and vulnary (I) and (II) can be used
CC in gene therapy and vaccine production. (I) and (II) can be used in the
CC prevention, diagnosis and treatment of immune disorders (e.g. multiple
CC sclerosis, systemic lupus erythematosus and human immunodeficiency virus
CC [HIV] infections), hyperproliferative disorders (e.g. cancers and
CC Gaucher's disease), cardiovascular diseases (e.g. Scimitar syndrome,
CC Chaga's cardiomyopathy and coronary arteriosclerosis), angiogenic
CC disorders (e.g. corneal graft neovascularisation and diabetic
CC retinopathy), neurological disorders (e.g. Huntington's chorea,
CC Alzheimer's disease and Parkinson's disease), infectious diseases and/or
CC for promoting wound healing, regeneration and/or chemotaxis. ABA83185 to
CC ABA83193 and ABB50300 represent sequences used in the exemplification of
CC the present invention.
XX
SQ Sequence 1292 BP; 319 A; 387 C; 329 G; 253 T; 4 other;

Alignment Scores:
Pred. No.: 5.52e-105 Length: 1292
Score: 1258.00 Matches: 229
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 22 Gaps: 0

US-09-856-320A-2_COPY_54_282 (1-229) x ABA83372 (1-1292)

Qy 1 IleIleLysGlyPheGluCysLysProHisSerGlnProTGGlnAlaLeuPheGlu 20
Db 270 ATCACTAAGGGTTCAGTGTGAGTGCAGCTCTCCAGCCCTGCGAGGAGCCCTGTTTCAG 329
Qy 21 LysThrArgLeuLeuGlyAlaThrLeuIleAlaProArgTTPLeuLeuThrAlaAla 40
Db 330 AAGACGCGGCTACTCTGTGGGGGAGCGCTCATCGCCGCCAGATGGCTCTCGACAGCAGCC 389
Qy 41 HisCysLeuLysProArgTyrIleValHisLeuGlyGlnHisAsnLeuGlnLysGluGlu 60
Db 390 CACTGCTCAAGCCCGCTACATAGTTTCACTGGGGGAGCACAACCTCCAGAAGGAGGAG 449
Qy 61 GlyCysGluGlnThrArgThrAlaThrGluSerPheProHisProGlyPheAsnSer 80
Db 450 GGCTGTGAGCAGACCCCGCAGCAGCTGAGTCTTCCCTCCCGGCTTCAACACAGC 509
Qy 81 LeuProAsnLysAepHisArgAenAspIleMetLeuValLysMetAlaSerProValSer 100
Db 510 CTCCCAACAAAGACACCCCGCAATGACATCATGCTGGTGAAGATGGCATGCCAGTCTCC 569
Qy 101 IleThrTTPAlaValArgProLeuThrLeuSerSerArgCysValThrAlaGlyThrSer 120
Db 570 ATCACTGGGCTGTGGACCCCTCACCCTCTCTCTCAGCCTGTGTCTGCTGGCACCAGC 629
Qy 121 CysLeuIleSerGlyTTPGlySerThrSerSerProGlnLeuArgLeuProHisThrLeu 140
Db 630 TGCTCATTTTCGGCTGGGCGAGCAGCTCCAGCCGCCAGTTACGCTGCTCACCCTTG 689
Qy 141 ArgCysAlaSerIleThrIleLeuGluHisGlnLysCysGluAenAlaTyrProGlyAen 160
Db 690 CGATGCGCCCAACATCACTATTCAGGACCCAGAGTGTGAGAACCCCTACCCCGCAAC 749
Qy 161 IleThrAepThrMetValCysAlaSerValGlnGluGlyLysAspSerCysGlnGly 180
Db 750 ATCAGACACACCATGTGTGTCAGCTGCAGGAGCGGGGCAAGGAGTCTCTGCCAGGCT 809

Qy	181	AspSerGlyGlyProLeuValCysAsnGlnSerLeuGlnGlyValIleIleSerTrpGlyGln	200
Db	810	GACTCCGGGGGCTCTGGTCTGTAAACCACTCTCTCAAGGCATTATCTCTGGGGCCAG	869
Qy	201	AspProCysAlaIleThrAtcGlyProGlyValTyrThrLysValCysLysTyrValasp	220
Db	870	GATCCGTGTGGCATCACCCGAAGCCTGGTGTCTACACCAAGTCTGCATAATATGTGGAC	929
Qy	221	TrpIleGlnGluThrMetLysAsnAsn	229
Db	930	TGGATCCAGGAGACGATGAGAACAAAT	956

Search completed: October 23, 2003, 15:58:15
 Job time : 260.855 secs

[ExPASy Home](#)[page](#)[SiteMap](#)[Search ExPASy](#)[Contact us](#)[Swiss-Prot](#)[PROSITE](#)[Proteomics tools](#)

Search for

GoClear

ScanProsite

Search a sequence against PROSITE

No pro-site
Tang
6075 136
SID2

Sequence:

MQRLRWLRDW KSSGRGLTAA KEPGARSSPL QAMRILQLIL LALATGLVGG ETRIIGFEC
KPHSQPWQAA LFEKTRLLCG ATLIAPRWLL TAAHCLKPRY IVHLGQHNLQ KEEGCEQTRT
ATESFPHPGF NNSLPNKDHR NDIMLVKMAS PVSITWAVRP LTLSSRCVTA GTSCLISGWG
STSSPQLRLP HTLRCANITI IEHQKCNAY PGNITDTMVC ASVQEGGKDS CQDSSGGPLV
CNQSLQGIIS WGQDPCAIR KPGVYTKVCK YVDWIQETMK NN

PROSITE Release 18.10, of 12-Oct-2003

>PDOC00001 PS00001 ASN_GLYCOSYLATION N-glycosylation site [pattern] [Warning: pattern with a high probability of occurrence].

131 - 134 NNSL
197 - 200 NITI
213 - 216 NITD
242 - 245 NQSL

>PDOC00005 PS00005 PKC_PHOSPHO_SITE Protein kinase C phosphorylation site [pattern] [Warning: pattern with a high probability of occurrence].

13 - 15 SgR
164 - 166 SsR
192 - 194 TlR
259 - 261 TrK
278 - 280 TmK

>PDOC00006 PS00006 CK2_PHOSPHO_SITE Casein kinase II phosphorylation site [pattern] [Warning: pattern with a high probability of occurrence].

120 - 123 TatE
199 - 202 TiiE
222 - 225 SvqE

>PDOC00008 PS00008 MYRISTYL N-myristoylation site [pattern] [Warning: pattern with a high probability of occurrence].

16 - 21 GLtaAK
46 - 51 GLvgGE
114 - 119 GCeqTR
226 - 231 GGkdSC
252 - 257 GQdpCA

>PDOC00124 PS50240 TRYPSIN_DOM Serine proteases, trypsin domain [profile].

THIS PAGE BLANK (USPTO)

47 - 280 LVGGEtriikgfeCKPHSQPWQAALFEKT-RLLCGATLIAPRWLLTAAHCLKPR-----Y
IVHLGQHNLQKEEGCEQTRTATESFPHPGFNslpNKDHRNDIMLVKMASPV SITWAVRP
LTL--SSRCVTAGTSC LISGWGSTSSPqLRLPHTLR CANITII EHQKC-ENAYPGNITDT
MVCASVQEGGKDSCQGD SGGPLVC----NQSLQGII SWGqDPCA ITRKPGVYTKVCKYVD
WIQETMK

>PDOC00124 PS00134 TRYPSIN_HIS Serine proteases, trypsin family, histidine active site [pattern].


90 - 95 LTAABC

>PDOC00124 PS00135 TRYPSIN_SER Serine proteases, trypsin family, serine active site [pattern].

229 - 240 DScqGDSGGPLV

Graphical summary of hits (*java applet*)

Click on items to see a description. Drag the two red cursors to select a zoom region.



THIS PAGE BLANK (USPTO)